REVIEW article

Front. Genet., 20 April 2021

Sec. Genomic Assay Technology

Volume 12 - 2021 | https://doi.org/10.3389/fgene.2021.615491

Advances in Genome Editing and Application to the Generation of Genetically Modified Rat Models

  • VC

    Vanessa Chenouard 1,2

  • SR

    Séverine Remy 1

  • LT

    Laurent Tesson 1

  • SM

    Séverine Ménoret 1,3

  • LO

    Laure-Hélène Ouisse 1

  • YC

    Yacine Cherifi 2

  • IA

    Ignacio Anegon 1*

  • 1. CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, Université de Nantes, Nantes, France

  • 2. genOway, Lyon, France

  • 3. CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes Université, Nantes, France

Article metrics

View details

49

Citations

16,4k

Views

5,8k

Downloads

Abstract

The rat has been extensively used as a small animal model. Many genetically engineered rat models have emerged in the last two decades, and the advent of gene-specific nucleases has accelerated their generation in recent years. This review covers the techniques and advances used to generate genetically engineered rat lines and their application to the development of rat models more broadly, such as conditional knockouts and reporter gene strains. In addition, genome-editing techniques that remain to be explored in the rat are discussed. The review also focuses more particularly on two areas in which extensive work has been done: human genetic diseases and immune system analysis. Models are thoroughly described in these two areas and highlight the competitive advantages of rat models over available corresponding mouse versions. The objective of this review is to provide a comprehensive description of the advantages and potential of rat models for addressing specific scientific questions and to characterize the best genome-engineering tools for developing new projects.

Introduction

Genetically modified animal models are essential to answering questions in biology, modeling human and non-human animal diseases, and generating therapeutic recombinant proteins. Among animal models, small laboratory mammals are often used because they share many biological features with humans, housing them is easy and relatively inexpensive compared to maintenance of large animals, and ethical issues are less prominent than with species such as non-human primates.

Among the small laboratory animal models, the rat has been used since at least 1856 (Philipeaux, 1856) and still is an important experimental model (between 9 and 18% of all laboratory models in the EU, The Commission to the European Parliament and the Council, 2015-2017).

Certain intrinsic characteristics of the rat, such as its larger size (10 fold) compared to the mouse, allow easier and more rapid microsurgery, multiple sampling of larger blood and tissue volumes, precise injection of substances into the brain, and in vivo and ex vivo organ function analysis. Additionally, mice and rats differ in their physiology and more sophisticated traits in the rat have made it a model of choice for toxicology, complex human diseases and neurobehavioral as well as cardiovascular studies among several others (Jacob, 2010).

Such differences have been supported by comparative analyses of the rat and mouse genomes. The rat genome is 2.75 gigabases (Gb), smaller than the human genome (2.9 Gb) but larger than the mouse genome (2.6 Gb) (Gibbs et al., 2004). Overall, rats show enrichment of genes involved in immunity, metabolic detoxification and chemosensation, as well as conservation of many genes involved in human diseases (Dewey et al., 2004; Gibbs et al., 2004).

Despite these advantages, the use of rats has lagged behind the use of mice in research, mainly because genetically modified mice were generated earlier than genetically modified rats (Figure 1). In mice, DNA microinjection was used in the early 1980s and embryonic stem (ES) cells in the late 1980s (Gordon et al., 1980; Palmiter et al., 1982; Doetschman et al., 1987). In contrast, in rats, DNA microinjection and ES cells began in the early 1990s and 2010, respectively (Mullins et al., 1990; Kawamata and Ochiya, 2010). In the meantime, researchers used classical breeding approaches to develop a variety of rat strains that model human diseases (Szpirer, 2020). The need for genetic engineering tools for the rat and the continuous use of zygote pronuclei microinjection of DNA in the rat, explain why gene-specific nucleases were applied in rats in 2009, earlier than in mice (2010) (Geurts et al., 2009; Carbery et al., 2010). These gene-specific nucleases quickly facilitated the exponential generation of knockout (KO) rats for many genes. In synergy with these technological advances, sequencing of the rat genome (Dewey et al., 2004; Gibbs et al., 2004) and characterization of genetic quantitative trait loci (QTLs) linked to diseases (Aitman et al., 2010, 2016) further accelerated the use of models of genetically modified rats.

FIGURE 1

In this regard, different rat strains are prone to different diseases present in humans and reproduce better than mice some of these diseases. These rat strains have been used to introduce genetic modifications to analyze the role of genes (Aitman et al., 2010, 2016). For example, Wistar Kyoto, Dahl/SS, and spontaneously hypertensive strains develop hypertension and have extensively used to analyze the role of many genes (Moreno et al., 2011; Rudemiller et al., 2014; Nayak et al., 2015; Aitman et al., 2016; Lerman et al., 2019; Szpirer, 2020). The diabetes-prone biobreeding rat strain is another model that has been used to genetically modify genes involved in diabetes (Michalkiewicz et al., 2004; Pandey and Dvorakova, 2020). Lewis rats are more susceptible than mice to the induction of Th1-mediated autoimmune diseases, whereas Brown Norway rats are highly susceptible to Th2-mediated immune diseases. Genomic linkage analysis allowed identification of a region on chromosome 9 that controls these phenotypes (Bernard et al., 2010). Additionally, the rat has been extensively used to analyze autoimmune diseases involving multiple genes (Aitman et al., 2010; Bernard et al., 2010).

In this review, we first describe the evolution and advances in genome editing and in delivery optimization of CRISPRs for producing genetically modified models. Further details are given on the rat to highlight needs and future research paths. The second part of the review focuses on the advantages of genetically modified rat models compared to mouse to mimic human situation, in particular in genetic diseases and immunology studies. Rats differ from mice in several characteristics, manifesting different phenotypes for the same genetic alteration. Rats also can sometimes better reproduce clinical features observed in humans who carry these gene variants (Hammer et al., 1990; Larcher et al., 2014). Our final aim is thus to inform researchers about major progresses in rat genome editing and advantages of rats as model organisms, to give researchers the choice of the best experimental system to answer their scientific questions. To facilitate rat models access and development, major rat resources for finding existing models or designing new ones with the latest gene editing tools, are described in Table 1.

TABLE 1

ResourcesNameWebsite and referencesProposed resources
Genomic databasesNational Center for Biotechnology Information (NCBI) including Gene, Protein, Nucleotide, Blast, and otherswww.ncbi.nlm.nih.gov/ (Sayers et al., 2019)Comprehensive suite for molecular analysis from rat genome to protein expression and functionality
The European Bioinformatics Institute (EMBL-EBI) including Ensembl, UniProt, Clustal Omega and othershttps://www.ebi.ac.uk/services (Madeira et al., 2019)From rat genome to protein databases a full suite with analysis tools and multiple sequence alignments
The University of California, Santa Cruz Genome Browserhttps://genome.ucsc.edu/ (Lee et al., 2020)Genome browser, multiple sequence alignments and others
Model organism Aggregated Resources for Rare Variant exploration (MARRVEL)http://marrvel.org/ (Wang et al., 2019b)Comparison of human genes with model oragnisms’ genes such as the rat in a physiologic or pathologic context
Genomic databases and strains repositoryRat Genome Database (RGD) in the United Stateshttps://rgd.mcw.edu (Smith et al., 2020)Repository of hundreds or rat strains and genome edited rats, mostly for genes involved in hypertension and cardiovascular function. Genetic, phenotype and disease data, sequences, QTLs, mapping data, software tools.
Rat strains repositoryRat Resource and Research Center (RRRC) in the United Stateshttp://www.rrrc.us/Repository of hundreds or rat strains, genome edited lines, cryopreserved embryos, sperm, and ES cells.
National Bioresource Project for the rat (NBPR) in Japanhttp://www.anim.med.kyoto-u.ac.jp/nbr/Repository of hundreds or rat strains, ENU and genome edited lines, cryopreserved embryos and sperm, BAC libraries
Rat Resource Database in Chinahttp://www.ratresource.comRepository of rat strains and genomic data.
Rodent Model Research in Taiwanhttps://www.nlac.narl.org.tw/Strain depository of lines or rats including genome edited ones.
Academic platforms producing genome-edited rat modelsWisconsin Gene Editing Rat Resource Center and The Michigan University Transgenic Animal Core facility in the United Stateshttps://rgd.mcw.edu/wg/gerrc/https://brcf.medicine.umich.edu/cores/transgenic-animal-model/Distribution of already available models and generation of new ones on demand
Transgenic Rat ImmunoPhenomic (TRIP) facility in Francehttp://www.itun.nantes.inserm.fr/Core-facilities/TRIP-Transgenic-Rats-ImmunoPhenomic
Commercial vendors for rat modelsCharles River laboratorieshttps://www.criver.com/Distribution of already available models and generation of new ones on demand
Janvier Labshttps://www.janvier-labs.com/
Envigo (include Horizon discovery models)https://www.envigo.com/research-models
Taconic Bioscienceshttps://www.taconic.com
genOway (include Axenis models)https://www.genoway.com/
Cyagenhttps://www.cyagen.com/us/en/Custom rat model generation
Hera Biolabshttps://www.herabiolabs.com/ SRG OncoRats (Noto et al., 2020)Proprietary gene editing technologies and SRG OncoRats for oncology studies
Ligand pharmaceuticalshttps://www.ligand.com/technologies/omniab OmniRat (Joyce et al., 2020) OmniFlic (Harris et al., 2018)OmniRat and OmniFlic for human antibodies generation
Software for the use of CRISPRCRISPORhttp://crispor.tefor.net/ (Concordet and Haeussler, 2018)On and off target scores
CHOPCHOPhttps://chopchop.cbu.uib.no/ (Labun et al., 2019)
E-CRISPRhttp://www.e-crisp.org/E-CRISP/ (Heigwer et al., 2014)
CCTOPhttps://cctop.cos.uni-heidelberg.de:8043/index.html (Stemmer et al., 2015; Labuhn et al., 2018)
CRISPRscanhttps://www.crisprscan.org/ (Moreno-Mateos et al., 2015)
CRISPRdirecthttp://crispr.dbcls.jp/ (Naito et al., 2015)Off-target prediction only
CRISPR RGEN toolshttp://www.rgenome.net/Cas-OFFinder, Microhomology, Cas-designer, base-editing, prime-editing…
Private company webtool for design of gRNA targeting rat genomeIntegrated DNA Technologieshttps://eu.idtdna.com/pages/products/crispr-genome-editingInclude on and off target scores
Synthegohttps://www.synthego.com/products/bioinformatics/crispr-design-tool
Horizon Discoveryhttps://horizondiscovery.com/en/ordering-and-calculation-tools/crispr-design-tool
Benchlinghttps://www.benchling.com/crispr/

Resources on rat genomics and genome edited animals.

Gene-Editing Advances and Delivery System Optimization

The last four decades have brought major advances in genome editing allowing for generation of animal models that harbor targeted genetic modifications. Efforts have focused on increasing the precision of these modifications, production efficiency and on simplifying procedures to make them easier and cheaper. The evolution of genome editing approaches and tools is discussed in this section, illustrated in Figure 1 and nucleases compared in Table 2. Clustered, regularly interspaced short palindromic repeat (CRISPR)-associated (Cas) systems applied to rodents are detailed in Table 3, with details of specifics regarding rats given in this section. More particularly, Streptococcus pyogenes (SpCas) system components are described in Figure 2 and compared in Table 4. Published advances for enhancing knockin (KI) generation rate are also detailed here and illustrated in Figure 3. Finally, delivery systems and the evolution of their practice are detailed and compared in Table 5.

TABLE 2

Specificities, advantages, limitationsMeganucleasesZFNTALENCRISPR-Cas
DNA binding determinantProteinZF proteinTAL proteincrRNA/sgRNA

Binding specificityLong sequences of nucleotidesa3 nucleotides1 nucleotideb1/1 nucleotide pairing

EndonucleaseI-CreI and I-SceIaFokIcFokIcCas9

Function specificityMonomerDimerDimerMonomer

Design/EngineeringVery difficultDifficultSimpleVery simple

Restriction in target siteChromatin compactionG-rich sequenceStart with T and end with AEnd with a NGG sequence

Target site length18–44 bp18–36 bpd24–40 bp22–25 bp

Targeting frequencyLowHigh (one/100 bp)High (one/bp)High (one/4 or 8 bp)

SpecificityHighModerateeHighHigh

Sensitivity to DNA methylationYesYesYesNof

Off-targetsVariableLoweVery lowVariable

SizeSmall sizeSmall size (∼1 kb/monomer)Large size (∼3 kb/monomer)Large size (4.2 kb Cas9)

Commercially available, CostYes, highYes, highYes, moderateYes, low

Patents concernYesYesYesYes

Type of editing

Gene KO (Indels and frameshift)YesYesYesYes

Multiplex KONo datahVery limitedLimitedYes (up to eight alleles)g

Gene correction/point mutagenesis (repaired basepairs)No datahYesYesYes

Gene addition/sequence replacement (integrated gene cassette)No datahYesYesYes

Gene deletion (deleted gene fragments)No datahNo dataNo dataYes

Prime and base editingNo datahNo dataNo dataYes

Comparison of engineered endonucleases.

aDNA-binding specificities and cleavage mechanism combined in the same protein (Galetto et al., 2009). I-CreI and I-SceI are the main endonucleases used but a few others have been applied to genome editing. bTALE protein consist of 34 amino acid repeat domains, each one recognizing a single DNA nucleotide; highly conserved, excepting two hypervariable residues at positions 12 and 13, which confer the specificity of TALE. cFokI cleaves only in its dimeric form dAssociation of 3–6 ZF DNA binding domains fused to the FokI catalytic domain. Binding of two ZFN-FokI heterodimers to two contiguous DNA sequences and separated by a 5–7 bp gap. eSpecificity depends on number and selected ZF modules. fNo direct effect of methylation on Cas9 binding or effectivity (Verkuijl and Rots, 2019). gDifficult on same chromosome. Limitations overcome by Prime and base editing (cf Table 3). hThe difficulty in designing meganucleases has limited their application in creating new model organisms.

TABLE 3

ApplicationType – Variant - NamePAM 5′-3′CleavageGM miceGM rats
Classical GEII- SpCas9NGGBlunt DSBWang et al., 2013bLi D. et al., 2013; Li W. et al., 2013
Specificity enhancementII- E -Hypa SpCas9NGGBlunt DSBIkeda et al., 2019
II- E -SpCas9 nickaseNGGNickRan et al., 2013
Enlarge targeting possibilitiesII- E -SpCas9 VQRNGABlunt DSBRobertson et al., 2018
II- E -SpCas9 VRERNGCGBlunt DSBRobertson et al., 2018
II- E -SpCas9-NGNGNBlunt DSBFujii et al., 2019
II- SaCas9NNGRRTBlunt DSBZhang X. et al., 2016Zheng et al., 2020
II- E -SaCas9 KKHNNNRRTBlunt DSBRobertson et al., 2018
II- St1Cas9NNAGAAWBlunt DSBFujii et al., 2016
II- CjCas9NNNVRYMBlunt DSBKim et al., 2017
II- NmCas9NNNNGATTBlunt DSBXia et al., 2018
II- FnCas9NGG5′ staggeredHirano et al., 2016
V-A- AsCpf1 (Cas12a)TTTV5′ staggeredHur et al., 2016; Kim et al., 2016Lee J. G. et al., 2019; Yeo et al., 2019
V-A- LbCpf1 (Cas12a)TTTV5′ staggeredKim et al., 2016Lee J. G. et al., 2019
V-A- ErCas12a CRISPR-Mad7TTTN, CTTN5′ staggeredLiu Z. et al., 2020Liu Z. et al., 2020
V-A- CRISPR-Mb3Cas12aTTV5′ staggeredWang Z. et al., 2020
V-B- AaCas12b (C2c1)TTN5′ staggeredTeng et al., 2018
Alternative editingCytosine base editing II- E -SpBE2 II- E -HF2-SpBE2 II- E -SpBE3 II- E -Sp-BE4 II- E -Sp-VQR-BE3 II- E -SaBE3NGG from NGG/A to NGG NGG NGG NGA NNGRRTNone None Nick Nick Nick NickLee et al., 2018
Liang P. et al., 2017
Zhang H. et al., 2018
Lee et al., 2018
Lee et al., 2018
Liu et al., 2018
-
-
-
-
-
-
Adenosine base editing II- E -SpABE7.10 II- E -SpVQR-ABE II- E -SaKKH-ABENGG NGA NNNRRTNick Nick NickLiu et al., 2018
Yang L. et al., 2018
Yang L. et al., 2018
Yang L. et al., 2018
Prime editing PE3NGG2 NicksLiu Y. et al., 2020

CRISPR variants applied to genetically modified mouse and rat models.

GE, genome editing; E, engineered Cas; GM, genetically modified model; DSB, double strand break; St1Cas9, Streptococcus thermophilus Cas9; CjCas9, Campylobacter jejuni Cas9; NmCas9, Neisseria meningitidis Cas9; FnCas9, Francisella novicida Cas9.

FIGURE 2

TABLE 4

FormatAdvantagesLimitationsAdvances demonstrated in any species (rat in bold)
Cas9

PlasmidNo limit on insert size Easy engineering High expressionDelayed activity Mosaicism Increased off-targets Delayed activityCas9 protein allowing rapid and more efficient editing (Kim et al., 2014; Ménoret et al., 2015) Large editing toolbox variants (Table 3) Improved chromatin accessibility (Chen F. et al., 2017; Ding et al., 2019) Cas9 engineered to activate repair pathways (Charpentier et al., 2018; Tran et al., 2019) Cas9 engineering to be degraded in G1 (Gutschner et al., 2016; Charpentier et al., 2018; Lomova et al., 2019)
mRNAExpression faster than plasmid Limit mosaicism and off-targetsDelayed activity In vitro transcription efficiency/toxicity
ProteinReady to cut Limit mosaicism and off-targets Affordable and high qualityCrystallization at high dose In vivo stability potentially immunogenic

gRNA

PlasmidNo limit on insert size Easy to engineerDelayed activityChemical modification (Kim S. et al., 2018; Filippova et al., 2019) Essential sequence, secondary structures and functional modules of gRNA (Briner et al., 2014; Kartje et al., 2018) Overlapping gRNA (Jang et al., 2018) gRNA engineering to activate repair pathways (Nakade et al., 2018; Tran et al., 2019)
IVT sgRNAEasy to produce and use Flexible in sequence and length EfficientTime-consuming production Induced immune responses Limited in chemical modification
Synthetic sgRNAAffordable and high quality Chemical modifications Ready to use EfficientOrder full sgRNA for each project Long RNA synthesis Difficulties in adding fluorophore for tracking
Synthetic dgRNAShort RNA synthesis Low cost and high quality Same tracrRNA for all project Chemical modifications Fluorophores added for tracking EfficientcrRNA & tracrRNA hybridization in vitro

DNA donor

ssODNLow cost synthesis High efficacy for mutation or short KILimited in length to 200ntDNA synthesis progresses (Hao et al., 2020) Chemical modification (Renaud et al., 2016; Liang X. et al., 2017; Yu et al., 2020) Insertion close to cut site (Inui et al., 2014; Liang X. et al., 2017) 3′ overhang DNA donor (Liang X. et al., 2017; Hirotsune et al., 2020) Carry to cut site by Cas9 (Ma et al., 2017; Aird et al., 2018; Gu et al., 2018; Ling et al., 2020; Wang Z. et al., 2020) Carry to cut site by gRNA (Carlson-Stevermer et al., 2017; Lee et al., 2017) Carry to cut site by DNA donor engineering (Nguyen et al., 2020) DNA donor in vivo excision from plasmid (Aida et al., 2016; Yao et al., 2017; Zhang et al., 2017)
lsDNAUsable for long KILimited in length Difficult to produce Mutated KI Expensive to synthesize
dsDNAUsable for long KI Easy to produce and engineer No limit on insert sizeFew random insertions
PlasmidUsable for long KI Easy to produce and engineer No limit on insert sizeFew random insertions

CRISPR-Cas9 component format advantages, limits and advances.

IVT, in vitro–transcribed; gRNA, guide RNA; sgRNA, single gRNA; dgRNA, dual gRNA; ssODN, single-stranded oligonucleotides; lsDNA, long single-stranded DNA; dsDNA, linear double-stranded DNA.

FIGURE 3

TABLE 5

Delivery methodsCargoSpecies/cell targetLocationAdvantagesLimitationsReferences
Physical delivery

MicroinjectionDNA donor - dsDNA (linear/plasmid) - dsDNA encoding gene-specific nucleases - lsDNA (>200nt) - ssODN (∼100nt)Mouse and rat zygotePronucleus or cytoplasm- Delivery of large DNA fragments - Stable DNA in cell- Time-consuming method - Expertise required (less for Cyt-MI) - Poor visualization pronucleus, flexibility of the oolemma and nuclear membranes in rat - Variability in efficiency depending on size, DNA quality or purity - Persistent expression and depending on host transcriptional/transductional machinery1st description (Gordon et al., 1980; Palmiter et al., 1982; Mullins et al., 1990) dsDNA-ZFN (Geurts et al., 2009) dsDNA-TALEN (Tesson et al., 2011) dsDNA-Meganuclease (Ménoret et al., 2013) Efficiency (Charreau et al., 1996b; Hirabayashi et al., 2001) Complex/invasive method (Brinster et al., 1985; Charreau et al., 1996b)
mRNA encoding gene specific nucleasesMouse and rat zygotePronucleus or cytoplasm- Moderate efficiency - Transient expression - Cyt-MI more efficient than PN-MI - Off-target reduced - Independent expression dependency of host transcriptional/transductional machinery (mRNA)- Time-consuming - Expertise required (less for Cyt-MI) - Variation among batches of IVT mRNA - mRNA liable to degradationmRNA-ZFN (Geurts et al., 2009) mRNA-TALEN (Tesson et al., 2011; Remy et al., 2014) mRNA-CRISPR (Ménoret et al., 2015) Meganucleases (Wang et al., 2014)
Protein (RNP)Mouse and rat zygote Mouse/ESPronucleus or cytoplasm- Higher efficiency than using DNA or mRNA encoding gene specific nucleases - Short half-life within cells - Less mosaicism - Off-target cleavage reduced-In vivo stability -Potentially immunogenic(Ménoret et al., 2015; Wang et al., 2015; Jung C. J. et al., 2017)

ElectroporationDNA donor - dsDNA (linear/plasmid) - ssODN - lssDNA (600–1.5 kb)Mouse and rat zygoteUncontrolled cytoplasm (long DNA) Pronucleus (short lsDNA/ssODN)- Easier delivery than DNA-MI - Processing simultaneously 50–60 zygotes in a short time - Efficient to deliver ssODN or lsDNA (<1 kb)- Inefficient nuclear transport - Transient nuclear envelop breaking or cell-division required - Inefficient to deliver DNA > 1 kbssODN (Hashimoto and Takemoto, 2015; Kaneko and Mashimo, 2015; Qin et al., 2015; Chen et al., 2016; Wang et al., 2016; Remy et al., 2017) lsDNA (Miyasaka et al., 2018) Inefficient delivery dsDNA (Takabayashi et al., 2018)
mRNA encoding Cas9 + sgRNAMouse and rat zygoteUncontrolled- Easier delivery than mRNA-MI- Embryos are quite sensitive to pulse and toxicity is observedRat/mRNA encoding Cas9+sgRNA (Remy et al., 2017) CRISPR/mice/KO/HDR-KI (Qin et al., 2015) Mice/CRISPR/KO (Hashimoto and Takemoto, 2015; Hashimoto et al., 2016) Rat/ZFN/TALEN/Crispr/KO (Kaneko et al., 2014; Kaneko and Nakagawa, 2020) Rat/mice/Crispr/KO/KI (Kaneko and Nakagawa, 2020)
Protein (RNP)Mouse and rat zygoteUncontrolled- Easier delivery than RNP-MI- High amount of cargo - Uncontrolled delivery amountCas9-RNP/mice/indels/large KO/HDR-KI/ssODN-KI (Wang et al., 2016) Cas9-RNP/mice/KO (Hashimoto et al., 2016)
GONADDNA - ssODN - lsDNA (<1 kb)/ Cas9 mRNA/sgRNA RNPMouse and ratOviduct- Ex vivo embryo handling steps not required - Fewer animals used (e.g., recycling females possible)- Not yet applicable to deliver long donor DNA (db or long ss DNA)Cas9mRNA + sgRNA/mice/KO (Takahashi et al., 2015) RNP/lsDNA/mice/KO/ssODN and lsDNA-based KI (Ohtsuka et al., 2018) Rat/ssODN based KI (Kobayashi et al., 2018; Takabayashi et al., 2018)

Viral delivery methods

AAV vectors (Non-enveloped, lsDNA)DNA encoding Cas9/sgRNA (separate AAV or all-in-one AAV) – KI DNA cassetteMouse and rat zygote (transduction)Uncontrolled- minimal immunogenicity - low toxicity - wide-range serotypes - No incorporation into the host genomeLow capacity (<5 Kb)KO/Mice/separate AAV (Yoon et al., 2018) KO/KI/Mice/Rat/RNP Electroporation/AAVtransduction (Mizuno et al., 2018; Chen et al., 2019) (Edraki et al., 2019)
DNA (expression cassette)Mouse zygote microinjectionCytoplasmic injection(Yu et al., 2015)

Delivery methods.

MI, microinjection; Cyt-MI, cytoplasmic microinjection; PN-MI, pronuclear microinjection; DNA-MI, DNA microinjection; KI, Knockin; ssODN, single-stranded oligonucleotides; lsDNA, long single-stranded DNA; dsDNA, linear double-stranded DNA; HDR-KI, homology directed repair knockin; RNP, ribonucleoprotein complex.

Historical Overview of Major Gene-Editing Techniques Developed in Mice and Rats

Random Additive Transgenesis and Mutagenesis

The first transgenic rodents were successfully generated in the early 1980s and 1990s (Gordon et al., 1980; Palmiter et al., 1982; Mullins et al., 1990), by microinjection of exogenous donor DNA into the pronucleus of one-cell embryos. The reported efficiencies are quite low in rodents, ranging from 0.5 to 10% of injected embryos in mice and 0.5–5% of injected embryos in rats (Brinster et al., 1985; Charreau et al., 1996b; Hirabayashi et al., 2001). Other problems include random integration, a high copy number of integrated DNA sequences in cis and uncontrollable transgene expression. These challenges make this approach labor intensive and time-consuming and require considerable expertise.

N-ethyl-N-nitrosurea (ENU) is a highly potent mutagen that was first administered into adult male mice (Bode, 1984) and later into rats (Zan et al., 2003). Several ENU-induced mutant rat (van Boxtel et al., 2010) (for a review see Huang et al., 2011) and mouse models (for a review see Justice et al., 1999) have been described. This method presents some advantages: it requires no embryos or ES handling and the sperm of mutant offspring can be cryopreserved. Disadvantages include uncontrolled and random mutations in multiple loci throughout the genome, which must be identified and localized using high-throughput and time-consuming screening methods.

Transposon-mediated insertional transgenesis is an alternative tool developed to increase the integration frequency of the transgene into the host genome. Transposons are simple and mobile elements, consisting of a DNA sequence encoding transposase and a transgene flanked by binding sites (inverted terminal repeats, ITR) for the transposase, promoting integration into the genome. Transposon systems, such as Sleeping Beauty (SB), piggyBac (PB) or Tol2, have demonstrated their efficiency in rapidly producing stable lines of transgenic mice (Carlson et al., 2003; Horie et al., 2003) and rats (Kitada et al., 2007; Lu et al., 2007). The number of transgene insertions is, however, difficult to control.

Targeted Mutagenesis

The derivation of germline-competent mouse ES cells in the early 1980s (Evans and Kaufman, 1981; Martin, 1981) and the first experiments of targeted mutagenesis (Doetschman et al., 1987; Thomas and Capecchi, 1987), allowed introducing mutations into the host genome with a high precision (Joyner et al., 1989; Koller et al., 1989; Schwartzberg et al., 1989; Zijlstra et al., 1989) making mice a privileged model for genetic studies for two decades. Rat ES cells were described in 2008 (Buehr et al., 2008; Li et al., 2008) allowing generation of KO (Kawamata and Ochiya, 2010; Meek et al., 2010; Tong et al., 2010) and KI rats (Kobayashi et al., 2012; Yamamoto et al., 2015) with similar homologous recombination (HR) efficiencies to those observed in mice. Nevertheless, rat ES cells are less robust than mouse ES cells and maintaining their stability in culture and germline competence continues to be challenging.

The development of meganucleases, engineered zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and more recently the CRISPR-Cas system, has unquestionably revolutionized genome editing, opening new possibilities especially in the rat and other species in which ES cells were not available (Fernández et al., 2017). Each of these nucleases have their own properties of DNA-binding, recognition type/site specificities, their own advantages and limitations, which are listed in Table 2. Injection of these nucleases directly into rat or mouse zygotes allows creation of a double-strand break (DSB) at a targeted locus, repaired thereafter mainly by non-homologous end-joining (NHEJ) or HR (these mechanisms are reviewed in detail in a later section). Careful design of the associated tools makes it possible to better control repair outcome at any targeted locus of the genome with high efficiency and much faster than with ES cells. Several reports demonstrated the high efficiency of ZFN and TALEN in quickly generating different types of modifications in mice and rats, ranging from KO (Geurts et al., 2009; Carbery et al., 2010; Mashimo et al., 2010, 2013; Tesson et al., 2011; Tong et al., 2012; Sung et al., 2013; Sommer et al., 2014), simple point mutations, to large KI by homology-directed repair (HDR) (Sung et al., 2013; Wang et al., 2013a; Wefers et al., 2013; Ponce de León et al., 2014; Remy et al., 2014). Meganucleases, although less used than the other nucleases, were also applied to generate KO mouse and rats (Ménoret et al., 2013). Nevertheless, the design complexity and associated costs made these techniques accessible to only few laboratories, leading to a search for alternative approaches.

The simplicity and rapidity of guided RNA design, compared to complex protein engineering needed for ZFNs and TALENs, made the CRISPR-Cas system largely accessible at low cost, without sacrificing the specificity and reproducibility already observed with ZFNs and TALENs. Nevertheless, the success of CRISPR-Cas, especially in the generation of the first CRISPR mouse (Wang et al., 2013b) and rat (Li D. et al., 2013; Li W. et al., 2013), depended on knowledge gathered using the previous gene-specific nucleases in terms of DNA cleavage outcomes, repair pathways mechanisms (molecules involved and forms of DNA donors) and genotyping techniques.

CRISPR-Cas Systems

The CRISPR-Cas9 system is originally based on a ribonucleoprotein (RNP) complex composed of a nuclease (Cas9) driven by a dual-guide RNA (dgRNA) duplex (Jiang and Doudna, 2017). Cas9 cleavage capacity relies on its two nuclease domains, each cleaving one strand of the genomic DNA. Inactivation of either nuclease domain (nickase) generates a nick on the corresponding strand (Jinek et al., 2012), whereas inactivation of both domains (dead Cas9 or dCas9) completely abolishes its cleavage capacity. The native dgRNA (Deltcheva et al., 2011) is formed from a trans-activating CRISPR RNA (tracrRNA) harboring a complex secondary structure to interact with Cas9 and a CRISPR RNA (crRNA), that mostly encodes the 20 nucleotides that give the system its specificity. When formed, this RNP complex quickly interrogates genomic DNA for its specific protospacer adjacent motif (PAM). The PAM is a key factor because it defines the possibilities of DNA targeting sequences. For SpCas9, the targets are limited to a G-rich genomic region with a 5′-NGG-3′ PAM (Jinek et al., 2014; Nishimasu et al., 2014). PAM recognition is followed by specific gRNA (guide RNA) spacer (20 nucleotides) matching. A perfect match creates a targeted blunt DSB three nucleotides away from the PAM. A few mismatches between the gRNA and the targeted genomic DNA are tolerated at certain positions and may lead to off-target editing (Peng et al., 2018). Design of gRNA with the highest homology specificity possible for the targeted DNA sequence is essential to limit off-target edits (Ayabe et al., 2019). Available tools for rat genome editing with CRISPRs are described in Table 1. Off-target is less of an issue for animal model generation when compared to the use of gene editing as a therapeutic tool. Indeed, animals require multiple breeding, clearing lines from off-targets on chromosomes different from the one harboring the mutation of interest.

To expand the CRISPR toolbox, many variants of SpCas9 have been engineered and bacterial strains screened to either enhance specificity or broaden PAM opportunities. Variants (Pickar-Oliver and Gersbach, 2019) and SpCas9 ortholog classification (Makarova et al., 2020) have been recently reviewed. Many of these options have been used at least once to edit mouse embryos, but only a few have been applied to the rat. Those already applied to rodent genome editing are summarized in Table 3. Type V Cas have T-rich PAMs and other interesting features, such as staggered DSB generation, that make them complementary to SpCas9. For this reason, some orthologs of Cpf1 (Cas12a) are the most used after SpCas9, including Acidaminococcus sp. (AsCpf1) (Lee J. G. et al., 2019; Yeo et al., 2019) and Lachnospiraceae bacterium ND2006 (LbCpf1) (Lee J. G. et al., 2019).

Classical genome editing, alternatives and their context of application have been recently reviewed in detail (Anzalone et al., 2020). Two of these, namely base editing and prime editing, have been used for rodent genome editing and are summarized in Table 3. Cytosine base editor has been engineered using either dCas9 or nickase to transform cytosine into a thymine (Komor et al., 2016; Nishida et al., 2016) and was further improved (Rees and Liu, 2018; Schatoff et al., 2019). Adenine base editor was engineered to mutate adenine into guanine more efficiently than Cas9 genome editing in human cells (Gaudelli et al., 2017). Several base editor variants have been applied to mouse embryos for single (Liang P. et al., 2017) or multiple (Liu et al., 2018; Zhang H. et al., 2018) base editing, whereas only the SpABE7.10 system has been applied in rats (Ma Y. et al., 2018; Yang L. et al., 2018). The main advantage of base editing is its capacity to generate targeted indels or a particular mutation without a DNA donor, enhancing its efficiency compared to classical genome editing. By avoiding DSBs, this system also allows multiplex editing on the same region of a chromosome (Lee H.K. et al., 2019). Its major limitations are bystander effect on non-targeted bases, cytosine and adenine limitations, targeted precision that restrict possibilities, and off-target effects as with classical genome editing. Prime editing is overcoming some of these limitations (Anzalone et al., 2019). This system allows mutation, short insertion and short deletion editing with limited indels generation in contrast to classical Cas genome editing. The first two versions of this system relied on a Cas9 nickase fused to a reverse transcriptase and a prime editing gRNA (pegRNA). This system induces nicking on the non-target strand and reverse transcription of the template encoded in the pegRNA to specifically modify the targeted locus. Prime editing 3 and 3b have been enhanced by the use of a second nickase with its own guide RNA, to target the strand that was not nicked by the pegRNA. Very recently, prime editing 3 has been successfully applied to genetically modify mouse embryos for the first time (Liu Y. et al., 2020). This particularly interesting approach will be applied eventually to generate genetically modified rat models.

Advances in CRISPR-Cas Production and Design for Rodent Genome Editing

The components of the CRISPR-Cas system, both for KO or KI, have been closely studied and enhanced to increase efficiency, decrease side effects, and offer better control over repair outcomes, as reviewed below. In particular, we summarized CRISPR-Cas9 component formats and their evolution in Table 4 and Figure 2, and advances to increase KI efficiency are illustrated in Figure 3.

RNP Complex

KO and KI model’s generation mainly depends on RNP complex cleavage efficiency. Many studies have been done to find RNP complex best settings. It has been clearly demonstrated that the use of Cas9 protein allows transient and faster editing (Kim et al., 2014) necessary for proper animal model generation and increases efficiency of the RNP complex in mouse and rat zygotes (Figure 2A and Table 4) (Ménoret et al., 2015). Guide RNA’s sequence has been extensively studied to better understand its flexibility and structure (Table 4) (Briner et al., 2014; Kartje et al., 2018) for improved efficacy. In cells, the 5′ triphosphate group on in vitro–transcribed gRNA induces the cell immune system and reduces editing efficacy. This reaction can be limited by phosphatase treatment or prevented by chemical modification of synthetic gRNA (Kim S. et al., 2018). Chemical modifications and gRNA optimization have been recently reviewed (Filippova et al., 2019) and offer a clear advantage for synthetic gRNA (Figure 2A and Table 4). Regarding their format, both dgRNA and single gRNA (sgRNA) display similar efficiency (Terao et al., 2016; Shapiro et al., 2020). Chromatin state can influence editing efficiency (Janssen et al., 2019; Verkuijl and Rots, 2019) and even prevent editing of gRNA with predicted high on target score. Two main strategies have been developed in cells only to open chromatin locally and increase editing efficiency with SpCas9 and other orthologs (Table 4). The first approach uses one or multiple dCas molecules to open chromatin in close proximity to the targeted locus (Chen F. et al., 2017). The second approach relies on fused chromatin-modulating peptides on SpCas9 and other Cas proteins (Streptococcus pasteurianus Cas9, Campylobacter jejuni Cas9, and others) (Ding et al., 2019). This field is still emerging and requires further studies. There is a need for better understanding of genome editing hurdles to allow edits at any locus with high efficiency.

DNA Donor

DNA donors have been used in different formats to generate KI models: plasmids, single-stranded oligonucleotides (ssODNs), long single-stranded (ls)DNA, and linear double-stranded (ds)DNA (Figure 2B and Table 4). These formats and their design are important to direct repair toward KI. Because efficient KI generation is the most important issue currently, here we review the main aspects and advances regarding the DNA repair template and pathways.

Historically, transgenesis (Gordon and Ruddle, 1982; Palmiter et al., 1982; Mullins et al., 1990; Charreau et al., 1996b) and targeted mutagenesis using nucleases have been achieved using circular plasmids or an excised dsDNA, to introduce a complete expression cassette in rat and mouse genome (Cui et al., 2011; Brown et al., 2013). DNA synthesis advances in recent decades (Hao et al., 2020) have supported progress in genome editing (Table 4), allowing efficient synthesis of dsDNA, ssODNs and lsDNA, with increasing size and purity from commercial vendors. Nevertheless, yield issues persist with synthesis of long DNA fragments. Today, short sequence insertion and precise mutations are mostly generated using ssODNs. Its current synthesis limit is 200 nucleotides or fewer for most providers. A few years ago, lsDNA emerged as a new and efficient way to generate complex KI mouse (Miura et al., 2015; Miyasaka et al., 2018) and rat (Yoshimi et al., 2016; Miyasaka et al., 2018) models. Different production strategies have been developed, including in vitro transcription and reverse transcription (Miura et al., 2015), plasmid excision by nicking endonucleases (Yoshimi et al., 2016) and synthesis. High yield and purity are difficult to achieve for lsDNA production, leading to unexpected mutations in addition to the desired KI genotypes (Codner et al., 2018). Synthesis is quite expensive and limited to some kilobases depending on vendors (Figure 2B and Table 4). Chemically modified ssODNs, in cells and rodents, generally lead to higher editing efficiency (Renaud et al., 2016; Liang X. et al., 2017). A study on human cells showed increased KI efficacy using 5’-end–modified dsDNA (Yu et al., 2020). The proof of concept of this protection has clearly been demonstrated and will probably be tested for all DNA donor formats.

Several approaches have been developed to optimize DNA donor design, but no clear consensus has emerged regarding impact on KI efficiency. In human cells, some donors have shown better KI efficiency with ssODN complementary to the non-target strand (Richardson et al., 2016), but others have shown similar efficacy for both designs (Liang X. et al., 2017). In the same way, studies on human cells suggest better efficiency with asymmetric ssODNs (Richardson et al., 2016), whereas others report similar KI efficiency with both asymmetric and symmetric donors in mouse embryos (Lanza et al., 2018). Furthermore, in human cells (Liang X. et al., 2017) and mouse embryos (Hirotsune et al., 2020), dsDNA with 3’ overhangs displays better KI efficiency (Figure 2B and Table 4). This improvement could be explained by necessary genomic DNA end resection for KI generation during repair pathways, as discussed later. The only consensus regarding DNA donor design is that the inserted sequence should be as close as possible to the Cas9 cut site (Table 4) to yield efficient KI (Inui et al., 2014; Liang X. et al., 2017). To avoid multiple cleavages on the KI inserted sequences, silent mutations are introduced in the DNA donor close to the PAM.

Major hurdles remain for large (long donor) or complex KI (several ssODNs with complex sequence). One clear way to increase KI efficiency is to use the RNP complex to carry the DNA donor to the DSB (Figure 3A and Table 4). In this way, all KI components will be present at the same time and concentrate at the cut site. The stable and high affinity between biotin and streptavidin (Le et al., 2019) and the easy production of biotinylated DNA donor have inspired several approaches. Cas fused with avidin and a biotinylated DNA donor has been tested to generate modified mice (Ma et al., 2017; Gu et al., 2018; Wang Z. et al., 2020). The sgRNA has also been engineered to insert a specific S1M aptamer of streptavidin and improve KI generation in human cells (Carlson-Stevermer et al., 2017). To ensure tight linkage, guide RNA and the ssODN donor have also been chemically linked to crRNA (Lee et al., 2017). Covalent attachment of the DNA donor to a Cas9 fused to porcine circovirus 2 Rep protein has been also described (Aird et al., 2018). Recently, Cas9-ssODN conjugates generated chemically or via an adaptor complementary to part of the ssODN, have been used to enhance HDR-mediated genome editing in mouse zygotes (Ling et al., 2020). Another team has used the RNP complex itself in human cells, without modifying it, but by inserting 16-nucleotide truncated Cas9 target sequences (tCTSs) in the linear dsDNA donor (Nguyen et al., 2020). This tCTSs allows RNP recognition without cleavage or use of a dCas9.

Repair Pathways

NHEJ is the most used pathway for DSB repair which produces indels alleles by ligase IV direct ends ligation through well-described mechanisms (Frit et al., 2019). When a DNA repair template is available at the DSB, other pathways may be induced, based on homology recognition. In contrast to NHEJ, other repair pathways, i.e., HR, microhomology-mediated end joining (MMEJ), and single-strand annealing (SSA), depend on a DNA template and are predominant in S/G2 phases. To favor KI, different strategies with small molecules have been used to arrest cells at different phase of the cycle (Yeh et al., 2019; Bischoff et al., 2020) but these strategies are difficult to apply to embryos. To favor HDR pathways predominant in S/G2, Cas9 can be degraded by the proteasome in G1 phase (Figure 3B and Table 4) by fusion to geminin degron (Gutschner et al., 2016; Charpentier et al., 2018; Lomova et al., 2019). Mouse two-cell embryos have a long G2 phase (Palmer and Kaldis, 2016) and open chromatin state that is favorable for KI model generation. Gu et al. (2018) have taken advantage of these features to develop the two-cell homologous recombination (2C-HR)-CRISPR in mouse, to increase large KI efficiency with WT Cas9 or Cas9 fused to monomeric streptavidin coupled with a biotinylated donor. This approach has been reproduced in mouse using Mb3Cas12a (Wang Z. et al., 2020).

All of these repair mechanisms except NHEJ have a key first step in common: DSB end resection (for a review, see Ranjha et al., 2018). The MRE11-RAD50-NBS1 complex must first be recruited to DSB ends, where it drives CtIP and other resection molecules (Ranjha et al., 2018). Exo1 can further resect DSB ends to produce 3′ overhangs that will be coated by replication protein A (RPA). For HR, RPA will later be replaced by Rad51 to promote strand exchange, whereas for SSA, RPA-coated resected ends are recognized by Rad52 for processing by end annealing. Factors unique for MMEJ are still unclear, but it requires short resection, necessitating the inhibition by RPA end coating. The size of this resection is linked to the repair pathway that is active. Short resection will leave a short sequence for homology-driven repair, as with MMEJ (5–25 bp) and SSA (>20 bp), whereas long resection will allow for long homology recognition, as with HR (>500 bp), and no resection will trigger NHEJ. These features drive the design of DNA donor homology arms (Yao et al., 2017).

To favor KI, small inhibitors of NHEJ or essential molecules carried to the DSB via gRNA, via Cas9 (Figure 3C and Table 4) have been used. NHEJ inhibitors have mainly been tested on cells (for reviews, see Yeh et al., 2019; Bischoff et al., 2020) and SCR7, an inhibitor of ligase IV, has led to KI increase in mouse (Maruyama et al., 2015; Singh et al., 2015) and rat embryos (Ma et al., 2016). Cas9 in fusion with a domain of CtIP has shown increased KI efficiency in human cells and rats (Charpentier et al., 2018; Tran et al., 2019). In the same way, the use of a MS2 aptamer on the gRNA to carry CtIP showed better KI efficiency in cells than other molecules (Nakade et al., 2018; Tran et al., 2019). Small molecules treatments to increase KI efficiency have been reviewed (Yeh et al., 2019; Bischoff et al., 2020). No data was reported to date in rats or mice, and only two studies showed that RS-1 enhances KI efficiency in rabbit (Song et al., 2016) and bovine embryos (Lamas-Toranzo et al., 2020). Finally, tests on cells and mouse embryos have shown that ExoI overexpression enhances KI activity (Aida et al., 2016).

CRISPR-Cas9 has a repair profile closer to the environmental DSB’s one compared to other nucleases with a high frequency of insertions of one nucleotide (Trimidal et al., 2019) and mainly repairs using out-of-frame indels (>70%) and microhomologies (Guo et al., 2018; Taheri-Ghahfarokhi et al., 2018).

One study on mouse embryos showed that multiple overlapping (at least > 5 bases) sgRNAs with ssODNs increase KI efficiency, probably by inducing shorter deletions (Jang et al., 2018) (Table 4). Several studies have designed plasmid donors with inserts flanked by gRNA recognition sites to excise it within a cell or zygote (Figure 2B and Table 4). This strategy may coordinate DSB and DNA donor availability at the cut site but can also create the same ends on both the DNA donor and the genomic DNA. It has led to increased KI in cells with various lengths of the homologous arms (Zhang et al., 2017), in mouse and monkeys embryos with HMEJ arms of 800 bp (Yao et al., 2017) or in cells and mouse embryos MMEJ homology arms of 40 bp (Aida et al., 2016). The results of these studies suggest that repair outcomes can be influenced or used to favor KI. Further experiments should be done in the rat to confirm these results.

Delivery Strategy Overview and System Optimization

Gene-editing efficiency by targeted-mutagenesis approaches, unquestionably depends on the delivery system used. In the following section, we describe the commonly used methods and recently developed strategies, which are summarized in Table 5. Latest methods are reported in Figure 1.

Microinjection

Since its development in mice in the early 1980s (Gordon et al., 1980; Palmiter et al., 1982), microinjection has become the most commonly used method to introduce different cargos into mouse and rat zygotes. Pronuclear injection, is a well-established method and allows the delivery of purified nucleic acid in any form (plasmid or dsDNA, lsDNA or ssODN, mRNA, gRNA, RNP) and any size (for review, see Giraldo and Montoliu, 2001). Nevertheless, the efficiency of the method is variable, depending in particular on the quality and size of DNA sources, and also the skill of the manipulator (Charreau et al., 1996b; Hirabayashi et al., 2001). In some cases, the pronucleus is hard to visualize and the flexibility of the oolemma and nuclear membranes, as in the rat, make delivery of DNA constructs more complex and invasive (Brinster et al., 1985; Charreau et al., 1996b). Cytoplasmic injection (CI) is an alternative to overcome these technical problems and has been described to deliver linearized DNA (Brinster et al., 1985), mRNA-encoding nucleases or sgRNA (Geurts et al., 2009; Tesson et al., 2011; Remy et al., 2014; Wang et al., 2014; Ménoret et al., 2015; Doe et al., 2018), allowing for a transient expression of nucleases and thus reducing off-target events. TALEN and CRISPR-Cas in the form of proteins can also be directly injected into the zygote pronucleus, cytoplasm, or both sequentially to achieve gene modifications (KO and/or KI). For proteins, efficiencies are higher for CRISPR and lower for TALEN than those observed with delivery in their DNA or mRNA forms (Table 5; Ménoret et al., 2015; Wang et al., 2015; Jung C. J. et al., 2017).

Electroporation

Delivery of ZFN, TALEN, or CRISPR-Cas9 nucleic acids or protein components using zygote electroporation enables generation of mice (Hashimoto and Takemoto, 2015; Qin et al., 2015; Hashimoto et al., 2016; Wang et al., 2016) or rats (Kaneko et al., 2014; Kaneko and Mashimo, 2015; Remy et al., 2017) carrying various genetic modifications (Table 5). These modifications include NHEJ-mediated indels (Kaneko et al., 2014; Hashimoto and Takemoto, 2015; Kaneko and Mashimo, 2015; Qin et al., 2015; Hashimoto et al., 2016; Wang et al., 2016; Remy et al., 2017), large segment deletions (Hashimoto et al., 2016; Wang et al., 2016), conditional KO (Miyasaka et al., 2018), double-KO (Teixeira et al., 2018), HDR-mediated precise nucleotide substitutions (Kaneko and Mashimo, 2015; Qin et al., 2015; Wang et al., 2016) or short sequence insertions using ssODNs (typically < 200 bp) (Hashimoto and Takemoto, 2015; Chen et al., 2016; Wang et al., 2016; Remy et al., 2017) and lsDNA (from 600 bp to 1.5 kb) (Miyasaka et al., 2018). In some studies, electroporation was done in mouse zygotes that were denuded of the zona pellucida (ZP) by a Tyrod’s acid treatment (Qin et al., 2015; Chen et al., 2016; Wang et al., 2016), without affecting the early development unlike data reported in rats (Okuyama and Funahashi, 2012). Electroporation also can be applied to mouse and rat frozen zygotes for efficient introduction of CRISPR RNP complexes, without affecting embryo viability or development (Nakagawa et al., 2018; Kaneko and Nakagawa, 2020).

Electroporation is thus an excellent alternative to microinjection for genome editing in mice and rats, with similar or sometimes higher success rates. It also allows the simultaneous processing of many zygotes in a short time (e.g., a batch of 50 zygotes in few seconds) without requiring expensive equipment and operators with extensive training and expertise. Nevertheless, a major limitation is the low efficiency or even absence of efficacy of this method for introducing a large DNA fragment (>500 bp) using dsDNA; even if entry into the zygote cytoplasm is achieved, the migration into the nucleus is blocked (Remy et al., 2017). LsDNA (up to 1.5 kb) has been described as an alternative (Miyasaka et al., 2018) but with lower KI yields than those observed using short ssODNs. These results have not always been reproducible, probably because of an inefficient migration into the zygote pronucleus (Remy et al., 2017).

Genome Editing via Oviductal Nucleic Acid Delivery (GONAD)

GONAD has the advantages of electroporation without requiring sacrifice of embryo donor animals or ex vivo embryo manipulation. In this technique, the RNP complex is directly injected into the oviduct of a pregnant mouse or rat, followed by in situ electroporation. It was first described to generate NHEJ using Cas9 mRNA (Takahashi et al., 2015; Gurumurthy et al., 2016, 2019b) and then the improved GONAD (iGONAD) was reported by Ohtsuka et al. (2018) in mice to efficiently generate indels mutations, large deletions, and ssODN and lsDNA-based KI (up to 1 kb), by replacing Cas9 mRNA by Cas9 RNP. Other groups have demonstrated the efficiency of iGONAD in rats for gene disruption and ssODN-based KI (Kobayashi et al., 2018; Takabayashi et al., 2018) and in mice by substituting Cas9 with AsCpf1 (Ohtsuka et al., 2018) (for review see Sato et al., 2020).

Viral Vectors

Since efficacy of KI using long DNA donors is still low, AAV vectors have been used to deliver DNA cargo. Although AAV has a reduced packaging capacity (∼5.2 Kb), that limits their use in delivering large functional components of TALEN and SpCas9, some studies have reported AAV-mediated delivery (mainly with the serotype 6) (Ellis et al., 2013) to generate mutations in mouse and rat zygotes, by using either a dual-AAV system carrying SpCas9 and sgRNA in separate vectors (Yoon et al., 2018) or sgRNA and a shorter Cas9 ortholog in an “all-in-one” vector (Edraki et al., 2019). Two groups have also managed to generate KI mice (Mizuno et al., 2018; Chen et al., 2019) and rats (Mizuno et al., 2018) by combining zygote electroporation to deliver the RNP complex and AAV transduction to introduce a large donor dsDNA (up to 4.9 kb) with efficiency ranging from 6 to 100% depending on the viral concentration (Mizuno et al., 2018). The method has not been rigorously compared with other methods and requires generation of high-purity AAV vectors.

Sleeping Beauty and PiggyBac transposons systems have been optimized to deliver CRISPR-Cas system into cells to increase gene editing efficiency and allow multi-allele targeting (Weber et al., 2015; Xu et al., 2017; Hu et al., 2018; Ye et al., 2019). Note, however, that CRISPR-Cas integration by transposon into the genome and its long-term expression in the cells could lead to off-target effects.

Rat Research Models and Applications

Today, it is possible to generate a broad range of genetically modified models, from simple KOs with precise mutations or gene overexpression, to conditional or reporter models. Below, we describe the main strategies to develop these models, which also are illustrated in Figure 4. Main resources available to find and develop rat models are available in Table 1. Table 6 describes models already developed to study genes of the immune system. Genome editing application in genetic disease studies is also explained and illustrated by the existing models listed in Table 7. Advantages of the rat as a model for those two applications are highlighted in this section.

FIGURE 4

TABLE 6

(A)

Immunology domainGene/genetic modificationGenomic tool usedReferencesPhenotype and rats vs. miceDepository or breeder company ID
Immuno-deficient modelsRag1/KO or Rag2/KOMeganuclease CRISPRZschemisch et al., 2012; Ménoret et al., 2013; Tsuchida et al., 2014; Chang et al., 2015; Noto et al., 2018T-B-NK+. Rag1/KO or Rag2/KO rats and mice show similar phenotypesRag2 KO; NBRP Rat #0894
Foxn1/KOCRISPRGoto et al., 2016T-B+NK+. Foxn1/KO rats and mice show similar immune and albino phenotypesRGD #10053598 #10053601
Il2rg/KOTALENs CRISPRMashimo et al., 2010; Samata et al., 2015; Kuijk et al., 2016T-B+/-NK-. Il2rg/KO rats and mice show similar phenotype#0585
Rag1/KO or Rag2/KO or Prkdc/KO or and Il2rg/KOZFNs TALEN CRISPRMashimo et al., 2012; Ménoret et al., 2018; He et al., 2019T-B-NK-. KO rats and mice show similar phenotypesIL2Rg-Rag2 KO; NBRP Rat #0895 RRG (TRIP)
Human SIRPa/TgBAC microinjectionGoto et al., 2016; Jung et al., 2016; Yang X. et al., 2018; Ménoret et al., 2020↓ phagocytosis human cells. hSIRPa/Tg rats and mice show similar phenotype
Rag1/KO or Rag2/KO or Prkdc/KO or +Il2rg/KO+human SIRPa/TgZFNs, TALENs, CRISPRYang X. et al., 2018; Ménoret et al., 2020T-B- NK-, ↓ phagocytosis human cells Similar phenotypes in KO and Tg rats and corresponding mice as well in KO NOD mice which have a spontaneous mutation in SirpaRRGS (TRIP)
Ighm, Iglc, Igkc /KOZFNsMénoret et al., 2010; Panzer et al., 2018T+B-NK+. Ighm/KO and IgKc/KO rats and mice show similar phenotypeIgM KO (Ligand)
Human Ig heavy and/or light chain loci/TgBAC microinjectionOsborn et al., 2013; Ouisse et al., 2017; Xu et al., 2018Production of human IgG binding domains for the generation of fully human mAbs Human Ig heavy and/or light chain loci/Tg rats and mice show similar phenotypeLigand
C3/KOCRISPRXu et al., 2018Role of complement in neuropathy during chemotherapy model not available in mice because of defects in complement activation in miceRGD #19165133
CDs and membrane moleculesHLA-B27 + hb2m/TgDNA microinjectionHammer et al., 1990HLA-B27 + hb2m/Tg rats are a much better model of spondyloarthropathy than are HLA-B27 + hb2m/Tg miceHLA-B27 RGD #7387221
hCD55 + hCD59/TgDNA microinjectionCharreau et al., 1996a, 1999hCD55 + hCD59/Tg rat hearts were heterotopically grafted in primates Not possible for corresponding mice/
hCD46/TgDNA microinjectionNiewiesk et al., 1997Model of measles infection and complement control. hCD46/Tg rats and mice show similar phenotypes/
hCD4/hCCR5/TgDNA microinjectionKeppler et al., 2002hCD4/hCCR5/Tg rats are a closer model to human hCD4/hCCR5/Tg mice exhibited very little or no productive infection/
hFasL/TgDNA microinjectionTesson et al., 1999; Bouchet et al., 2002Expression in endothelial cells Model not available in mice/
hCD21/TgDNA microinjectionYang et al., 2003Model of EBV infection hCD21/Tg rats and mice show similar phenotypes/
hCD64/TgDNA microinjectionvan Vuuren et al., 2006Depletion of macrophages a CD64-immunotoxin and inhibition of arthritis Transgenic rats and mice have similar expression/
hP2Y2R/TgLentiviral vectorAgca et al., 2009Tissue inflammation, increase in certain leukocyte populations No hP2Y2R transgenic mouse line generated/
Cd247 (CD3 ζ chain)/KO*ZFNsRudemiller et al., 2014Fewer kidney lesions in a model of hypertension similar immune phenotype in Cd247/KO rats and mice in T cell signaling and depletion of T cells No model of hypertension analysis in Cd247/KO miceRGD #6484582 #6484564 #6484568
Tlr4/KOTALENsFerguson et al., 2013Tlr4/KO rats and mice show similar decreased pro-inflammatory cytokine secretion upon lipopolysaccharide stimulationRRRC #694
Cd40/KO*CRISPRHaller et al., 2017Cd40/KO rats have fewer kidney lesions in a model of hypertension than mice No model of hypertension analysis in Cd40/KO miceRRRC #840
Adora2b/KO*ZFNsNayak et al., 2015Adora2b/KO rats but not mice showed decreased pro-inflammatory cytokine secretion and less cardiac and renal injury/fibrosis in response to hypertensionRGD #6484715
Clec1/KOZFNsLopez Robles et al., 2017Clec1/KO rats but not mice showed increased inflammatory responses by DCs(TRIP)
Cd59/KOCRISPRYao and Verkman, 2017bCd59/KO rats and not mice (showed mild hemolytic anemia and a faithful model of neuromyelitis opticaRGD #13792606
Kv1.3/KOZFNsChiang et al., 2017Kv1.3 KO rats are a better and closer model to human. Mouse T cells, unlike rat or human T cells, co-express additional redundant Kv1 channels/
Cytokines/secreted products and their receptorsAvp/TgDNA microinjectionJessop et al., 1995A model for the study of thymic arginine vasopressin in T cell differentiation No analysis of AVP expression in thymus of transgenic mice/
Ifng/TgDNA microinjectionEgwuagu et al., 1999a,bIFNgamma expression in the eye in a model of uveitis Conflicting results: IFN-g exacerbates uveitis in the rat and confers protection in the mouse/
TGFb1/KO*ZFNsChen et al., 2013Rats and mice TGFb1/KO with a T cell-specific deletion of the Tgfb1 gene developed lethal immunopathology in multiple organsRGD #5131989
Il22bp/KOCRISPRMartin et al., 2016IL22BP protective in models of colitis and psoriasis(TRIP)
Ifnar1/KOCRISPRQaisar et al., 2017Absence of IFN-I responses Ifnar1/KO rats and mice not analyzed in the same wayRGD #12910493 #12910494
Il15/KOZFNsRenaud et al., 2017A genetic model of NK-cell deficiency in rats Il15/KO rats and mice show similar phenotypesRRRC #769
Tbet/KOZFNsMa Z. G. et al., 2018T-bet can direct Th1 lineage commitment Tbet/KO rats and mice show similar phenotypes/
Csf1r/KOES cellsPridans et al., 2018Absence of most macrophages in most tissues. Macrophages effects in development of multiple organ systems in rats were distinct from those reported in mice/
Csf1r-GFP/KIDNA microinjectionIrvine et al., 2020Csf1r-GFP/KI rats and mice show similar phenotypes/
Intracellular moleculesHMOX1/TgDNA microinjectionBraudeau et al., 2003HMOX1/Tg only described in rats/
Hmox1/KOZFNsAtsaves et al., 2017Hmox1/KO rats and mice show similar phenotype with generalized inflammation and kidney lesions and lethality
Ian5/TgPAC microinjectionMichalkiewicz et al., 2004A model that shows the essential role of IAN5 for lymphoid development. IAN5 rescues lymphopenia in BB rats with a mutation in the Ian5 gene/
Notch1/TgDNA microinjectionvan den Brandt et al., 2005Blockade of thymic development and T cell lymphopenia Notch1/Tg rats and mice show similar phenotypes/
Selenoprotein M/TgDNA microinjectionHwang et al., 2008Maintenance of a high level of antioxidant status Selenoprotein M/Tg rats and mice show similar phenotypes in brain/
Bcl2/TgDNA microinjectionIscache et al., 2011Increased B cells and immunoglobulins Bcl2/Tg rats and mice show similar phenotypes/
Cyp2j4/KOZFNsBehmoaras et al., 2015Cyp2j4 determines a profibrotic macrophage transcriptome Implications in various inflammatory conditions Similar results in Cyp2j4/KO rats and miceRGD #12904679
Ahr/KOZFNs TALENs CRISPRHarrill et al., 2013; Phadnis-Moghe et al., 2016A variety of T and B cell alterations. Ahr/KO rats are more analyzed than Ahr/KO mice Rats showed other organ alterationsRGD #12903250 (Horizon Discovery); RGD #12903272 (Horizon discovery) RGD #13838845 (not available)
RRRC#831 (CRISPR) RGD #15090819 #15090817 (TALEN, not available)
Aire/KOZFNsOssart et al., 2018Autoimmunity in several organs Aire/KO rats not observed in Aire/KO mice(TRIP)
Prox1 promoter-EGFP/TgBAC microinjectionJung E. et al., 2017Visualization of all lymphatic vessels Prox1 promoter-EGFP/Tg rats and mice show similar phenotypes/
Eogt/KOTALENsHao et al., 2018O-GlcNAc glycosylation deficiency with defect in Notch signaling in autoimmune hepatitis Eogt/KO rats and mice show similar phenotypes/
Paraoxonase 1/KOCRISPRBai et al., 2018Thymocyte blockade at the CD4/CD8 double-negative to double-positive transition stage No mouse model reportedRGD #12790692 #12790698 #12790695
S100A8 transgenic rats/TgDNA microinjectionOkada et al., 2018Altered macrophage function in a colitis model S100A8/Tg rats and mice show similar phenotypes/

(B)

Gene/KO

MiscellaneousSnx25/KO, Axl/KO*, Cd14/KO*, Cd55/KO, Cd226/KO, Cyba/KO*, Cybb/KO*, Fyn/KO*, Gpr183/KO*, Ifnar1/KOUnpublished, available at MCW RGD

Genetically engineered rat models for genes of the immune system.

*Performed in the Dahl/S strain. WCM RGD, Wisconsin Medical College Rat Genomic Database. EBV; Epstein Barr virus.

TABLE 7

System/organ affectedHuman genetic diseaseGene/genetic modificationGenomic tool usedReferencesRats vs. miceDepository or breeder company ID
Cardiovascularpulmonary arterial hypertensionBMPR2/KOZFNRanchoux et al., 2015; Hautefort et al., 2019; Manaud et al., 2020Bmpr2KO rats showed pulmonary vascular cell phenotypes closer to human patients than inBmpr2 KOmiceRGD#38501086 (not available) RGD #14975305 #14981588
Primary pulmonary hypertension 4 (PPH4)Kcnk3/KOCRISPR-Cas9Lambert et al., 2019Rats have a Kcnk3 gene as humans do but mice do not/
Atrial fibrillation, familial, 18 (ATFB18)Myl4/KOCRISPR-Cas9Peng et al., 2017This model reproduces the human disease NoMyl4/KO mouse model is reported/
Familial hypertrophic cardiomyopathy and myocardial genetic diseasesMyh7b/KOCRISPR-Cas9Chen et al., 2020This model reproduces the human disease No Myh7b/KO mouse model is reported/
Danon diseaseLamp2/KOTALENWang et al., 2017; Ma S. et al., 2018Lamp2-KO rats could be a more valuable animal model for DD than Lamp2/KO miceRGD #13703119
Nervous systemEpileptic encephalopathy, early infantile, 63 (EIEE63)Cplx1/KOCRISPR-Cas9Xu et al., 2020Cplx1/KO rats and mice show different phenotypes Rat model reproduces the disease better
Dystonia 25 (DYT25)Gnal/KOCRISPR-Cas9Yu-Taeger et al., 2020Gnal/KO rats show early symptoms as in patients not seen inGnal/KO mice/
Cockayne syndromeErcc6/KO (KI R571X)CRISPR-Cas9Xu et al., 2019The brain is more affected in CSB-deficient rats vs. mice/
Neonatal hydrocephalusL1cam/KOCRISPR-Cas9Emmert et al., 2019bL1cam/KO rats and mice show similar phenotypes similar to those of patientsRRRC #850 + 851
Ccdc39/KI point mutation c.916+2TCRISPR-Cas9Emmert et al., 2019aCcdc39KO rats and mice show similar phenotypes Rats are more suitable for imaging and surgical experiments/
SchizophreniaDrd2/KI reporterCRISPR-Cas9Yu et al., 2016Inter-species difference of DRD2 expression between rats and mice/
Amyotrophic lateral sclerosisFus/KI point mutation R521CCRISPR-Cas9Zhang T. et al., 2018Fus/KI rats and mice show an altered phenotype with subtle differences/
Neurofibromatosis type 1Nf1/KOCRISPR-Cas9Moutal et al., 2017; Dischinger et al., 2018Nf1/KO rats have a more pronounced phenotype than Nf/ KO mice/
Cystic leukoencephalopathyRNaseT2/KO BigDelCRISPR-Cas9Sinkevicius et al., 2018No RNaseT2/KO mice reportedRGD #13781890, not available
Epileptic encephalopathy, early infantile, 24 (EIEE24)Hcn1/KOTALENNishitani et al., 2019Hcn1/KO rats but not Hcn1/KO mice exhibited epilepsyNBRP Rat #0821 #0820 #0819 #0822
MECP2-related severe neonatal encephalopathy, Rett-like syndrome (RTT)Mecp2/KOZFNEngineer et al., 2015Mecp2/KO rats displayed more symptoms of RTT than KO miceRGD #11567272; Horizon Discovery
Fragile X syndrome/Asperger syndrome, X-linked, 1 (ASPGX1)Fmr1/Nlgn3/DKOZFNHamilton et al., 2014Similar phenotype for Fmr1/Nlgn3/DKO rats and mice. Rats more suitable than mice for analysis of complex behavioral and social activitiesRGD #11568700; Horizon Discovery; Nlgn3) RGD #11568040; Horzon Discovery; Fmr1 KO; RGD #11553873
Phelan-McDermid syndromeShank3/KO Shank3/KO BigDelZFN CRISPR-Cas9Harony-Nicolas et al., 2017
Song et al., 2019
Shank3-KO rats showed normal social interaction and self-grooming behaviors whereas Shank3-KO mice do not/
Angelman syndromeUbe3A/KO BigDelCRISPR-Cas9Dodge et al., 2020As in patients, Ube3A/KO ratsbear a large deletion of the gene whereasUbe3A/KOmice not/
Intellectual deficiency from genetic originCplx1/KOCRISPR-Cas9Xu et al., 2020Cplx1/KO rats showed ataxia, dystonia, exploratory deficits, anxiety and sensory deficits but normal cognitive function/
Essential tremorAspa and Hcn1/KOTALENNishitani et al., 2020Aspa and Hcn1/KO rats developed tremorNBRP Rat #0806 #0805 (Aspa KO); Cf Table 6pour Hcn1 KO
Ataxia-telangiectasiaAtm/KOZFNQuek et al., 2017Atm/KO rats show cerebellar atrophy and neurodegeneration which are poorly recapitulated in Atm/KO miceNBRP #0627 #0649
Autism spectrum disorderCntnap2/KOZFN CRISPRScott et al., 2018Cntnap2/KO rats better recapitulate certain behavioral symptoms thando Cntnap2/KO miceRGD #11568646; Horizon Discovery; RGD #25330087 (CRISPR);
Shank2/KOZFNModi et al., 2018Shank2/KO rats show behavior and electroencephalography abnormalities not seen inShank2/KO mice/
Canavan diseaseAspa/KOTALENNishitani et al., 2016Aspa/KO rats and mice show similar phenotypes similar to those of patientsNBRP Rat #0806 #0805
Familial focal epilepsyDepdc5/KOTALENMarsan et al., 2016Homozygous Depdc5/KO rats and mice have similar phenotypes but heterozygous Depdc5/KO rats and not mice had altered neuron excitability and firing patternsNBRP Rat #0739
Parkinson’s diseaseLrrk2/KOZFNNess et al., 2013LrrK2/KO rats and mice show similar phenotypes similar to those of patientsRGD #7241053; Lrrk1/Lrrk2 KO Horizon Discovery RGD #7241047; Lrrk1/Lrrk2 KO Horizon Discovery RGD #7241050; Lrrk2/KO; Horizon discovery RGD #7241056; Lrrk2/KO; Horizon Discovery
Alpha-synuclein autosomal dominants forms of Parkinson’s diseaseSNCA-A53T-A30P/TgDNA microinjectionLelan et al., 2011SNCA-A53T transgenic rats and mice have similar phenotypes/
Familial Parkinson’s diseaseDJ-1 and Pink1/KOZFNsSun et al., 2013DJ-1 and Pink1/KO rats and mice show similar phenotypes similar to those of patientsDJ-1 RGD #7241054 + RGD #7241049 Pink1/KO; Horizon discovery
congenital generalized lipodystrophyBscl2/KOENUEbihara et al., 2015Bscl2/KO rats have brain reduction and azoospermia as in patients, Bscl2/KO mice do not reproduce these pathologiesNBRP Rat #0763
Autosomal-dominant lateral temporal lobe epilepsyLGI1/KOENUBaulac et al., 2012Rats reproduce the human disease and are complementary to the KO miceNBRP Rat #0656
GastrointestinalHereditary tyrosinemia type IFah/KOCRISPRZhang et al., 2016Fah/KO rats developed liver fibrosis and cirrhosis, not observed in Fah/KO mutant miceRGD #10002791 (TALEN; PhysGenKO) RGD #14398825 (CRISPR) RGD #14398828 (CRISPR
Hirschsprung diseaseEdnrb/KOCRISPR-Cas9Wang et al., 2019aEdnrb/KO rats in a particular strain caused embryonic lethality and megacolon as in certain strains of Ednrb/KO mice/
Rotor syndromeOATP1B2/KOCRISPR-Cas9Ma et al., 2020OATP1B2/KO rats reproduce the hyperbilirubinemia observed in patients/
Atypical hereditary non-polyposis colorectal cancerMsh6/KOENU mutagenesisvan Boxtel et al., 2008Msh6/KO develop a spectrum of tumors/
familial colon cancerApc/KOENU mutagenesisAmos-Landgraf et al., 2007Apc/KO recapitulates pathology better than mouse modelsRRRC#00782 + RRRC#718 (Amos-Landgraf) NBRP Rat #0443
MuscleMuscular dystrophy (Duchenne and Becker forms)Dmd/KO and BigDelTALENs and CRISPR-Cas9Larcher et al., 2014; Nakamura et al., 2014Dmd/KOrats better recapitulate the pathology than Dmd/KO miceNBRP Rat #0779 NBRP Rat #0780 NBRP Rat #0781 RGD #12880037; (TRIP)
Myostatin-related muscle hypertrophyMstn/KOZFNMendias et al., 2015; Gu et al., 2016In contrast to Mstn/KO mice, Mstn/KO rats showed higher muscle fiber contractibility and lifelong increase in weight in male but not femaleRGD #5131964 (PhysGen KO) RGD #5143985 (PhysGenKO) RGD #5131954 (PhysGen KO)
LungCystic fibrosisCftr/KOZFNTuggle et al., 2014Cftr/KO rat and mice show similar phenotypes that are mostly similar to those in patients. Rats but not mice have tracheal and bronchial submucosal glands.RGD #14392817 (SAGE, not available) RGD #14392813; Horizon discovery RGD #14392815; Horizon discovery
Cftr/KO and DF508CRISPR-Cas9Dreano et al., 2019Cftr/KO and DF508rats and mice show similar phenotypes. DF508rats and mice show phenotypes that are milder than in their Cftr/KO counterparts. Rats but not mice have tracheal and bronchial submucosal glands/
CFTR/KI and G5551DZFNBirket et al., 2020CFTR/KI G5551D humanized rats display normalization of several pulmonary parameters after ivacaftor treatment/
EndocrineGlucocorticoid resistanceNr3c1/cKOCRISPR-Cas9Scheimann et al., 2019Nr3c1/cKO in CNS specific brain regions using injection of AAV-Cre vectors not possible in mice/
Estrogen resistance (ESTRR)Esr1/KOandEsr2/KOZFNRumi et al., 2014; Khristi et al., 2019Esr1/KOrats and mice show similar phenotypes similar to those of patientsRRRC#701 (Esr1 KO) RRRC#849 (Esr1 KO) RRRC#742 (Esr2 KO) RRRC#677 (Esr2 KO)
Congenital hypothyroidismTshr/KOCRISPR-Cas9Yang et al., 2018Tshr/KO rats and certain strains ofTshrKO mice show similar phenotypes similar to those of patients/
Allan-Herndon Dudley-syndromeMct8/KOCRISPR-Cas9Bae et al., 2020Mct8/KO rats showed growth and reduced sperm motility and viability Mct8/KO mice did not show growth retardation/
MetabolicCongenital leptin deficiencyLep/KOCRISPR-Cas9Guan et al., 2017Lep/KO rats and mice show similar phenotypes similar to those of patients/
Leptin receptor deficiencyLepr/KOCRISPR-Cas9 and TALENBao et al., 2015; Chen Y. et al., 2017Lep/KO rats and mice show similar phenotypes similar to those of patients/
AceruloplasminemiaCp/KOCRISPR-Cas9Kenawi et al., 2019Cp/KO rats show similar plasma biochemical alterations and profile of iron overload in liver and spleen as in humans Cp/KO mice showed different resultsRGD #38501060 #38501061 #38501059; not available
Multiple mitochondrial dysfunctions syndrome, among them pulmonary artery hypertensionNfu1/KI point mutation G206CCRISPR-Cas9Niihori et al., 2020Nfu1/KI point mutation G206C is only reported in rats. The model shows both mitochondrial dysfunction, and pulmonary artery hypertension with more prevalence in females than in males, as in patients/
Generalized arterial calcification of infancy and pseudoxanthoma elasticumAbcc6/KOZFNLi et al., 2017Abcc6/KO rats allowed ex vivo perfusion of liver and spleen and definition of the liver as the primary site of the diseaseRGD #13792683 #13792682 #10413850 #10413852 #10413854 #10413858 #10413856
Diabetes mellitus, non-insulin-dependent, 5 (NIDDM5)AS160 (TBC1D4)/KOCRISPR-Cas9Arias et al., 2019AS160-KOrats and mice showed similar alterations in whole body assessment Rats’ bigger size allowed measurements using single myofibersRGD #38596327
multiple mitochondrial dysfunctions syndromeIsca1/KI-mCherry-CreCRISPR-Cas9Yang et al., 2019Developmental block in embryos at 8.5 days Not reported in mice/
Primary hyperoxaluria type 1 (PH1)Agxt/KOCRISPR-Cas9Zheng et al., 2020Agxt/KO rat model better recapitulate the disease than the Agxt/KOmice/
Agxt/KI mutation D205NCRISPR-Cas9Zheng et al., 2018Agxt/KI mutation D205N model recapitulates the disease in rats Not reported in mice/
Familial hypercholesterolemiaLdlr-ApoE/DKOCRISPR-Cas9 and CRISPR-Cpf1Zhao et al., 2018; Lee J. G. et al., 2019DoubleLdlr-ApoE/DKO rats better recapitulate the pathology than do doubleLdlr-ApoE/DKO mice/
DwarfismGhsr/Tg Ghsr/KODNA microinjection ENU mutagenesisFlavell et al., 1996
Shuto et al., 2002
Dwarfism in rats as in GshR/KO mice Analysis of the role of GSHR in behavioral pathologies including eating disordersRGD #12910127 RGD #1642278 (PhysGen) RRRC#421RRRC #405
Ghsr/KOCRISPR-Cas9Zallar et al., 2019RRRC#827
Hyaline fibromatosis syndromeAntxr2/KOCRISPR-Cas9Liu X. et al., 2017Antxr2/KO rats and mice show similar phenotype Antxr2/KO rats did not develop hypertension/
Obesity (OBESITY)Mc3R-Mc4R/DKOCRISPR-Cas9You et al., 2016DoubleMc3R-Mc4R/DKO rats better recapitulate the pathology than do doubleMc3R-Mc4R/DKO miceRGD #13825199 (Mc4R KO) (Hubrecht Laboratory, Centre for Biomedical Genetics, 3584 CT Utrecht, The Netherlands. Hera Biolabs, Taconic.)
Congenital hyperinsulinismSur1/KOTALENZhou et al., 2019Sur1/KO rats and mice reproduce the disease Rats showed a particular glucose control profile/
Fumarase deficiencyFh/KOTALENYu et al., 2019Fh/KO rats and mice show similar phenotype and reproduce the diseaseRGD #13792795 #13792794 (not available)
Fabry diseaseGla/KOCRISPR-Cas9Miller et al., 2018Gla/KO rats better recapitulate the pathology than do Gla/KO miceRGD #10054398
Oculocutaneous albinism type 1Tyr/KOTALENMashimo et al., 2013Tyr/KO rats and mice show similar phenotype and reproduce the diseaseNBRP Rat #0666
Wolfram syndromeWfs1/KOZFNPlaas et al., 2017Wfs1/KOrats better recapitulate the pathology than Wfs1/KO mice/
NephrologyFocal segmental glomerulosclerosis 2 (FSGS2)Trpc6/KO BigDelCRISPR-Cas9Kim E. Y. et al., 2018Trpc6/KO rats and mice were protected from FSGS2RGD #11553908 #11553912 #11553902
C3 glomerulopathyC3/KO C3/KOZFN CRISPR-Cas9Negishi et al., 2018) Xu et al., 2018C3/KO rats and mice display a similar phenotype Most mouse strains have a defective complement system downstream of C3/ RGD #19165133
REN-related kidney diseaseRen/KOZFNMoreno et al., 2011Rats like humans have 1 copy of the Ren gene whereas mice have 2 copies Rats faithfully recapitulate the diseaseRGD #4139880 (PhysGen)
OphthalmologyAutosomal dominant congenital stationary night blindness and retinitis pigmentosaRho s334ter/TgDNA microinjectionLiu et al., 1999This is a unique widely used model of this disease
Retinitis pigmentosa 85 (RP85)Ahr/KOZFNHarrill et al., 2013Ahr/KO rats and mice showed distinct phenotypes in the eye, liver and kidneys during normal development and toxic responsesCf Table 6
Autosomal dominant congenital stationary night blindnessPde6b/KOCRISPR-Cpf1Yeo et al., 2019Pde6b /KO rats and mice reproduce the disease Slower progression and larger anatomic architecture in rats are advantages versus the mouse model/
Familial exudative vitreoretinopathyLrp5/KOCRISPR-Cas9Ubels et al., 2020Lrp5/KOrats show retinal and bone abnormalities Similar phenotype inLrp5/KOmice/
CancerLi-Fraumeni syndromeTp53ES ZFNMcCoy et al., 2013Tp53/KO rats developed more diverse tumors and more frequently than Tp53/KO miceRGD #12904897 (Horizon Discovery) RGD #11553886NBRP Rat #0726 RRRC #00485 (ES)
Immune and hematological systemsVon Willebrand diseaseVwf/KO BigDelCRISPR-Cas9Garcia et al., 2020Vwf/KO rats and mice display a similar phenotypeRGD #18182946 #39128242 #18182944
Hemophilia AF8/KOZFNNielsen et al., 2014F8/KO rats and mice show similar phenotypeRGD #11531094 (Novo Nordisk, Maaloev, Denmark)
F8/KO (gene inversion)CRISPR-Cas9Shi et al., 2020RGD #13800746
ALSPCsf1r/KOES cellsPridans et al., 2018Csf1r/KO rats showed a more severe phenotype than patients and Csf1r/KO mice an even stronger one/
SCIDRag1/KOMeganucleases and CRISPR-Cas9Tsuchida et al., 2014; Zschemisch et al., 2012; Ménoret et al., 2013Rag1/KO rats and mice show similar phenotypeCf Table 6
Rag2/KOCRISPR-Cas9Liu Q. et al., 2017; Noto et al., 2018Rag2/KO rats and mice show similar phenotypeCf Table 6
Prkdc/KOCRISPR-Cas9Mashimo et al., 2012; Ma et al., 2014aPrkdc/KO rats and mice show similar phenotypeCf Table 6
X-linked SCIDIl2Rg/KOZFN, TALEN and CRISPR-Cas9Mashimo et al., 2012; Samata et al., 2015; Kuijk et al., 2016; Ménoret et al., 2018Il2rg/KO rats and mice show similar phenotypeCf Table 6
APECEDAire/KOTALENOssart et al., 2018Aire/KO rats showed a more pronounced phenotype than Aire/KO miceCf Table 6
Agammaglobulinemia non-Bruton typeIghm/KOTALEN CRISPR-Cas9Ménoret et al., 2010; Panzer et al., 2018Ighm/KO rats and mice show similar phenotypeCf Table 6

Genetically modified rat models of human genetic diseases.

Strategies to Develop Genetically Modified Models

Single, Multiple or Large Modifications

A KO model can be efficiently generated through out-of-frame indels (Figure 4A) by careful design of gRNA. Some of these will lead to a reading frame shift with a premature termination codon followed by mRNA degradation and no translation of the protein. All mechanisms of premature termination codon followed by mRNA degradation are not fully understood on mammals and exceptions exist (Dyle et al., 2020). Most often, the CRISPR-Cas system is designed to target one of the first exons of the gene, but another approach is to generate a promoter-less allele that can lead to a more severe phenotype than the KO model (El-Brolosy et al., 2019). In that case, KO can be easily confirmed by detection at the mRNA level. This strategy has not been used commonly, but it could be particularly useful in the rat, for which protein detection tools are limited. Mainly, these models have been developed by nuclease DSB induction, but adenosine-base editor is also an alternative with mouse and rat (Ma Y. et al., 2018; Yang L. et al., 2018; Wang X. et al., 2020).

Multiple KO models can be generated using multiple RNP complexes (Ma et al., 2014a,b), but to avoid large deletions, they should not be located on the same chromosome (Figure 4A). Translocation between chromosomes is also a risk that can be reduced using ssODNs and different Cas (Bothmer et al., 2020). Outcomes analysis for multiple KO can be challenging and should be carefully considered when designing CRISPR tools.

For large genomic KOs involving several consecutive genes, two DSBs can be induced by designing gRNA on both sides of the region of interest (Figure 4A). If both DSBs occur at the same time, the result will be a large deletion of this region of interest. To our knowledge, the biggest deletion achieved to date in rats is 24,499 Kb (Birling et al., 2017).

ssODNs that include a STOP codon can be used to create a nonsense mutation and inactivate a specific gene (Figure 4B). The rate of KI is usually lower than the frequency of indels, but because both the KI and a large fraction (>70%) of indels (Guo et al., 2018; Taheri-Ghahfarokhi et al., 2018) induce out-of-frame mutations, this increases the chance of obtaining a KO animal.

ssODNs containing a mutation observed in a human disease have been used to generate animal models (Figure 4B) such as for cystic fibrosis (Dreano et al., 2019; Table 7). The use of ssODNs will allow inclusion of specific features, such as restriction sites, to facilitate KI genotyping. Base- and prime-editing, are particularly fitting tools for generating mutations. Base editing has already been applied in the rat (Yang L. et al., 2018) but prime editing only in the mouse for now (Liu Y. et al., 2020).

Gene Overexpression

Overexpression of the gene of interest might be useful for gaining a better understanding of its role. The gene can be overexpressed by its insertion with its promoter or with an ubiquitous promoter (Figure 4C, right panel). In the past, this effect has been achieved through transgenesis, but expression of a randomly inserted cassette is affected by the genomic locus where it is inserted. Advances in genome-editing tools have made it possible to target a permissive locus, also called a “safe harbor,” to overcome this issue (Saunders, 2020). Rosa26 and Hprt are the most commonly used safe harbors that have been targeted in rat embryos (Kobayashi et al., 2012; Remy et al., 2014).

Humanized animal models are of great value to better study human diseases by insertion of the human gene into the animal genome (Figure 4C, right panel). For some projects, cDNA of the gene of interest is enough and can be used to generate humanized models, as it was done for a humanized model of cystic fibrosis (Birket et al., 2020).

Conditional Models

Site-specific recombinase systems (SSR) are used for conditional excision or inversion of the targeted site. Their application requires the generation of two lines, one expressing the specific SSR and one displaying the two specific DNA sites flanking the locus of interest (Figure 4C, lower panel). These lines are then crossed to combine both mutations in a single animal line (Birling et al., 2009). The Cre/lox system is the most commonly used SSR system option for mouse conditional models, even though other variants and other systems (FLP-FRT, Dre-rox, Nigri-nox, and others) have been used and combined. To the best of our knowledge, Cre/lox is the only SSR system that has been used to generate conditional rat models. The use of targeted nucleases permits precise insertion of Cre behind the endogenous promoter (Figure 4C, lower panel), allowing reliable and relevant tissue or cell specific expression of Cre (for a review see Kim H. et al., 2018). To achieve temporal control of the gene of interest, drug-inducible systems are used (Navabpour et al., 2020). Fusion of Cre with estrogen receptor 2 (Cre-ERT2) leads to sequestration of Cre in the cytoplasm, and the addition of tamoxifen at a certain time point induces Cre-ERT2 translocation into the nucleus, allowing Cre to recombine loxP sites (Figure 4C, lower panel). These animal lines should be carefully bred and analyzed to limit toxicity and leakage (Song and Palmiter, 2018). Cre/CreERT2 models characterization at some point requires the use of Cre reporter models expressing a floxed STOP before a reporter gene (Figure 4C, lower panel). After Cre recombination, reporter expression is turned on and specific expression can be characterized. Validation of loxP models requires Cre or CreERT2 models (Figure 4C, lower panel). The observed phenotype will then be specific to the Cre expressing tissues and the loxP line tested.

Other systems have been used in mouse and rat for spatiotemporal control. Tetracycline (Tet) on or off systems, like SSR systems, require two lines, one carrying a Tet (or doxycycline, its derivative)-sensitive transcriptional activator and one on the targeted locus carrying the Tet-responsive promoter element (Kim H. et al., 2018). The use of Tet systems for the development of transgenic mice has been reviewed previously (Sun et al., 2007) and applied to the generation of inducible rat models (Tesson et al., 1999; Table 6). For cell specific depletion, the diphtheria toxin receptor can be expressed under a cell specific promoter such as CX3CR1 for microglia depletion in rat (Vichaya et al., 2020).

Rat research is long way behind mouse studies for development of conditional models because of the decades-long use of mouse ES cells (Ramírez-Solis et al., 1995). Use of ES cells remains time consuming in mouse and technically challenging in rat. Efforts have currently been deployed to generate conditional models using CRISPR-Cas9 with all the difficulties previously discussed for large and complex insertion. Overcoming these hurdles is a major issue for both mouse and rat but it is required for the rat. A multicenter study in mice showed that loxP KI using two ssODNs and RNP complexes is less efficient than using a single long DNA donor (Gurumurthy et al., 2019a). Sequential insertion of each loxP ssODN by microinjection and electroporation of one and two-cell embryos has also been tested but is technically demanding (Horii et al., 2017).

Reporter and Tagged Rat Models

Transgenic ubiquitous reporter models have been generated with different fluorophores and promoters. The most developed and used models are animals that express fluorogenic proteins in different tissues, such as CAG-GFP rats (Remy et al., 2014; Ménoret et al., 2015). Today, with CRISPR-Cas systems, a reporter gene or a tag can directly be inserted at the end of the reading frame by replacing the stop codon of the endogenous locus of interest (Figures 4B,C, upper left panel). A fusion protein or two separated molecules expressed at the same level can be generated using self-cleaving peptides. Our team has generated a KI IL22bp-T2A-eGFP rat model to identify cells expressing this gene (submitted). For advanced reporter models, conditional tools can be used and combined, in particular for genetic lineage tracing (Liu K. et al., 2020).

Models to Study Genes of the Immune System

In general terms, rats share more immune characteristics with humans than mice do (Wildner, 2019). As an example, complement levels in humans and rats are comparable (Ong and Mattes, 1989; Ménoret et al., 2020), whereas in most inbred mouse strains, they are undetectable or very low because of different genetic mutations (Ong and Mattes, 1989; Wetsel et al., 1990; Shultz et al., 1995).

The roles of genes identified in different immune pathophysiological processes, as well as others involved in normal immune responses, also have been analyzed and are listed in Table 6. For the sake of space and relevance of the rat model, only some of these generated genetically modified models are described in more detail below.

Immunodeficient Rat Strains

KO of genes involved in early rearrangements of immunoglobulin in B cells and of the T cell receptor genes in T cells, such as Rag1 (Zschemisch et al., 2012; Ménoret et al., 2013; Tsuchida et al., 2014), Rag2 (Kuijk et al., 2016; Liu Q. et al., 2017; Noto et al., 2018), and Prkdc (Mashimo et al., 2012; Ma et al., 2014a; Beldick et al., 2018) have resulted in defective development of B and T cells (Tables 6, 7). KO of the gamma chain receptor of the IL-2 receptor (Il2rg) results in defects of differentiation of T, B, natural killer (NK), and innate lymphoid cells (Mashimo et al., 2010; Samata et al., 2015; Kuijk et al., 2016). Additionally, rat lines combining several genetic modifications, such as with the Rag1, Rag2, Il2rg, Prkdc, and Foxn1 genes, have been developed (Mashimo et al., 2012; Goto et al., 2016; Ménoret et al., 2018; He et al., 2019). Transgenic rats for human SIRPa to inhibit phagocytosis in human cells have been described in recent years (Goto et al., 2016; Jung et al., 2016; Yang X. et al., 2018; Ménoret et al., 2020). These rats have been used in humanization of their immune system and/or other tissues in transplantation and regenerative medicine settings (for a review, see Adigbli et al., 2020) and in cancer research (He et al., 2019). In these models as in others, the larger size of the rat allows to do analysis of human cells of the blood more frequently than in mice. Furthermore, the normal complement levels in rats allow to analyze the effector function of different anti-human antibodies, not possible to do in mice (Ménoret et al., 2020). Other genetic modifications to improve immune or liver humanization that have been developed in mice, will probably also be applied to the present generation of immunodeficient rats (Adigbli et al., 2020).

B cell–deficient rats have been described (Ménoret et al., 2010; Panzer et al., 2018) and used in organ transplantation models, and the rat may better recapitulate lesions mediated by complement activation through antibodies in the transplantation setting (Platt and Cascalho, 2018). One of these B cell–deficient strains (Ménoret et al., 2010) was obtained by disrupting the J sequence of the immunoglobulin heavy chain and further rendered deficient for both immunoglobulin light chains (Osborn et al., 2013). With the objective of generating fully human monoclonal antibodies (mAbs), these immunoglobulin-deficient rats were humanized for immunoglobulins by transgenesis using BACs (Osborn et al., 2013). These animals can generate human mAbs with diversity and affinity (Osborn et al., 2013) and different versions of these animals have been generated (Harris et al., 2018; Clarke et al., 2019).

Inactivation of the C3 complement gene has allowed confirmation of a new role for complement in a model of polyneuropathy following chemotherapy. As stated earlier, the fact that complement levels in humans and rats are comparable (Ong and Mattes, 1989; Ménoret et al., 2020), makes the rat a model of choice for exploring the role of complement in different pathological situations (Xu et al., 2018).

Cluster of Differentiation (CD) or Other Cell Membrane Molecules

In model of neuromyelitis optica induced by passive administration of human IgG autoantibodies targeting aquaporin-4, rats deficient in the cell membrane inhibitor of complement activation CD59 showed a much more pronounced neurological pathology than CD59 KO mice (Yao and Verkman, 2017a,b). This model emphasizes the role of complement in this pathology and the availability of a more relevant model of the disease than mice.

CLEC-1 is a cell membrane receptor expressed by dendritic cells (DCs) that reduces immune responses and plays a role in immune tolerance models (Thebault et al., 2009). CLEC-1 KO rats show enhanced Il12p40 subunit mRNA expression in DCs and an exacerbation of downstream in vitro and in vivo CD4+ Th1 and Th17 responses (Lopez Robles et al., 2017).

Human and rat (Maruoka et al., 2004) but not mouse cells express the Fc receptor for IgA (FcaRI, CD89; mice bear only a FcarI pseudogene) (Launay et al., 2000). CD89 KO rats have been generated and have provided interesting new information on a model of IgA-induced nephropathy a frequent pathology in humans (submitted).

Similarly, human and rat DCs display quite similar profiles of Toll-like receptor (TLR) expression in different DC subsets, allowing to better explore their role in infectious and inflammatory diseases. DCs from both species express the TLR10, whereas mouse DC subsets do not show a particular profile of TLR expression and TLR10 is not expressed (mice bear only a Tlr10 pseudogene) (Hubert et al., 2006). Rats deficient for TLR10 have been generated and are being characterized (in preparation).

A human CD4/CCR5 transgenic rat model (Keppler et al., 2002) has been extensively used to analyze different aspects of HIV infection and treatment with more relevant results as compared to mice with similar transgenes (Goffinet et al., 2007).

In humans, HLA-B27 is strongly associated with a series of inflammatory diseases grouped together under the term “spondyloarthropathies.” In contrast to the negative results in transgenic mice, transgenic HLA-B27 rats spontaneously develop inflammatory disease in the same organs as those involved in humans (Hammer et al., 1990). This model has been extensively used and is the model of choice in this pathology (for a review, see Braem and Lories, 2012).

Cytokines and Their Receptors

Il22bp KO rats show that IL22-binding protein is protective in models of inflammatory colitis (Martin et al., 2016) and psoriasis (Martin et al., 2017). Il22bp-GFP KI rats have facilitated precise definition of cell subsets that express IL22bp by different subsets of DCs in different tissues (submitted).

Viral infections can trigger autoimmune diabetes in rats and type I IFN α/β receptor (IFNAR1) KO rats have a significantly delayed onset and frequency of diabetes. These findings support the idea that innate immunity influences autoimmune diabetes and encourage the use of targeted strategies to inhibit type I IFN α/β (Qaisar et al., 2017).

NK cells could play a role in placenta generation, and IL-15 KO rats showed an absence of NK cells and several abnormal placental characteristics, supporting a role for NK cells (Renaud et al., 2017).

A Csf1r reporter gene (Irvine et al., 2020) and Csf1r KO (Pridans et al., 2018) lines are useful tools for the analysis of macrophages and of CSF1R biology (Hume et al., 2020). CSF1R is also the receptor for IL-34, and Il34-mutated rats exhibit depletion of microglia and Langerhans cells, as well as defects in tolerogenic immune responses (submitted).

Intracellular Molecules

Certain molecules that regulate metabolic functions in many cell types, including in immune cells, have been analyzed using genetically modified rats. Transgenic rats for heme oxygenase-1 (HO-1) under the control of the ubiquitous H-2Kb promoter (Braudeau et al., 2003) and HO-1 KO rats (Atsaves et al., 2017) have facilitated dissection of different aspects of HO-1 effects, particularly in kidney, where the lesions observed in rats differ from those in mice.

The hydrocarbon receptor (AHR) is a transcription factor with an essential role in mediating toxic responses to environmental pollutants and in regulating many cellular pathways involving endogenous ligands. In Ahr KO rats, the percentages of T CD3+, T CD8+, and CD11c+ cells in the spleen and the activation of T cells are decreased, whereas the percentage of NK T cells and the activation of B cells is increased compared to wild-type rats (Phadnis-Moghe et al., 2016).

The lymphopenia observed in diabetic biobreeding rats results from a spontaneous mutation in the immune-associated nucleotide gene 5 (Ian5), a protein expressed in the mitochondria membrane where it regulates apoptosis. Lymphocyte numbers are normalized when a normal Ian5 gene is transgenically expressed (Michalkiewicz et al., 2004).

Some of the most commonly used immune system models developed in rats are based on intrinsic characteristics of the species. For example, the rat has always been an important model of autoimmune arthritis (Holmdahl et al., 2001) and HLA-B27 transgenic rats recapitulate spondyloarthropathies much better than do HLA-B27 transgenic mice.

Certain immune reagents, such as antibodies recognizing leukocyte differentiation antigens, are less abundant in rats than in mice but more so than in other experimental species. High-density flow cytometry techniques have not yet been applied in the analysis of the rat immune system and will clearly be of great interest when coupled with modification of rat immune system genes.

Genetic Diseases Models

For 150 years, spontaneous or induced (ENU) genetic mutations in the rat have been used as models of human genetic diseases. For a decade, the advent of genetic engineering tools such as ZFN, TALEN, and CRISPR-Cas have led to a real revolution in obtaining specific and targeted genetic mutations in rats for the study of human genetic diseases. These advances, coupled with historical knowledge and use of the rat in many research fields, have increased the generation of rat models of human genetic diseases. More than 6000 genetic diseases have been described, and several databases have recorded variants that are associated with or responsible for genetic diseases. Several important genetic diseases have been modeled in rats. A complete list is presented in Table 7, and a brief description of the most useful models is provided below.

Cardiovascular Diseases (CVD)

Because of its larger size allowing catheterization, lower cardiac frequency versus mice, and historical use in CVD, the rat has been an important model for a series of genetically modified rat models of CVD.

Pulmonary arterial hypertension (PAH) results from a reshaping and thickening of the walls of medium and small caliber pulmonary vessels. By their frequencies and effects, the mutations in the BMPR2 gene are the main variants responsible for inheritable forms of isolated PAH. Bmpr2 KO rats show some of the critical clinical, cellular, and molecular dysfunctions described in human PAH both in the heart and vessels (Ranchoux et al., 2015; Hautefort et al., 2019; Manaud et al., 2020). Although rarer, mutations in the KCNK3 gene encoding a potassium channel have also been described as causative in PAH. Kcnk3 KO rats develop age-dependent PAH associated with characteristic electrophysiological and molecular alterations in the myocardium and vessels (Lambert et al., 2019). Because the Kcnk3 gene is not functional in mice, this rat model offers new insights into the mechanisms of PAH and in the testing of therapeutics.

To investigate the role of the MYL4 gene in atrial cardiomyopathy, Myl4-KO or mutated rats have been generated. Both show a phenotype similar to affected patients and are new models for further mechanistic analysis (Peng et al., 2017).

Danon disease (DD) is a metabolic disease caused by mutations in the LAMP2 gene, and the most common symptom is cardiomyopathy. Recently generated Lamp2 KO rats show similarities to DD patients at the heart tissue level and with multisystem lesions, constituting an important new animal model of DD (Ma S. et al., 2018).

Neurological Diseases

In neurobiology and cognitive studies, the rat, because of its larger size and more complex and richer behavior, is preferred as a rodent model. Genetically modified rats have provided several important models for neurological disorders with a genetic component.

Mutations in complexin-1 (CPLX1) gene lead to epileptic encephalopathy with onset on infancy. Cplx1 KO rats have different phenotypes from mice. Both show profound ataxia, but in rats, behavior is more affected, and they have more abnormal histomorphology of the stomach and intestine, resulting in early death (Xu et al., 2020).

A nonsense mutation in the Cockayne syndrome B gene, Ercc6, more profoundly affects the rat brain than the mouse KO for the same gene (Xu et al., 2019). In these rats, RNA-seq analysis has revealed transcription dysregulation that contributes to the neurologic disease.

Neonatal hydrocephalus has been analyzed using two different models of mutated rats, one with an invalidation of the L1cam gene (Emmert et al., 2019b) and the other with a KI of a specific mutation in the Ccdc39 gene (Emmert et al., 2019a). These models allow for neurosurgery procedures that are difficult to perform in mice, with resulting characterization of the lymphatic-mediated cerebrospinal fluid circulation and inflammation in this disease.

As a model for familial amyotrophic lateral sclerosis, rats with a FUS point mutation KI via CRISPR-Cas9 express a physiological level of this mutant, along with cognitive impairment and neuromuscular signs. In this rat model, FUS KI highlighted sleep–wake and circadian disturbances as early alarm signals (Zhang T. et al., 2018).

Neurofibromatosis type 1 is an autosomal dominant disease arising from mutations in the NF1 gene that results in the development of tumors in the nervous system, neurological disorders and chronic idiopathic pain (Dischinger et al., 2018). Nf1 KO rats show increased nociceptor excitability and hyperalgesia. These models are important in the search for a potential key target (CRMP2) for therapeutic intervention (Moutal et al., 2017).

RNASET2 deficiency in humans is associated with cystic leukoencephalopathy. RnaseT2 KO rats are the only rodent model of this disease. Despite a less severe neurodegeneration phenotype than in patients, this model is useful for studying RNASET2 function, especially for hippocampal neuroinflammation (Sinkevicius et al., 2018).

A group of neurodevelopmental diseases, gathered under the name of autism spectrum disorders (ASDs), are characterized by heterogeneous capabilities in social interactions and by stereotyped behaviors. One subtype of ASD is associated with mutations in the MECP2 gene, causing an X-linked neurodevelopmental disorder named Rett syndrome. Mecp2 KO rats clearly show both motor and behavioral deficits early in development, more pronounced than in mice (Patterson et al., 2016). Another subtype of ASD is ASD/Fragile X syndrome. Two KO rat models have been generated for this condition, one syndromic (Fmr1) and one non-syndromic (Ngln3) (Hamilton et al., 2014). These KO rats show some ASD-relevant phenotypes for investigations at the genetic level. Phelan–McDermid syndrome is another ASD-associated condition, caused by mutations in the SHANK3 gene. In contrast to Shank3 KO mice, Shank3 KO rats showed normal social interaction but impaired social memory (Harony-Nicolas et al., 2017; Song et al., 2019). Similarly, Shank2 KO rats better recapitulate the condition than the KO mice (Modi et al., 2018). Angelman syndrome results from mutations in the UBE3A gene, which in most cases is a large gene deletion, and in a small fraction with mutations in exon 2. The Ube3A mouse model bears a null mutation of exon 2, whereas the rat model is closer to the human condition with a large deletion of the Ube3a gene. The rat model mimics human Angelman syndrome with abnormalities in motor coordination and cognitive function (Dodge et al., 2020).

Muscular Diseases

Myopathies are a set of neuromuscular diseases, the most common of which is Duchenne’s muscular dystrophy (1 in 3300 newborn babies) resulting from mutations in the dystrophin gene (DMD). As in humans, Dmd KO rats show decreased muscle strength as well as a degradation/regeneration phenotype in skeletal muscles, heart, and diaphragm (Larcher et al., 2014; Nakamura et al., 2014). Of note, Dmd KO rats but not mice present cardiovascular alterations close to those observed in humans, which are the main cause of death in patients. All of these clinical signs and pathological features are much more pronounced than in Dmd KO mice. Rats are becoming an increasingly used model for the study of different aspects of Duchenne’s and Becker’s myopathies, including biomarkers, neurological abnormalities, and immune/inflammatory responses (Robertson et al., 2017; Ouisse et al., 2019; Caudal et al., 2020; Szabó et al., 2021).

Pulmonary Diseases

Cystic fibrosis is one of the most common genetic diseases in western populations (approximately 1 in 4000 newborns) and is caused by mutations in the CFTR gene. The most common mutation in humans is the missense mutation DF508, which leads to abnormal CFTR function and mucus accumulation. Cystic fibrosis is characterized by airway and digestive pathology with a reduced life expectancy. Mice do not have submucosal glands, in contrast to humans and rats. Rats with the DF508 mutation (Dreano et al., 2019), as well as with a complete KO for Cftr, have been generated (Tuggle et al., 2014; Dreano et al., 2019). Cftr KO rats showed a very severe digestive phenotype and lung lesions in surviving older animals, and reduced weight and life expectancy, although milder in DF508 rats. Very recently, a humanized model of cystic fibrosis was created by inserting the human CFTR cDNA sequence harboring a G551D mutation by KI into the rat genome, downstream of the endogenous Cftr promoter (Birket et al., 2020).

Metabolic Diseases

To study disorders of metabolism, leptin, a cytokine-like hormone principally produced by white adipose tissues, was deleted in rats. Microarray analysis has been performed in Lep KO rats to evaluate alterations in white adipose gene expression and to explore pathways involved in metabolic diseases with leptin deficiency (Guan et al., 2017). The leptin receptor (Lepr) has also been deleted in rats, and these animals show hyperphagia, obesity, hyperglycemia, and dyslipidemia. This model could complement the existing models (db/db mice and Zucker rats) and be useful for research in obesity and diabetes (Bao et al., 2015; Chen Y. et al., 2017).

Hereditary aceruloplasminemia is a genetic disease characterized by progressive iron overload (liver and brain) and is related to mutations in the ceruloplasmin (CP) gene. In contrast to Cp KO mice, Cp KO rats mimic the human phenotype with hepatosplenic iron load and could be more appropriate for providing information to understand and treat the disease (Kenawi et al., 2019).

Abnormal calcification and phosphate deposition are the basis of generalized arterial calcification of infancy and pseudoxanthoma elasticum, both caused by mutations in the ABCC6 gene. These mutations lead to generalized arterial calcification through the body in infancy. Because ABCC6 is expressed in liver and kidney, an important question is the respective role of these organs in the generalized disease. Given their small size, mice KO for Abcc6 are not suitable for ex vivo perfusion experiments. Ex vivo perfusion of liver and kidneys from Abcc6 KO rats has revealed that the liver is the primary site of molecular pathology in these process and points to a preferential target of the liver to treat them (Li et al., 2017).

The low-density lipoprotein receptor (LDLR) and apolipoprotein E (APOE) genes control normal levels of cholesterol and other forms of fat in the blood. A deficiency in LDLR is the cause of familial hypercholesterolemia and a deficiency in APOE is involved in several age-related fatty acid diseases. Recently, two reports (Zhao et al., 2018; Lee J. G. et al., 2019) described double-KO for Ldlr and Apoe genes in rats. These rats mimic more closely than KO mice the pathological changes observed in hyperlipidemia and atherosclerosis in humans with genetic deficiencies and in normal individuals.

Melanocortin-3 and -4 receptors (MC3R and MC4R) regulate energy and body weight. Mc3R-Mc4R double-KO rats exhibit worse phenotypic features than single-KO rats and Mc3R-Mc4R double-KO mice (You et al., 2016).

Fabry disease is an X-linked lysosomal storage disease caused by α-galactosidase A (α-Gal A) deficiency resulting from mutations in the GLA gene. α-Gal A KO mouse models do not recapitulate the cardiorenal findings observed in humans and Gla KO rats more closely mimic the disease phenotypes observed in patients (Miller et al., 2018).

Wolfram syndrome (WS) is a genetic disorder caused by mutations in the WFS1 gene. Previous mouse models of WS involved only partial diabetes and other symptoms of the disease, whereas Wfs1 KO rats developed diabetes as well as neuronal degeneration, as do patients (Plaas et al., 2017).

Kidney Diseases

Renin (REN) mutations are involved in REN-related kidney disease and tubular dysgenesis. The role of RAS in the regulation of blood pressure and kidney function has been extensively analyzed in rats (Jacob, 2010), including the generation of one of the first transgenic rat models (Mullins et al., 1990). Although humans and rats have only one copy of the renin gene, mice have two genes and thus increased renin expression levels (10-fold higher than their one-copy counterparts) (Hansen et al., 2004). Ren KO rats have lower blood pressure and severe kidney underdevelopment, reproducing the kidney lesions observed in REN-related kidney disease and tubular dysgenesis (Moreno et al., 2011).

Ophthalmology Diseases

Retinitis pigmentosa (RP) is a group of inherited mutations causing photoreceptor degeneration, loss of night vision, and blindness. Rhodopsin mutations comprise an important fraction of autosomal dominant RP. Transgenic rats harboring the Rho s334ter mutation are a widely used model for this pathology (Liu et al., 1999).

As noted, AHR is a ligand-activated transcription factor involved in the development of multiple tissues and activated by a large number of exogenous toxic compounds and endogenous ligands, such as kynurenines. Ahr KO rats and mice show ophthalmologic lesions as well as different renal and hepatic developmental and homeostatic lesions (Harrill et al., 2013).

Cancer

The tumor suppressor TP53 is a central player in cancer biology, and mutations in the TP53 gene are the most frequent mutations observed in human cancers. Tp53 KO rats develop a wide variety of tumors, most frequently sarcomas, which are rarely observed in mice. These rats have been used in carcinogenicity assays for drug development (McCoy et al., 2013).

Immune and Hematological Systems

For hemophilia A, FvIII KO rats have no detectable FVIII activity, and their activated thromboplastin time and clotting time are significantly prolonged. Episodes of spontaneous bleeding requiring treatments were observed in 70% of the FvIII KO rats (Nielsen et al., 2014; Shi et al., 2020). In the rat genome, it is interesting to note that the F8 gene is situated on chromosome 18, rather than the X chromosome as in humans, mice, dogs, and sheep (Lozier and Nichols, 2013).

Monocyte colony-stimulating factor (CSF-1) is, along with IL-34, a regulator of macrophages and myeloid DC development, acting through the CSF-1R (Ma et al., 2012). Humans with point mutations or less frequently deficiency for CSF-1R develop adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, likely because of a decrease in the number of microglia (Hume et al., 2020). Csf1r KO rats (Pridans et al., 2018) develop some or all of the symptoms and lesions of the disease, but with greater severity and more bone lesions than in humans, whereas Csf1r KO mouse models show an even more severe phenotype (Hume et al., 2020).

AIRE plays a key role in central tolerance by regulating the expression of peripheral tissue antigens in epithelial cells of the thymus and by eliminating autoreactive T cells. Patients with the autoimmune polyendocrinopathy-candidiasis-ectodermal-dystrophy syndrome have genetic defects in AIRE. Aire KO rats show signs of generalized autoimmunity and clinical signs of disease that are much more pronounced than in Aire KO mice and closer to manifestations in humans (Ossart et al., 2018).

Conclusion and Perspectives

CRISPR-Cas system is now the tool of choice for genome editing, particularly for the rat for which ES cells are limited compared to the mouse. In the last decade, efforts have been made to improve this tool and its delivery but two main hurdles persist. Some loci are still difficult or impossible to edit, and the efficiency of large or complex KI is still too low. Although many advances have been developed in the application of the CRISPR-Cas system to human cells and sometimes in mice, many remain to be applied in rat model generation.

Rats often proved to be better mimics of human situation than mice. It is particularly evident in CVD, neurobiology, ophthalmology, muscular diseases, and immunology, but few of the large number of genetic diseases in these or other organ systems have been modeled in rats. It is difficult to predict when the rat will be better than the mouse, nevertheless, it seems reasonable to try to generate new genetically modified rats in these areas. Moreover, to the best of our knowledge and among the models that can be compared, there are no mouse genetic or immune models that better reproduce human disease than rat. Future work using the CRISPR-Cas system will likely generate new rat models of genetic diseases and to study genes functions. Extensive work in QTLs associated with major polygenic diseases has been performed in rats (Gauguier, 2016; Shimoyama et al., 2017). Within these QTLs, the genes that could be responsible for a given disease will likely be targets of choice in future studies.

Other genes that would be logical to target in rats are those that are absent in mice and present in humans, given that 78 out of the 2544 Mb of the rat genome is common between humans and rats but not humans and mice (Gibbs et al., 2004). Examples within the immune system include Tlr10 and Cd89.

A limitation of rats versus mice that cannot be resolved is also one of its advantages: its bigger size, which brings higher breeding costs.

The rat will continue to be a critical experimental model based on its bigger size and its inherent physiological characteristics, as well as a large and growing body of physiology and genomic data. Tools for modifying the rat genome as well as analyzing the genome are key to the development of new models for understanding biology and diseases.

Statements

Author contributions

All authors performed the bibliographic research and participated in writing the manuscript. IA planned the review and secured the funding.

Funding

This work was performed in the context of different programs: Biogenouest by Région Pays de la Loire, IBiSA program, TEFOR (Investissements d’Avenir French Government program, ANRII-INSB-0014), LabCom SOURIRAT project (ANR-14-LAB5-0008), Labex IGO project (Investissements d’Avenir French Government program, ANR-11-LABX-0016-01), IHU-Cesti project (Investissements d’Avenir French Government program, ANR-10-IBHU-005, Nantes Métropole and Région Pays de la Loire), Fondation Progreffe, and collaboration with genOway.

Conflict of interest

YC and VC are genOway employees. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • 1

    AdigbliG.MénoretS.CrossA. R.HesterJ.IssaF.AnegonI. (2020). Humanization of immunodeficient animals for the modeling of transplantation, graft versus host disease and regenerative medicine.Transplantation10422902306. 10.1097/TP.0000000000003177

  • 2

    AgcaC.SeyeC.Kashuba BensonC. M.RikkaS.ChanA. W. S.WeismanG. A.et al (2009). Development of a novel transgenic rat overexpressing the P2Y(2) nucleotide receptor using a lentiviral vector.J. Vasc. Res.46447458. 10.1159/000194274

  • 3

    AidaT.NakadeS.SakumaT.IzuY.OishiA.MochidaK.et al (2016). Gene cassette knock-in in mammalian cells and zygotes by enhanced MMEJ.BMC Genomics17:979. 10.1186/s12864-016-3331-9

  • 4

    AirdE. J.LovendahlK. N.St MartinA.HarrisR. S.GordonW. R. (2018). Increasing Cas9-mediated homology-directed repair efficiency through covalent tethering of DNA repair template.Commun. Biol.1:54. 10.1038/s42003-018-0054-2

  • 5

    AitmanT.DhillonP.GeurtsA. M. (2016). A RATional choice for translational research?Dis. Model Mech.910691072. 10.1242/dmm.027706

  • 6

    AitmanT. J.PetrettoE.BehmoarasJ. (2010). “Genetic mapping and positional cloning,” in Rat Genomics: Methods and Protocols Methods in Molecular Biology, ed.AnegonI. (Totowa, NJ: Humana Press), 1332. 10.1007/978-1-60327-389-3_2

  • 7

    Amos-LandgrafJ. M.KwongL. N.KendziorskiC. M.ReichelderferM.TorrealbaJ.WeichertJ.et al (2007). A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer.Proc. Natl. Acad. Sci. U.S.A.10440364041. 10.1073/pnas.0611690104

  • 8

    AnzaloneA. V.KoblanL. W.LiuD. R. (2020). Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.Nat. Biotechnol.38824844. 10.1038/s41587-020-0561-9

  • 9

    AnzaloneA. V.RandolphP. B.DavisJ. R.SousaA. A.KoblanL. W.LevyJ. M.et al (2019). Search-and-replace genome editing without double-strand breaks or donor DNA.Nature576149157. 10.1038/s41586-019-1711-4

  • 10

    AriasE. B.ZhengX.AgrawalS.CarteeG. D. (2019). Whole body glucoregulation and tissue-specific glucose uptake in a novel Akt substrate of 160 kDa knockout rat model.PLoS One14:e0216236. 10.1371/journal.pone.0216236

  • 11

    AtsavesV.DetsikaM. G.PoulakiE.GakiopoulouH.LianosE. A. (2017). Phenotypic characterization of a novel HO-1 depletion model in the rat.Transgenic Res.265164. 10.1007/s11248-016-9986-9

  • 12

    AyabeS.NakashimaK.YoshikiA. (2019). Off- and on-target effects of genome editing in mouse embryos.J. Reprod. Dev.6515. 10.1262/jrd.2018-128

  • 13

    BaeH. S.JinY.-K.HamS.KimH. K.ShinH.ChoG.-B.et al (2020). CRISRP/Cas9-mediated knockout of Mct8 reveals a functional involvement of Mct8 in testis and sperm development in a rat.Sci. Rep.10:11148. 10.1038/s41598-020-67594-2

  • 14

    BaiL.ShiG.MaY.ZhangL.GuanF.ZhangX.et al (2018). Paraoxonase 1 knockout rats have impaired T cell development at the CD4/CD8 double-negative to double-positive transition stage.Sci. Rep.8:14457. 10.1038/s41598-018-32780-w

  • 15

    BaoD.MaY.ZhangX.GuanF.ChenW.GaoK.et al (2015). Preliminary characterization of a leptin receptor knockout rat created by CRISPR/Cas9 system.Sci. Rep.5:15942. 10.1038/srep15942

  • 16

    BaulacS.IshidaS.MashimoT.BoillotM.FumotoN.KuwamuraM.et al (2012). A rat model for LGI1-related epilepsies.Hum. Mol. Genet.2135463557. 10.1093/hmg/dds184

  • 17

    BehmoarasJ.DiazA. G.VendaL.KoJ.-H.SrivastavaP.MontoyaA.et al (2015). Macrophage epoxygenase determines a profibrotic transcriptome signature.J. Immunol.19447054716. 10.4049/jimmunol.1402979

  • 18

    BeldickS. R.HongJ.AltamentovaS.KhazaeiM.HundalA.ZavvarianM.-M.et al (2018). Severe-combined immunodeficient rats can be used to generate a model of perinatal hypoxic-ischemic brain injury to facilitate studies of engrafted human neural stem cells.PLoS One13:e0208105. 10.1371/journal.pone.0208105

  • 19

    BernardI.FourniéG. J.SaoudiA. (2010). Genomics studies of immune-mediated diseases using the BN-LEW rat model.Methods Mol. Biol.597389402. 10.1007/978-1-60327-389-3_26

  • 20

    BirketS. E.DavisJ. M.Fernandez-PettyC. M.HendersonA. G.OdenA. M.TangL.et al (2020). Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.Am. J. Respir. Crit. Care Med.20212711282. 10.1164/rccm.202002-0369OC

  • 21

    BirlingM.-C.GofflotF.WarotX. (2009). Site-specific recombinases for manipulation of the mouse genome.Methods Mol. Biol.561245263. 10.1007/978-1-60327-019-9_16

  • 22

    BirlingM.-C.SchaefferL.AndréP.LindnerL.MaréchalD.AyadiA.et al (2017). Efficient and rapid generation of large genomic variants in rats and mice using CRISMERE.Sci. Rep.7:43331. 10.1038/srep43331

  • 23

    BischoffN.WimbergerS.MarescaM.BrakebuschC. (2020). Improving precise CRISPR genome editing by small molecules: is there a magic potion?Cells9:1318. 10.3390/cells9051318

  • 24

    BodeV. C. (1984). Ethylnitrosourea mutagenesis and the isolation of mutant alleles for specific genes located in the T region of mouse chromosome 17.Genetics108457470.

  • 25

    BothmerA.GareauK. W.AbdulkerimH. S.BuquicchioF.CohenL.ViswanathanR.et al (2020). Detection and modulation of DNA translocations during multi-gene genome editing in T cells.CRISPR J.3177187. 10.1089/crispr.2019.0074

  • 26

    BouchetD.TessonL.MénoretS.CharreauB.MathieuP.YagitaH.et al (2002). Differential sensitivity of endothelial cells of various species to apoptosis induced by gene transfer of Fas ligand: role of FLIP levels.Mol. Med.8612623.

  • 27

    BraemK.LoriesR. J. (2012). Insights into the pathophysiology of ankylosing spondylitis: contributions from animal models.Joint Bone Spine79243248. 10.1016/j.jbspin.2011.09.008

  • 28

    BraudeauC.BouchetD.ToquetC.TessonL.MénoretS.IyerS.et al (2003). Generation of heme oxygenase-1-transgenic rats.Exp. Biol. Med.228466471.

  • 29

    BrinerA. E.DonohoueP. D.GomaaA. A.SelleK.SlorachE. M.NyeC. H.et al (2014). Guide RNA functional modules direct Cas9 activity and orthogonality.Mol. Cell56333339. 10.1016/j.molcel.2014.09.019

  • 30

    BrinsterR. L.ChenH. Y.TrumbauerM. E.YagleM. K.PalmiterR. D. (1985). Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs.Proc. Natl. Acad. Sci. U.S.A.8244384442. 10.1073/pnas.82.13.4438

  • 31

    BrownA. J.FisherD. A.KouranovaE.McCoyA.ForbesK.WuY.et al (2013). Whole-rat conditional gene knockout via genome editing.Nat. Methods10638640. 10.1038/nmeth.2516

  • 32

    BuehrM.MeekS.BlairK.YangJ.UreJ.SilvaJ.et al (2008). Capture of authentic embryonic stem cells from rat blastocysts.Cell13512871298. 10.1016/j.cell.2008.12.007

  • 33

    CarberyI. D.JiD.HarringtonA.BrownV.WeinsteinE. J.LiawL.et al (2010). Targeted genome modification in mice using zinc-finger nucleases.Genetics186451459. 10.1534/genetics.110.117002

  • 34

    CarlsonC. M.DupuyA. J.FritzS.Roberg-PerezK. J.FletcherC. F.LargaespadaD. A. (2003). Transposon mutagenesis of the mouse germline.Genetics165243256.

  • 35

    Carlson-StevermerJ.AbdeenA. A.KohlenbergL.GoedlandM.MoluguK.LouM.et al (2017). Assembly of CRISPR ribonucleoproteins with biotinylated oligonucleotides via an RNA aptamer for precise gene editing.Nat. Commun.8:1711. 10.1038/s41467-017-01875-9

  • 36

    CaudalD.FrançoisV.LafouxA.LedevinM.AnegonI.Le GuinerC.et al (2020). Characterization of brain dystrophins absence and impact in dystrophin-deficient Dmdmdx rat model.PLoS One15:e0230083. 10.1371/journal.pone.0230083

  • 37

    ChangN. K.GuJ.GuS.OsorioR. W.ConcepcionW.GuE. (2015). Arterial flow regulator enables transplantation and growth of human fetal kidneys in rats.Am. J. Transplant.1516921700. 10.1111/ajt.13149

  • 38

    CharpentierM.KhedherA. H. Y.MenoretS.BrionA.LamribetK.DardillacE.et al (2018). CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair.Nat. Commun.9:1133. 10.1038/s41467-018-03475-7

  • 39

    CharreauB.MénoretS.TessonL.AzimzadehA.AudetM.WolfP.et al (1999). Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates.Mol. Med.5617630.

  • 40

    CharreauB.TessonL.BuscailJ.SoulillouJ. P.AnegonI. (1996a). Analysis of human CD59 tissue expression directed by the CMV-IE-1 promoter in transgenic rats.Transgenic Res.5443450.

  • 41

    CharreauB.TessonL.SoulillouJ. P.PourcelC.AnegonI. (1996b). Transgenesis in rats: technical aspects and models.Transgenic Res.5223234. 10.1007/BF01972876

  • 42

    ChenC. C. A.GeurtsA. M.JacobH. J.FanF.RomanR. J. (2013). Heterozygous knockout of transforming growth factor-β1 protects Dahl S rats against high salt-induced renal injury.Physiol. Genomics45110118. 10.1152/physiolgenomics.00119.2012

  • 43

    ChenF.DingX.FengY.SeebeckT.JiangY.DavisG. D. (2017). Targeted activation of diverse CRISPR-Cas systems for mammalian genome editing via proximal CRISPR targeting.Nat. Commun.8:14958. 10.1038/ncomms14958

  • 44

    ChenY.LuW.GaoN.LongY.ShaoY.LiuM.et al (2017). Generation of obese rat model by transcription activator-like effector nucleases targeting the leptin receptor gene.Sci. China Life Sci.60152157. 10.1007/s11427-016-5049-y

  • 45

    ChenP.LiZ.NieJ.WangH.YuB.WenZ.et al (2020). MYH7B variants cause hypertrophic cardiomyopathy by activating the CaMK-signaling pathway.Sci. China. Life Sci.63116. 10.1007/s11427-019-1627-y

  • 46

    ChenS.LeeB.LeeA. Y.-F.ModzelewskiA. J.HeL. (2016). Highly efficient mouse genome editing by CRISPR ribonucleoprotein electroporation of zygotes.J. Biol. Chem.2911445714467. 10.1074/jbc.M116.733154

  • 47

    ChenS.SunS.MoonenD.LeeC.LeeA. Y.-F.SchafferD. V.et al (2019). CRISPR-READI: efficient generation of knockin mice by CRISPR RNP electroporation and AAV donor infection.Cell Rep.273780.e43789.e4. 10.1016/j.celrep.2019.05.103

  • 48

    ChiangE. Y.LiT.JeetS.PengI.ZhangJ.LeeW. P.et al (2017). Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions.Nat. Commun.8:14644. 10.1038/ncomms14644

  • 49

    ClarkeS. C.MaB.TrinkleinN. D.SchellenbergerU.OsbornM. J.OuisseL.-H.et al (2019). Multispecific antibody development platform based on human heavy chain antibodies.Front. Immunol.9:3037. 10.3389/fimmu.2018.03037

  • 50

    CodnerG. F.MiannéJ.CaulderA.LoefflerJ.FellR.KingR.et al (2018). Application of long single-stranded DNA donors in genome editing: generation and validation of mouse mutants.BMC Biol.16:70. 10.1186/s12915-018-0530-7

  • 51

    ConcordetJ.-P.HaeusslerM. (2018). CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens.Nucleic Acids Res.46W242W245. 10.1093/nar/gky354

  • 52

    CuiX.JiD.FisherD. A.WuY.BrinerD. M.WeinsteinE. J. (2011). Targeted integration in rat and mouse embryos with zinc-finger nucleases.Nat. Biotechnol.296467. 10.1038/nbt.1731

  • 53

    DeltchevaE.ChylinskiK.SharmaC. M.GonzalesK.ChaoY.PirzadaZ. A.et al (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.Nature471602607. 10.1038/nature09886

  • 54

    DeweyC.WuJ. Q.CawleyS.AlexanderssonM.GibbsR.PachterL. (2004). Accurate identification of novel human genes through simultaneous gene prediction in human.Mouse, and Rat. Genome Res.14661664. 10.1101/gr.1939804

  • 55

    DingX.SeebeckT.FengY.JiangY.DavisG. D.ChenF. (2019). Improving CRISPR-Cas9 genome editing efficiency by fusion with chromatin-modulating peptides.CRISPR J.25163. 10.1089/crispr.2018.0036

  • 56

    DischingerP. S.TovarE. A.EssenburgC. J.MadajZ. B.GardnerE. E.CallaghanM. E.et al (2018). NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer.NPJ Breast Cancer4:29. 10.1038/s41523-018-0080-8

  • 57

    DodgeA.PetersM. M.GreeneH. E.DietrickC.BotelhoR.ChungD.et al (2020). Generation of a novel rat model of angelman syndrome with a complete Ube3a gene deletion.Autism. Res.13397409. 10.1002/aur.2267

  • 58

    DoeB.BrownE.BoroviakK. (2018). Generating CRISPR/Cas9-derived mutant mice by zygote cytoplasmic injection using an automatic microinjector.Methods Protoc.1:5. 10.3390/mps1010005

  • 59

    DoetschmanT.GreggR. G.MaedaN.HooperM. L.MeltonD. W.ThompsonS.et al (1987). Targetted correction of a mutant HPRT gene in mouse embryonic stem cells.Nature330576578. 10.1038/330576a0

  • 60

    DreanoE.BacchettaM.SimoninJ.GalmicheL.UsalC.SlimaniL.et al (2019). Characterization of two rat models of cystic fibrosis—KO and F508del CFTR—generated by Crispr-Cas9.Anim. Model. Exp. Med.2297311. 10.1002/ame2.12091

  • 61

    DyleM. C.KolakadaD.CortazarM. A.JagannathanS. (2020). How to get away with nonsense: mechanisms and consequences of escape from nonsense-mediated RNA decay.Wiley Interdiscip. Rev. RNA11:e1560. 10.1002/wrna.1560

  • 62

    EbiharaC.EbiharaK.Aizawa-AbeM.MashimoT.TomitaT.ZhaoM.et al (2015). Seipin is necessary for normal brain development and spermatogenesis in addition to adipogenesis.Hum. Mol. Genet.2442384249. 10.1093/hmg/ddv156

  • 63

    EdrakiA.MirA.IbraheimR.GainetdinovI.YoonY.SongC.-Q.et al (2019). A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing.Mol. Cell73714.e4726.e4. 10.1016/j.molcel.2018.12.003

  • 64

    EgwuaguC. E.MahdiR. M.ChanC. C.SzteinJ.LiW.SmithJ. A.et al (1999a). Expression of interferon-gamma in the lens exacerbates anterior uveitis and induces retinal degenerative changes in transgenic Lewis rats.Clin. Immunol.91196205. 10.1006/clim.1999.4701

  • 65

    EgwuaguC. E.SzteinJ.MahdiR. M.LiW.Chao-ChanC.SmithJ. A.et al (1999b). IFN-gamma increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats.J. Immunol.162510517.

  • 66

    El-BrolosyM. A.KontarakisZ.RossiA.KuenneC.GüntherS.FukudaN.et al (2019). Genetic compensation triggered by mutant mRNA degradation.Nature568193197. 10.1038/s41586-019-1064-z

  • 67

    EllisB. L.HirschM. L.BarkerJ. C.ConnellyJ. P.SteiningerR. J.PorteusM. H. (2013). A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype.Virol. J.10:74. 10.1186/1743-422X-10-74

  • 68

    EmmertA. S.IwasawaE.ShulaC.SchultzP.LindquistD.DunnR. S.et al (2019a). Impaired neural differentiation and glymphatic CSF flow in the Ccdc39 rat model of neonatal hydrocephalus: genetic interaction with L1cam.Dis. Model Mech.12:dmm040972. 10.1242/dmm.040972

  • 69

    EmmertA. S.VuongS. M.ShulaC.LindquistD.YuanW.HuY.-C.et al (2019b). Characterization of a novel rat model of X-linked hydrocephalus by CRISPR-mediated mutation in L1cam.J. Neurosurg.132945958. 10.3171/2018.10.JNS181015

  • 70

    EngineerC. T.RahebiK. C.BorlandM. S.BuellE. P.CentanniT. M.FinkM. K.et al (2015). Degraded neural and behavioral processing of speech sounds in a rat model of Rett syndrome.Neurobiol. Dis.832634. 10.1016/j.nbd.2015.08.019

  • 71

    EvansM. J.KaufmanM. H. (1981). Establishment in culture of pluripotential cells from mouse embryos.Nature292154156. 10.1038/292154a0

  • 72

    FergusonC.McKayM.HarrisR. A.HomanicsG. E. (2013). Toll-like receptor 4 (Tlr4) knockout rats produced by transcriptional activator-like effector nuclease (TALEN)-mediated gene inactivation.Alcohol47595599. 10.1016/j.alcohol.2013.09.043

  • 73

    FernándezA.JosaS.MontoliuL. (2017). A history of genome editing in mammals.Mamm. Genome28237246. 10.1007/s00335-017-9699-2

  • 74

    FilippovaJ.MatveevaA.ZhuravlevE.StepanovG. (2019). Guide RNA modification as a way to improve CRISPR/Cas9-based genome-editing systems.Biochimie1674960. 10.1016/j.biochi.2019.09.003

  • 75

    FlavellD. M.WellsT.WellsS. E.CarmignacD. F.ThomasG. B.RobinsonI. C. (1996). Dominant dwarfism in transgenic rats by targeting human growth hormone (GH) expression to hypothalamic GH-releasing factor neurons.EMBO J.1538713879.

  • 76

    FritP.RoparsV.ModestiM.CharbonnierJ. B.CalsouP. (2019). Plugged into the Ku-DNA hub: the NHEJ network.Prog. Biophys. Mol. Biol.1476276. 10.1016/j.pbiomolbio.2019.03.001

  • 77

    FujiiW.ItoH.KankeT.IkedaA.SugiuraK.NaitoK. (2019). Generation of genetically modified mice using SpCas9-NG engineered nuclease.Sci. Rep.9:12878. 10.1038/s41598-019-49394-5

  • 78

    FujiiW.KakutaS.YoshiokaS.KyuwaS.SugiuraK.NaitoK. (2016). Zygote-mediated generation of genome-modified mice using Streptococcus thermophilus 1-derived CRISPR/Cas system.Biochem. Biophys. Res. Commun.477473476. 10.1016/j.bbrc.2016.06.070

  • 79

    GalettoR.DuchateauP.PâquesF. (2009). Targeted approaches for gene therapy and the emergence of engineered meganucleases.Expert Opin. Biol. Ther.912891303. 10.1517/14712590903213669

  • 80

    GarciaJ.FloodV. H.HaberichterS. L.FahsS. A.MattsonJ. G.GeurtsA. M.et al (2020). A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9.Res. Pract. Thromb. Haemost.46471. 10.1002/rth2.12280

  • 81

    GaudelliN. M.KomorA. C.ReesH. A.PackerM. S.BadranA. H.BrysonD. I.et al (2017). Programmable base editing of AT to GC in genomic DNA without DNA cleavage.Nature551464471. 10.1038/nature24644

  • 82

    GauguierD. (2016). Application of quantitative metabolomics in systems genetics in rodent models of complex phenotypes.Arch. Biochem. Biophys.589158167. 10.1016/j.abb.2015.09.016

  • 83

    GeurtsA. M.CostG. J.FreyvertY.ZeitlerB.MillerJ. C.ChoiV. M.et al (2009). Knockout rats via embryo microinjection of zinc-finger nucleases.Science325433433. 10.1126/science.1172447

  • 84

    GibbsR. A.WeinstockG. M.MetzkerM. L.MuznyD. M.SodergrenE. J.SchererS.et al (2004). Genome sequence of the Brown Norway rat yields insights into mammalian evolution.Nature428493521. 10.1038/nature02426

  • 85

    GiraldoP.MontoliuL. (2001). Size matters: use of YACs, BACs and PACs in transgenic animals.Transgenic Res.1083103. 10.1023/a:1008918913249

  • 86

    GoffinetC.AllespachI.KepplerO. T. (2007). HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.Proc. Natl. Acad. Sci. U.S.A.10410151020. 10.1073/pnas.0607414104

  • 87

    GordonJ. W.RuddleF. H. (1982). Germ line transmission in transgenic mice.Prog. Clin. Biol. Res.85(Pt B), 111124.

  • 88

    GordonJ. W.ScangosG. A.PlotkinD. J.BarbosaJ. A.RuddleF. H. (1980). Genetic transformation of mouse embryos by microinjection of purified DNA.Proc. Natl. Acad. Sci. U.S.A7773807384.

  • 89

    GotoT.HaraH.NakauchiH.HochiS.HirabayashiM. (2016). Hypomorphic phenotype of Foxn1 gene-modified rats by CRISPR/Cas9 system.Transgenic Res.25533544. 10.1007/s11248-016-9941-9

  • 90

    GuB.PosfaiE.RossantJ. (2018). Efficient generation of targeted large insertions by microinjection into two-cell-stage mouse embryos.Nat. Biotechnol.36632637. 10.1038/nbt.4166

  • 91

    GuH.CaoY.QiuB.ZhouZ.DengR.ChenZ.et al (2016). Establishment and phenotypic analysis of an Mstn knockout rat.Biochem. Biophys. Res. Commun.477115122. 10.1016/j.bbrc.2016.06.030

  • 92

    GuanL.-J.XuK.-X.XuS.-Y.LiN.-N.WangX.-R.XiaY.-K.et al (2017). Profiles of metabolic gene expression in the white adipose tissue, liver and hypothalamus in leptin knockout (LepΔI14/ΔI14) rats.J Biomed Res.31528540. 10.7555/JBR.31.20170021

  • 93

    GuoT.FengY.-L.XiaoJ.-J.LiuQ.SunX.-N.XiangJ.-F.et al (2018). Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing.Genome Biol.19:170. 10.1186/s13059-018-1518-x

  • 94

    GurumurthyC. B.O’BrienA. R.QuadrosR. M.AdamsJ.AlcaideP.AyabeS.et al (2019a). Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation.Genome Biol.20:171. 10.1186/s13059-019-1776-2

  • 95

    GurumurthyC. B.SatoM.NakamuraA.InuiM.KawanoN.IslamM. A.et al (2019b). Creation of CRISPR-based germline-genome-engineered mice without ex vivo handling of zygotes by i-GONAD.Nat. Protoc.1424522482. 10.1038/s41596-019-0187-x

  • 96

    GurumurthyC. B.TakahashiG.WadaK.MiuraH.SatoM.OhtsukaM. (2016). GONAD: a novel CRISPR/Cas9 genome editing method that does not require ex vivo handling of embryos.Curr. Protoc. Hum. Genet.8815.8.115.8.12. 10.1002/0471142905.hg1508s88

  • 97

    GutschnerT.HaemmerleM.GenoveseG.DraettaG. F.ChinL. (2016). Post-translational Regulation of Cas9 during G1 enhances homology-directed repair.Cell Rep.1415551566. 10.1016/j.celrep.2016.01.019

  • 98

    HallerS. T.KumarasamyS.FoltD. A.WuescherL. M.StepkowskiS.KaramchandaniM.et al (2017). Targeted disruption of Cd40 in a genetically hypertensive rat model attenuates renal fibrosis and proteinuria, independent of blood pressure.Kidney Int.91365374. 10.1016/j.kint.2016.08.015

  • 99

    HamiltonS. M.GreenJ. R.VeeraragavanS.YuvaL.McCoyA.WuY.et al (2014). Fmr1 and Nlgn3 knockout rats: novel tools for investigating autism spectrum disorders.Behav. Neurosci.128103109. 10.1037/a0035988

  • 100

    HammerR. E.MaikaS. D.RichardsonJ. A.TangJ. P.TaurogJ. D. (1990). Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders.Cell6310991112. 10.1016/0092-8674(90)90512-d

  • 101

    HansenP. B.YangT.HuangY.MizelD.BriggsJ.SchnermannJ. (2004). Plasma renin in mice with one or two renin genes.Acta Physiol. Scand.181431437. 10.1111/j.1365-201X.2004.01315.x

  • 102

    HaoM.QiaoJ.QiH. (2020). Current and emerging methods for the synthesis of single-stranded DNA.Genes11:116. 10.3390/genes11020116

  • 103

    HaoX.LiY.WangJ.MaJ.ZhaoS.YeX.et al (2018). Deficient O-GlcNAc glycosylation impairs regulatory T cell differentiation and notch signaling in autoimmune hepatitis.Front. Immunol.9:2089. 10.3389/fimmu.2018.02089

  • 104

    Harony-NicolasH.KayM.du HoffmannJ.KleinM. E.Bozdagi-GunalO.RiadM.et al (2017). Oxytocin improves behavioral and electrophysiological deficits in a novel Shank3-deficient rat.Elife6:e18904. 10.7554/eLife.18904

  • 105

    HarrillJ. A.HukkanenR. R.LawsonM.MartinG.GilgerB.SoldatowV.et al (2013). Knockout of the aryl hydrocarbon receptor results in distinct hepatic and renal phenotypes in rats and mice.Toxicol. Appl. Pharmacol.272503518. 10.1016/j.taap.2013.06.024

  • 106

    HarrisK. E.AldredS. F.DavisonL. M.OganaH. A. N.BoudreauA.BrüggemannM.et al (2018). Sequence-based discovery demonstrates that fixed light chain human transgenic rats produce a diverse repertoire of antigen-specific antibodies.Front. Immunol.9:889. 10.3389/fimmu.2018.00889

  • 107

    HashimotoM.TakemotoT. (2015). Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas9-based genome editing.Sci. Rep.5:11315. 10.1038/srep11315

  • 108

    HashimotoM.YamashitaY.TakemotoT. (2016). Electroporation of Cas9 protein/sgRNA into early pronuclear zygotes generates non-mosaic mutants in the mouse.Dev. Biol.41819. 10.1016/j.ydbio.2016.07.017

  • 109

    HautefortA.Mendes-FerreiraP.SabourinJ.ManaudG.BerteroT.Rucker-MartinC.et al (2019). Bmpr2 mutant rats develop pulmonary and cardiac characteristics of pulmonary arterial hypertension.Circulation139932948. 10.1161/CIRCULATIONAHA.118.033744

  • 110

    HeD.ZhangJ.WuW.YiN.HeW.LuP.et al (2019). A novel immunodeficient rat model supports human lung cancer xenografts.FASEB J.33140150. 10.1096/fj.201800102RR

  • 111

    HeigwerF.KerrG.BoutrosM. (2014). E-CRISP: fast CRISPR target site identification.Nat. Methods11122123. 10.1038/nmeth.2812

  • 112

    HirabayashiM.TakahashiR.ItoK.KashiwazakiN.HiraoM.HirasawaK.et al (2001). A comparative study on the integration of exogenous DNA into mouse, rat, rabbit, and pig genomes.Exp. Anim.50125131. 10.1538/expanim.50.125

  • 113

    HiranoH.GootenbergJ. S.HoriiT.AbudayyehO. O.KimuraM.HsuP. D.et al (2016). Structure and engineering of francisella novicida Cas9.Cell164950961. 10.1016/j.cell.2016.01.039

  • 114

    HirotsuneS.KiyonariH.JinM.KumamotoK.YoshidaK.ShinoharaM.et al (2020). Enhanced homologous recombination by the modulation of targeting vector ends.Sci. Rep.10:2518. 10.1038/s41598-020-58893-9

  • 115

    HolmdahlR.LorentzenJ. C.LuS.OlofssonP.WesterL.HolmbergJ.et al (2001). Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis.Immunol. Rev.184184202. 10.1034/j.1600-065x.2001.1840117.x

  • 116

    HorieK.YusaK.YaeK.OdajimaJ.FischerS. E. J.KengV. W.et al (2003). Characterization of Sleeping Beauty transposition and its application to genetic screening in mice.Mol. Cell. Biol.2391899207. 10.1128/mcb.23.24.9189-9207.2003

  • 117

    HoriiT.MoritaS.KimuraM.TerawakiN.ShibutaniM.HatadaI. (2017). Efficient generation of conditional knockout mice via sequential introduction of lox sites.Sci. Rep.7:7891. 10.1038/s41598-017-08496-8

  • 118

    HuK.LiY.WuW.ChenH.ChenZ.ZhangY.et al (2018). High-performance gene expression and knockout tools using sleeping beauty transposon system.Mob. DNA9:33. 10.1186/s13100-018-0139-y

  • 119

    HuangG.AshtonC.KumbhaniD. S.YingQ.-L. (2011). Genetic manipulations in the rat: progress and prospects.Curr. Opin. Nephrol. Hypertens.20391399. 10.1097/MNH.0b013e328347768a

  • 120

    HubertF.-X.VoisineC.LouvetC.HeslanJ.-M.OuabedA.HeslanM.et al (2006). Differential pattern recognition receptor expression but stereotyped responsiveness in rat spleen dendritic cell subsets.J. Immunol.17710071016. 10.4049/jimmunol.177.2.1007

  • 121

    HumeD. A.CarusoM.Ferrari-CestariM.SummersK. M.PridansC.IrvineK. M. (2020). Phenotypic impacts of CSF1R deficiencies in humans and model organisms.J. Leukoc. Biol.107205219. 10.1002/JLB.MR0519-143R

  • 122

    HurJ. K.KimK.BeenK. W.BaekG.YeS.HurJ. W.et al (2016). Targeted mutagenesis in mice by electroporation of Cpf1 ribonucleoproteins.Nat. Biotechnol.34807808. 10.1038/nbt.3596

  • 123

    HwangD. Y.SinJ. S.KimM. S.YimS. Y.KimY. K.KimC. K.et al (2008). Overexpression of human selenoprotein M differentially regulates the concentrations of antioxidants and H2O2, the activity of antioxidant enzymes, and the composition of white blood cells in a transgenic rat.Int. J. Mol. Med.21169179.

  • 124

    IkedaA.FujiiW.SugiuraK.NaitoK. (2019). High-fidelity endonuclease variant HypaCas9 facilitates accurate allele-specific gene modification in mouse zygotes.Commun. Biol.2:371. 10.1038/s42003-019-0627-8

  • 125

    InuiM.MiyadoM.IgarashiM.TamanoM.KuboA.YamashitaS.et al (2014). Rapid generation of mouse models with defined point mutations by the CRISPR/Cas9 system.Sci. Rep.4:5396. 10.1038/srep05396

  • 126

    IrvineK. M.CarusoM.CestariM. F.DavisG. M.KeshvariS.SehgalA.et al (2020). Analysis of the impact of CSF-1 administration in adult rats using a novel Csf1r-mApple reporter gene.J. Leukoc. Biol.107221235. 10.1002/JLB.MA0519-149R

  • 127

    IscacheA.-L.MénoretS.TessonL.RémyS.UsalC.PedrosC.et al (2011). Effects of BCL-2 over-expression on B cells in transgenic rats and rat hybridomas.Int. Immunol.23625636. 10.1093/intimm/dxr071

  • 128

    JacobH. J. (2010). “The Rat: a model used in biomedical research,” in Rat Genomics: Methods and Protocols Methods in Molecular Biology, ed.AnegonI. (Totowa, NJ: Humana Press), 111. 10.1007/978-1-60327-389-3_1

  • 129

    JangD. E.LeeJ. Y.LeeJ. H.KooO. J.BaeH. S.JungM. H.et al (2018). Multiple sgRNAs with overlapping sequences enhance CRISPR/Cas9-mediated knock-in efficiency.Exp. Mol. Med.50:16. 10.1038/s12276-018-0037-x

  • 130

    JanssenJ. M.ChenX.LiuJ.GonçalvesM. A. F. V. (2019). The chromatin structure of CRISPR-Cas9 Target DNA controls the balance between mutagenic and homology-directed gene-editing events.Mol. Ther. Nucleic Acids16141154. 10.1016/j.omtn.2019.02.009

  • 131

    JessopD. S.MurphyD.LarsenP. J. (1995). Thymic vasopressin (AVP) transgene expression in rats: a model for the study of thymic AVP hyper-expression in T cell differentiation.J. Neuroimmunol.628590. 10.1016/0165-5728(95)00107-d

  • 132

    JiangF.DoudnaJ. A. (2017). CRISPR-Cas9 structures and mechanisms.Annu. Rev. Biophys.46505529. 10.1146/annurev-biophys-062215-010822

  • 133

    JinekM.ChylinskiK.FonfaraI.HauerM.DoudnaJ. A.CharpentierE. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.Science337816821. 10.1126/science.1225829

  • 134

    JinekM.JiangF.TaylorD. W.SternbergS. H.KayaE.MaE.et al (2014). Structures of Cas9 endonucleases reveal RNA-mediated conformational activation.Science343:1247997. 10.1126/science.1247997

  • 135

    JoyceC.BurtonD. R.BrineyB. (2020). Comparisons of the antibody repertoires of a humanized rodent and humans by high throughput sequencing.Sci. Rep.10:1120. 10.1038/s41598-020-57764-7

  • 136

    JoynerA. L.SkarnesW. C.RossantJ. (1989). Production of a mutation in mouse En-2 gene by homologous recombination in embryonic stem cells.Nature338153156. 10.1038/338153a0

  • 137

    JungC. J.MénoretS.BrusselleL.TessonL.UsalC.ChenouardV.et al (2016). Comparative analysis of piggyBac, CRISPR/Cas9 and TALEN mediated BAC transgenesis in the zygote for the generation of humanized SIRPA rats.Sci. Rep.6:31455. 10.1038/srep31455

  • 138

    JungC. J.ZhangJ.TrenchardE.LloydK. C.WestD. B.RosenB.et al (2017). Efficient gene targeting in mouse zygotes mediated by CRISPR/Cas9-protein.Transgenic Res.26263277. 10.1007/s11248-016-9998-5

  • 139

    JungE.GardnerD.ChoiD.ParkE.Jin SeongY.YangS.et al (2017). Development and characterization of A Novel Prox1-EGFP lymphatic and schlemm’s canal reporter rat.Sci. Rep.7:5577. 10.1038/s41598-017-06031-3

  • 140

    JusticeM. J.NoveroskeJ. K.WeberJ. S.ZhengB.BradleyA. (1999). Mouse ENU mutagenesis.Hum. Mol. Genet.819551963. 10.1093/hmg/8.10.1955

  • 141

    KanekoT.MashimoT. (2015). Simple genome editing of rodent intact embryos by electroporation.PLoS One10:e0142755. 10.1371/journal.pone.0142755

  • 142

    KanekoT.NakagawaY. (2020). Genome editing of rodents by electroporation of CRISPR/Cas9 into frozen-warmed pronuclear-stage embryos.Cryobiology92231234. 10.1016/j.cryobiol.2020.01.016

  • 143

    KanekoT.SakumaT.YamamotoT.MashimoT. (2014). Simple knockout by electroporation of engineered endonucleases into intact rat embryos.Sci. Rep.4:6382. 10.1038/srep06382

  • 144

    KartjeZ. J.BarkauC. L.RohillaK. J.AgeelyE. A.GagnonK. T. (2018). Chimeric guides probe and enhance Cas9 biochemical activity.Biochemistry5730273031. 10.1021/acs.biochem.8b00107

  • 145

    KawamataM.OchiyaT. (2010). Generation of genetically modified rats from embryonic stem cells.Proc. Natl. Acad. Sci. U.S.A.1071422314228. 10.1073/pnas.1009582107

  • 146

    KenawiM.RougerE.IslandM.-L.LeroyerP.RobinF.RémyS.et al (2019). Ceruloplasmin deficiency does not induce macrophagic iron overload: lessons from a new rat model of hereditary aceruloplasminemia.FASEB J.331349213502. 10.1096/fj.201901106R

  • 147

    KepplerO. T.WelteF. J.NgoT. A.ChinP. S.PattonK. S.TsouC.-L.et al (2002). Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1.J. Exp. Med.195719736. 10.1084/jem.20011549

  • 148

    KhristiV.GhoshS.ChakravarthiV. P.WolfeM. W.RumiM. A. K. (2019). Transcriptome data analyses of prostatic hyperplasia in Esr2 knockout rats.Data Brief.24:103826. 10.1016/j.dib.2019.103826

  • 149

    KimE.KooT.ParkS. W.KimD.KimK.ChoH.-Y.et al (2017). In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni.Nat Commun8:14500. 10.1038/ncomms14500

  • 150

    KimE. Y.Yazdizadeh ShotorbaniP.DryerS. E. (2018). Trpc6 inactivation confers protection in a model of severe nephrosis in rats.J. Mol. Med.96631644. 10.1007/s00109-018-1648-3

  • 151

    KimH.KimM.ImS.-K.FangS. (2018). Mouse Cre-LoxP system: general principles to determine tissue-specific roles of target genes.Lab. Anim. Res.34147159. 10.5625/lar.2018.34.4.147

  • 152

    KimS.KooT.JeeH.-G.ChoH.-Y.LeeG.LimD.-G.et al (2018). CRISPR RNAs trigger innate immune responses in human cells.Genome Res.28367373. 10.1101/gr.231936.117

  • 153

    KimS.KimD.ChoS. W.KimJ.KimJ.-S. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins.Genome Res.2410121019. 10.1101/gr.171322.113

  • 154

    KimY.CheongS.-A.LeeJ. G.LeeS.-W.LeeM. S.BaekI.-J.et al (2016). Generation of knockout mice by Cpf1-mediated gene targeting.Nat. Biotechnol.34808810. 10.1038/nbt.3614

  • 155

    KitadaK.IshishitaS.TosakaK.TakahashiR.UedaM.KengV. W.et al (2007). Transposon-tagged mutagenesis in the rat.Nat. Methods4131133. 10.1038/nmeth1002

  • 156

    KobayashiT.Kato-ItohM.YamaguchiT.TamuraC.SanboM.HirabayashiM.et al (2012). Identification of rat Rosa26 locus enables generation of knock-in rat lines ubiquitously expressing tdTomato.Stem Cells Dev.2129812986. 10.1089/scd.2012.0065

  • 157

    KobayashiT.NambaM.KoyanoT.FukushimaM.SatoM.OhtsukaM.et al (2018). Successful production of genome-edited rats by the rGONAD method.BMC Biotechnol.18:19. 10.1186/s12896-018-0430-5

  • 158

    KollerB. H.HagemannL. J.DoetschmanT.HagamanJ. R.HuangS.WilliamsP. J.et al (1989). Germ-line transmission of a planned alteration made in a hypoxanthine phosphoribosyltransferase gene by homologous recombination in embryonic stem cells.Proc. Natl. Acad. Sci. U.S.A.8689278931. 10.1073/pnas.86.22.8927

  • 159

    KomorA. C.KimY. B.PackerM. S.ZurisJ. A.LiuD. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.Nature533420424. 10.1038/nature17946

  • 160

    KuijkE. W.RasmussenS.BlokzijlF.HuchM.GehartH.ToonenP.et al (2016). Generation and characterization of rat liver stem cell lines and their engraftment in a rat model of liver failure.Sci. Rep.6:22154. 10.1038/srep22154

  • 161

    LabuhnM.AdamsF. F.NgM.KnoessS.SchambachA.CharpentierE. M.et al (2018). Refined sgRNA efficacy prediction improves large- and small-scale CRISPR–Cas9 applications.Nucleic Acids Res.4613751385. 10.1093/nar/gkx1268

  • 162

    LabunK.MontagueT. G.KrauseM.Torres CleurenY. N.TjeldnesH.ValenE. (2019). CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing.Nucleic Acids Res.47W171W174. 10.1093/nar/gkz365

  • 163

    Lamas-ToranzoI.Martínez-MoroA.O CallaghanE.Millán-BlancaG.SánchezJ. M.LonerganP.et al (2020). RS-1 enhances CRISPR-mediated targeted knock-in in bovine embryos.Mol. Reprod. Dev.87542549. 10.1002/mrd.23341

  • 164

    LambertM.CapuanoV.BoetA.TessonL.BerteroT.NakhlehM. K.et al (2019). Characterization of Kcnk3-Mutated rat, a novel model of pulmonary hypertension.Circ. Res.125678695. 10.1161/CIRCRESAHA.119.314793

  • 165

    LanzaD. G.GasperoA.LorenzoI.LiaoL.ZhengP.WangY.et al (2018). Comparative analysis of single-stranded DNA donors to generate conditional null mouse alleles.BMC Biol.16:69. 10.1186/s12915-018-0529-0

  • 166

    LarcherT.LafouxA.TessonL.RemyS.ThepenierV.FrançoisV.et al (2014). Characterization of dystrophin deficient rats: a new model for duchenne muscular dystrophy.PLoS One9:e110371. 10.1371/journal.pone.0110371

  • 167

    LaunayP.GrossetêteB.Arcos-FajardoM.GaudinE.TorresS. P.BeaudoinL.et al (2000). Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice.J. Exp. Med.19119992009. 10.1084/jem.191.11.1999

  • 168

    LeQ.NguyenV.ParkS. (2019). Recent advances in the engineering and application of streptavidin-like molecules.Appl. Microbiol. Biotechnol.10373557365. 10.1007/s00253-019-10036-5

  • 169

    LeeC. M.BarberG. P.CasperJ.ClawsonH.DiekhansM.GonzalezJ. N.et al (2020). UCSC Genome Browser enters 20th year.Nucleic Acids Res.48D756D761. 10.1093/nar/gkz1012

  • 170

    LeeH. K.WilliM.MillerS. M.KimS.LiuC.LiuD. R.et al (2018). Targeting fidelity of adenine and cytosine base editors in mouse embryos.Nat. Commun.9:4804. 10.1038/s41467-018-07322-7

  • 171

    LeeH. K.WilliM.SmithH. E.MillerS. M.LiuD. R.LiuC.et al (2019). Simultaneous targeting of linked loci in mouse embryos using base editing.Sci. Rep.9:1662. 10.1038/s41598-018-33533-5

  • 172

    LeeJ. G.HaC. H.YoonB.CheongS.-A.KimG.LeeD. J.et al (2019). Knockout rat models mimicking human atherosclerosis created by Cpf1-mediated gene targeting.Sci. Rep.9:2628. 10.1038/s41598-019-38732-2

  • 173

    LeeK.MackleyV. A.RaoA.ChongA. T.DewittM. A.CornJ. E.et al (2017). Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering.Elife6:e25312. 10.7554/eLife.25312

  • 174

    LelanF.BoyerC.ThinardR.RémyS.UsalC.TessonL.et al (2011). Effects of human alpha-synuclein A53T-A30P mutations on SVZ and local olfactory bulb cell proliferation in a transgenic rat model of parkinson disease.Parkinsons Dis.2011:987084. 10.4061/2011/987084

  • 175

    LermanL. O.KurtzT. W.TouyzR. M.EllisonD. H.ChadeA. R.CrowleyS. D.et al (2019). Animal models of hypertension: a scientific statement from the american heart association.Hypertension73e87e120. 10.1161/HYP.0000000000000090

  • 176

    LiD.QiuZ.ShaoY.ChenY.GuanY.LiuM.et al (2013). Heritable gene targeting in the mouse and rat using a CRISPR-Cas system.Nat. Biotechnol.31681683. 10.1038/nbt.2661

  • 177

    LiW.TengF.LiT.ZhouQ. (2013). Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems.Nat. Biotechnol.31684686. 10.1038/nbt.2652

  • 178

    LiP.TongC.Mehrian-ShaiR.JiaL.WuN.YanY.et al (2008). Germline competent embryonic stem cells derived from rat blastocysts.Cell13512991310. 10.1016/j.cell.2008.12.006

  • 179

    LiQ.KingmanJ.van de WeteringK.TannouriS.SundbergJ. P.UittoJ. (2017). Abcc6 knockout rat model highlights the role of liver in PPi homeostasis in pseudoxanthoma elasticum.J. Invest. Dermatol.13710251032. 10.1016/j.jid.2016.11.042

  • 180

    LiangP.SunH.SunY.ZhangX.XieX.ZhangJ.et al (2017). Effective gene editing by high-fidelity base editor 2 in mouse zygotes.Protein Cell8601611. 10.1007/s13238-017-0418-2

  • 181

    LiangX.PotterJ.KumarS.RavinderN.ChesnutJ. D. (2017). Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA.J. Biotechnol.241136146. 10.1016/j.jbiotec.2016.11.011

  • 182

    LingX.XieB.GaoX.ChangL.ZhengW.ChenH.et al (2020). Improving the efficiency of precise genome editing with site-specific Cas9-oligonucleotide conjugates.Sci. Adv.6:eaaz0051. 10.1126/sciadv.aaz0051

  • 183

    LiuC.LiY.PengM.LatiesA. M.WenR. (1999). Activation of caspase-3 in the retina of transgenic rats with the rhodopsin mutation s334ter during photoreceptor degeneration.J. Neurosci.1947784785.

  • 184

    LiuK.JinH.ZhouB. (2020). Genetic lineage tracing with multiple DNA recombinases: a user’s guide for conducting more precise cell fate mapping studies.J. Biol. Chem.29564136424. 10.1074/jbc.REV120.011631

  • 185

    LiuY.LiX.HeS.HuangS.LiC.ChenY.et al (2020). Efficient generation of mouse models with the prime editing system.Cell Discovery6:27. 10.1038/s41421-020-0165-z

  • 186

    LiuZ.SchielJ. A.MaksimovaE.StrezoskaŽZhaoG.AndersonE. M.et al (2020). ErCas12a CRISPR-MAD7 for model generation in human cells, mice, and rats.CRISPR J.397108. 10.1089/crispr.2019.0068

  • 187

    LiuQ.ZhouS.FanC.HuangW.LiQ.LiuS.et al (2017). Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging.Sci. Rep.7:3597. 10.1038/s41598-017-03852-0

  • 188

    LiuX.YuanW.LiJ.YangL.CaiJ. (2017). ANTXR2 knock-out does not result in the development of hypertension in rats.Am. J. Hypertens.30182187. 10.1093/ajh/hpw125

  • 189

    LiuZ.LuZ.YangG.HuangS.LiG.FengS.et al (2018). Efficient generation of mouse models of human diseases via ABE- and BE-mediated base editing.Nat. Commun.9:2338. 10.1038/s41467-018-04768-7

  • 190

    LomovaA.ClarkD. N.Campo-FernandezB.Flores-BjurströmC.KaufmanM. L.Fitz-GibbonS.et al (2019). Improving gene editing outcomes in human hematopoietic stem and progenitor cells by temporal control of DNA repair.Stem Cells37284294. 10.1002/stem.2935

  • 191

    Lopez RoblesM. D.PallierA.HuchetV.Le TexierL.RemyS.BraudeauC.et al (2017). Cell-surface C-type lectin-like receptor CLEC-1 dampens dendritic cell activation and downstream Th17 responses.Blood Adv.1557568. 10.1182/bloodadvances.2016002360

  • 192

    LozierJ. N.NicholsT. C. (2013). Animal models of hemophilia and related bleeding disorders.Semin. Hematol.50175184. 10.1053/j.seminhematol.2013.03.023

  • 193

    LuB.GeurtsA. M.PoirierC.PetitD. C.HarrisonW.OverbeekP. A.et al (2007). Generation of rat mutants using a coat color-tagged sleeping beauty transposon system.Mamm. Genome18338346. 10.1007/s00335-007-9025-5

  • 194

    MaM.ZhuangF.HuX.WangB.WenX.-Z.JiJ.-F.et al (2017). Efficient generation of mice carrying homozygous double-floxp alleles using the Cas9-Avidin/Biotin-donor DNA system.Cell Res.27578581. 10.1038/cr.2017.29

  • 195

    MaS.ZhangM.ZhangS.WangJ.ZhouX.GuoG.et al (2018). Characterisation of Lamp2-deficient rats for potential new animal model of danon disease.Sci. Rep.8:6932. 10.1038/s41598-018-24351-w

  • 196

    MaY.YuL.ZhangX.XinC.HuangS.BaiL.et al (2018). Highly efficient and precise base editing by engineered dCas9-guide tRNA adenosine deaminase in rats.Cell Discov.4:39. 10.1038/s41421-018-0047-9

  • 197

    MaZ.-G.DaiJ.YuanY.-P.BianZ.-Y.XuS.-C.JinY.-G.et al (2018). T-bet deficiency attenuates cardiac remodelling in rats.Basic Res. Cardiol.113:19. 10.1007/s00395-018-0678-x

  • 198

    MaX.LinW. Y.ChenY.StawickiS.MukhyalaK.WuY.et al (2012). Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R.Structure20676687. 10.1016/j.str.2012.02.010

  • 199

    MaX.ShangX.QinX.LuJ.LiuM.WangX. (2020). Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease.Acta Pharm Sin. B10850860. 10.1016/j.apsb.2019.11.007

  • 200

    MaY.ChenW.ZhangX.YuL.DongW.PanS.et al (2016). Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing in rats by inhibiting NHEJ and using Cas9 protein.RNA Biol.13605612. 10.1080/15476286.2016.1185591

  • 201

    MaY.ShenB.ZhangX.LuY.ChenW.MaJ.et al (2014a). Heritable multiplex genetic engineering in rats using CRISPR/Cas9.PLoS One9:e89413. 10.1371/journal.pone.0089413

  • 202

    MaY.ZhangX.ShenB.LuY.ChenW.MaJ.et al (2014b). Generating rats with conditional alleles using CRISPR/Cas9.Cell Res.24122125. 10.1038/cr.2013.157

  • 203

    MadeiraF.MadhusoodananN.LeeJ.TiveyA. R. N.LopezR. (2019). Using EMBL-EBI services via web interface and programmatically via web services.Curr. Protoc. Bioinformatics66:e74. 10.1002/cpbi.74

  • 204

    MakarovaK. S.WolfY. I.IranzoJ.ShmakovS. A.AlkhnbashiO. S.BrounsS. J. J.et al (2020). Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants.Nat. Rev. Microbiol.186783. 10.1038/s41579-019-0299-x

  • 205

    ManaudG.NossentE. J.LambertM.GhignaM.-R.BoëtA.VinhasM.-C.et al (2020). Comparison of human and experimental pulmonary veno-occlusive disease.Am. J. Respir. Cell Mol. Biol.63118131. 10.1165/rcmb.2019-0015OC

  • 206

    MarsanE.IshidaS.SchrammA.WeckhuysenS.MuracaG.LecasS.et al (2016). Depdc5 knockout rat: a novel model of mTORopathy.Neurobiol. Dis.89180189. 10.1016/j.nbd.2016.02.010

  • 207

    MartinG. R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells.Proc. Natl. Acad. Sci. U.S.A.7876347638. 10.1073/pnas.78.12.7634

  • 208

    MartinJ. C.BériouG.HeslanM.BossardC.JarryA.AbidiA.et al (2016). IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis.Mucosal Immunol.9539549. 10.1038/mi.2015.83

  • 209

    MartinJ. C.WolkK.BériouG.AbidiA.Witte-HändelE.LouvetC.et al (2017). Limited presence of IL-22 binding protein, a natural IL-22 inhibitor, strengthens psoriatic skin inflammation.J. Immunol.19836713678. 10.4049/jimmunol.1700021

  • 210

    MaruokaT.NagataT.KasaharaM. (2004). Identification of the rat IgA Fc receptor encoded in the leukocyte receptor complex.Immunogenetics55712716. 10.1007/s00251-003-0626-1

  • 211

    MaruyamaT.DouganS. K.TruttmannM. C.BilateA. M.IngramJ. R.PloeghH. L. (2015). Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.Nat. Biotechnol.33:538. 10.1038/nbt.3190

  • 212

    MashimoT.KanekoT.SakumaT.KobayashiJ.KunihiroY.VoigtB.et al (2013). Efficient gene targeting by TAL effector nucleases coinjected with exonucleases in zygotes.Sci. Rep.3:1253. 10.1038/srep01253

  • 213

    MashimoT.TakizawaA.KobayashiJ.KunihiroY.YoshimiK.IshidaS.et al (2012). Generation and characterization of severe combined immunodeficiency rats.Cell Rep.2685694. 10.1016/j.celrep.2012.08.009

  • 214

    MashimoT.TakizawaA.VoigtB.YoshimiK.HiaiH.KuramotoT.et al (2010). Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases.PLoS One5:e8870. 10.1371/journal.pone.0008870

  • 215

    McCoyA.Besch-WillifordC. L.FranklinC. L.WeinsteinE. J.CuiX. (2013). Creation and preliminary characterization of a Tp53 knockout rat.Dis. Model Mech.6269278. 10.1242/dmm.009704

  • 216

    MeekS.BuehrM.SutherlandL.ThomsonA.MullinsJ. J.SmithA. J.et al (2010). Efficient gene targeting by homologous recombination in rat embryonic stem cells.PLoS One5:e14225. 10.1371/journal.pone.0014225

  • 217

    MendiasC. L.LynchE. B.GumucioJ. P.FloodM. D.RittmanD. S.Van PeltD. W.et al (2015). Changes in skeletal muscle and tendon structure and function following genetic inactivation of myostatin in rats.J. Physiol.59320372052. 10.1113/jphysiol.2014.287144

  • 218

    MénoretS.De CianA.TessonL.RemyS.UsalC.BouléJ.-B.et al (2015). Homology-directed repair in rodent zygotes using Cas9 and TALEN engineered proteins.Sci. Rep.5:14410. 10.1038/srep14410

  • 219

    MénoretS.FontanièreS.JantzD.TessonL.ThinardR.RémyS.et al (2013). Generation of Rag1-knockout immunodeficient rats and mice using engineered meganucleases.FASEB J.27703711. 10.1096/fj.12-219907

  • 220

    MénoretS.IscacheA.-L.TessonL.RémyS.UsalC.OsbornM. J.et al (2010). Characterization of immunoglobulin heavy chain knockout rats.Eur. J. Immunol.4029322941. 10.1002/eji.201040939

  • 221

    MénoretS.OuisseL.-H.TessonL.DelbosF.GarnierD.RemyS.et al (2018). Generation of immunodeficient rats with Rag1 and Il2rg gene deletions and human tissue grafting models.Transplantation10212711278. 10.1097/TP.0000000000002251

  • 222

    MénoretS.OuisseL.-H.TessonL.RemyS.UsalC.GuiffesA.et al (2020). In vivo analysis of human immune responses in immunodeficient rats.Transplantation104715723. 10.1097/TP.0000000000003047

  • 223

    MichalkiewiczM.MichalkiewiczT.EttingerR. A.RutledgeE. A.FullerJ. M.MoralejoD. H.et al (2004). Transgenic rescue demonstrates involvement of the Ian5 gene in T cell development in the rat.Physiol. Genomics19228232. 10.1152/physiolgenomics.00126.2004

  • 224

    MillerJ. J.AokiK.MoehringF.MurphyC. A.O’HaraC. L.TiemeyerM.et al (2018). Neuropathic pain in a Fabry disease rat model.JCI Insight3:e99171. 10.1172/jci.insight.99171

  • 225

    MiuraH.GurumurthyC. B.SatoT.SatoM.OhtsukaM. (2015). CRISPR/Cas9-based generation of knockdown mice by intronic insertion of artificial microRNA using longer single-stranded DNA.Sci. Rep.5:12799. 10.1038/srep12799

  • 226

    MiyasakaY.UnoY.YoshimiK.KunihiroY.YoshimuraT.TanakaT.et al (2018). CLICK: one-step generation of conditional knockout mice.BMC Genomics19:318. 10.1186/s12864-018-4713-y

  • 227

    MizunoN.MizutaniE.SatoH.KasaiM.OgawaA.SuchyF.et al (2018). Intra-embryo gene cassette knockin by CRISPR/Cas9-mediated genome editing with adeno-associated viral vector.iScience9286297. 10.1016/j.isci.2018.10.030

  • 228

    ModiM. E.BrooksJ. M.GuilmetteE. R.BeynaM.GrafR.ReimD.et al (2018). Hyperactivity and Hypermotivation associated with increased striatal mGluR1 signaling in a Shank2 Rat model of autism.Front. Mol. Neurosci.11:107. 10.3389/fnmol.2018.00107

  • 229

    MorenoC.HoffmanM.StodolaT. J.DidierD. N.LazarJ.GeurtsA. M.et al (2011). Creation and characterization of a renin knockout rat.Hypertension57614619. 10.1161/HYPERTENSIONAHA.110.163840

  • 230

    Moreno-MateosM. A.VejnarC. E.BeaudoinJ.-D.FernandezJ. P.MisE. K.KhokhaM. K.et al (2015). CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo.Nat. Methods12982988. 10.1038/nmeth.3543

  • 231

    MoutalA.YangX.LiW.GilbraithK. B.LuoS.CaiS.et al (2017). CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.Pain15823012319. 10.1097/j.pain.0000000000001002

  • 232

    MullinsJ. J.PetersJ.GantenD. (1990). Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene.Nature344541544. 10.1038/344541a0

  • 233

    NaitoY.HinoK.BonoH.Ui-TeiK. (2015). CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites.Bioinformatics3111201123. 10.1093/bioinformatics/btu743

  • 234

    NakadeS.MochidaK.KuniiA.NakamaeK.AidaT.TanakaK.et al (2018). Biased genome editing using the local accumulation of DSB repair molecules system.Nat. Commun.9:3270. 10.1038/s41467-018-05773-6

  • 235

    NakagawaY.SakumaT.TakeoT.NakagataN.YamamotoT. (2018). Electroporation-mediated genome editing in vitrified/warmed mouse zygotes created by IVF via ultra-superovulation.Exp. Anim.67535543. 10.1538/expanim.18-0062

  • 236

    NakamuraK.FujiiW.TsuboiM.TanihataJ.TeramotoN.TakeuchiS.et al (2014). Generation of muscular dystrophy model rats with a CRISPR/Cas system.Sci. Rep.4:5635. 10.1038/srep05635

  • 237

    NavabpourS.KwapisJ. L.JaromeT. J. (2020). A neuroscientist’s guide to transgenic mice and other genetic tools.Neurosci. Biobehav. Rev.108732748. 10.1016/j.neubiorev.2019.12.013

  • 238

    NayakS.KhanM. A. H.WanT. C.PeiH.LindenJ.DwinellM. R.et al (2015). Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension.Purinergic Signal.11519531. 10.1007/s11302-015-9470-7

  • 239

    NegishiE.FukudaN.OtsukiT.KatakawaM.KomatsuK.ChenL.et al (2018). Involvement of complement 3 in the salt-sensitive hypertension by activation of renal renin-angiotensin system in spontaneously hypertensive rats.Am. J. Physiol. Renal Physiol.315F1747F1758. 10.1152/ajprenal.00370.2018

  • 240

    NessD.RenZ.GardaiS.SharpnackD.JohnsonV. J.BrennanR. J.et al (2013). Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis.PLoS One8:e66164. 10.1371/journal.pone.0066164

  • 241

    NguyenD. N.RothT. L.LiP. J.ChenP. A.ApathyR.MamedovM. R.et al (2020). Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency.Nat. Biotechnol.384449. 10.1038/s41587-019-0325-6

  • 242

    NielsenL. N.WiinbergB.HägerM.HolmbergH. L.HansenJ. J.RoepstorffK.et al (2014). A novel F8 -/- rat as a translational model of human hemophilia A.J. Thromb. Haemost.1212741282. 10.1111/jth.12635

  • 243

    NiewieskS.Schneider-SchauliesJ.OhnimusH.JassoyC.Schneider-SchauliesS.DiamondL.et al (1997). CD46 expression does not overcome the intracellular block of measles virus replication in transgenic rats.J. Virol.7179697973.

  • 244

    NiihoriM.EcclesC. A.KurdyukovS.ZemskovaM.VargheseM. V.StepanovaA. A.et al (2020). Rats with a human mutation of NFU1 develop pulmonary hypertension.Am. J. Respir. Cell Mol. Biol.62231242. 10.1165/rcmb.2019-0065OC

  • 245

    NishidaK.ArazoeT.YachieN.BannoS.KakimotoM.TabataM.et al (2016). Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems.Science353:aaf8729. 10.1126/science.aaf8729

  • 246

    NishimasuH.RanF. A.HsuP. D.KonermannS.ShehataS. I.DohmaeN.et al (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA.Cell156935949. 10.1016/j.cell.2014.02.001

  • 247

    NishitaniA.KunisawaN.SugimuraT.SatoK.YoshidaY.SuzukiT.et al (2019). Loss of HCN1 subunits causes absence epilepsy in rats.Brain Res.1706209217. 10.1016/j.brainres.2018.11.004

  • 248

    NishitaniA.NagayoshiH.TakenakaS.AsanoM.ShimizuS.OhnoY.et al (2020). Involvement of NMDA receptors in tremor expression in Aspa/Hcn1 double-knockout rats.Exp. Anim.69388394. 10.1538/expanim.20-0025

  • 249

    NishitaniA.TanakaM.ShimizuS.KunisawaN.YokoeM.YoshidaY.et al (2016). Involvement of aspartoacylase in tremor expression in rats.Exp. Anim.65293301. 10.1538/expanim.16-0007

  • 250

    NotoF. K.Adjan-SteffeyV.TongM.RavichandranK.ZhangW.AreyA.et al (2018). Sprague dawley Rag2-null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts.Mol. Cancer Ther.1724812489. 10.1158/1535-7163.MCT-18-0156

  • 251

    NotoF. K.SangodkarJ.AdedejiB. T.MoodyS.McClainC. B.TongM.et al (2020). The SRG rat, a sprague-dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.PLoS One15:e0240169. 10.1371/journal.pone.0240169

  • 252

    OhtsukaM.SatoM.MiuraH.TakabayashiS.MatsuyamaM.KoyanoT.et al (2018). i-GONAD: a robust method for in situ germline genome engineering using CRISPR nucleases.Genome Biol.19:25. 10.1186/s13059-018-1400-x

  • 253

    OkadaK.ItohH.KamikuboY.AdachiS.IkemotoM. (2018). Establishment of S100A8 transgenic rats to understand innate property of S100A8 and its immunological role.Inflammation415972. 10.1007/s10753-017-0664-8

  • 254

    OkuyamaM.FunahashiH. (2012). Glycosaminoglycans improves early development of zona-free 8-cell rat embryos to blastocysts in a chemically defined medium, but not the pregnancy rate following transfer of the blastocysts.J. Reprod. Dev.58295301. 10.1262/jrd.11-092h

  • 255

    OngG. L.MattesM. J. (1989). Mouse strains with typical mammalian levels of complement activity.J. Immunol. Methods125147158. 10.1016/0022-1759(89)90088-4

  • 256

    OsbornM. J.MaB.AvisS.BinnieA.DilleyJ.YangX.et al (2013). High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region.J. Immunol.19014811490. 10.4049/jimmunol.1203041

  • 257

    OssartJ.MoreauA.AutrusseauE.MénoretS.MartinJ. C.BesnardM.et al (2018). Breakdown of immune tolerance in AIRE-deficient rats induces a severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy-like autoimmune disease.J. Immunol.201874887. 10.4049/jimmunol.1701318

  • 258

    OuisseL.-H.Gautreau-RollandL.DevilderM.-C.OsbornM.MoyonM.VisentinJ.et al (2017). Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies.BMC Biotechnol.17:3. 10.1186/s12896-016-0322-5

  • 259

    OuisseL.-H.RemyS.LafouxA.LarcherT.TessonL.ChenouardV.et al (2019). Immunophenotype of a Rat model of duchenne’s disease and demonstration of improved muscle strength after anti-CD45RC antibody treatment.Front. Immunol.10:2131. 10.3389/fimmu.2019.02131

  • 260

    PalmerN.KaldisP. (2016). “Chapter One - regulation of the embryonic cell cycle during mammalian preimplantation development,” in Current Topics in Developmental Biology Mammalian Preimplantation Development, ed.DePamphilisM. L. (Cambridge, MA: Academic Press), 153. 10.1016/bs.ctdb.2016.05.001

  • 261

    PalmiterR. D.BrinsterR. L.HammerR. E.TrumbauerM. E.RosenfeldM. G.BirnbergN. C.et al (1982). Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes.Nature300611615. 10.1038/300611a0

  • 262

    PandeyS.DvorakovaM. C. (2020). Future perspective of diabetic animal models.Endocr. Metab. Immune Disord. Drug Targets202538. 10.2174/1871530319666190626143832

  • 263

    PanzerS. E.WilsonN. A.VerhovenB. M.XiangD.RubinsteinC. D.RedfieldR. R.et al (2018). Complete B cell deficiency reduces allograft inflammation and intragraft macrophages in a rat kidney transplant model.Transplantation102396405. 10.1097/TP.0000000000002010

  • 264

    PattersonK. C.HawkinsV. E.ArpsK. M.MulkeyD. K.OlsenM. L. (2016). MeCP2 deficiency results in robust Rett-like behavioural and motor deficits in male and female rats.Hum. Mol. Genet.2533033320. 10.1093/hmg/ddw179

  • 265

    PengH.ZhengY.ZhaoZ.LiuT.LiJ. (2018). Recognition of CRISPR/Cas9 off-target sites through ensemble learning of uneven mismatch distributions.Bioinformatics34i757i765. 10.1093/bioinformatics/bty558

  • 266

    PengW.LiM.LiH.TangK.ZhuangJ.ZhangJ.et al (2017). Dysfunction of myosin light-chain 4 (MYL4) leads to heritable atrial cardiomyopathy with electrical, contractile, and structural components: evidence from genetically-engineered rats.J. Am. Heart Assoc.6:e007030. 10.1161/JAHA.117.007030

  • 267

    Phadnis-MogheA. S.ChenW.LiJ.CrawfordR. B.BachA.D’IngilloS.et al (2016). Immunological characterization of the aryl hydrocarbon receptor (AHR) knockout rat in the presence and absence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).Toxicology368–369172182. 10.1016/j.tox.2016.08.019

  • 268

    PhilipeauxJ. (1856). Note sur l’extirpation des capsules surrénales chez les rats albinos (Mus ratus).C. R. Acad. Sci.43904906.

  • 269

    Pickar-OliverA.GersbachC. A. (2019). The next generation of CRISPR-Cas technologies and applications.Nat. Rev. Mol. Cell Biol.20490507. 10.1038/s41580-019-0131-5

  • 270

    PlaasM.SeppaK.ReimetsR.JagomäeT.TootsM.KoppelT.et al (2017). Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration.Sci. Rep.7:10220. 10.1038/s41598-017-09392-x

  • 271

    PlattJ. L.CascalhoM. (2018). B Cells in transplantation of rat, mouse, and man.Transplantation102357358. 10.1097/TP.0000000000002051

  • 272

    Ponce de LeónV.MérillatA.-M.TessonL.AnegónI.HummlerE. (2014). Generation of TALEN-mediated GRdim knock-in rats by homologous recombination.PLoS One9:e88146. 10.1371/journal.pone.0088146

  • 273

    PridansC.RaperA.DavisG. M.AlvesJ.SauterK. A.LefevreL.et al (2018). Pleiotropic impacts of macrophage and microglial deficiency on development in rats with targeted mutation of the Csf1r locus.J. Immunol.20126832699. 10.4049/jimmunol.1701783

  • 274

    QaisarN.LinS.RyanG.YangC.OikemusS. R.BrodskyM. H.et al (2017). A critical role for the type I interferon receptor in virus-induced autoimmune diabetes in rats.Diabetes66145157. 10.2337/db16-0462

  • 275

    QinW.DionS. L.KutnyP. M.ZhangY.ChengA. W.JilletteN. L.et al (2015). Efficient CRISPR/Cas9-mediated genome editing in mice by zygote electroporation of nuclease.Genetics200423430. 10.1534/genetics.115.176594

  • 276

    QuekH.LuffJ.CheungK.KozlovS.GateiM.LeeC. S.et al (2017). Rats with a missense mutation in Atm display neuroinflammation and neurodegeneration subsequent to accumulation of cytosolic DNA following unrepaired DNA damage.J. Leukoc. Biol.101927947. 10.1189/jlb.4VMA0716-316R

  • 277

    Ramírez-SolisR.LiuP.BradleyA. (1995). Chromosome engineering in mice.Nature378720724. 10.1038/378720a0

  • 278

    RanF. A.HsuP. D.LinC.-Y.GootenbergJ. S.KonermannS.TrevinoA. E.et al (2013). Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.Cell15413801389. 10.1016/j.cell.2013.08.021

  • 279

    RanchouxB.AntignyF.Rucker-MartinC.HautefortA.PéchouxC.BogaardH. J.et al (2015). Endothelial-to-mesenchymal transition in pulmonary hypertension.Circulation13110061018. 10.1161/CIRCULATIONAHA.114.008750

  • 280

    RanjhaL.HowardS. M.CejkaP. (2018). Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes.Chromosoma127187214. 10.1007/s00412-017-0658-1

  • 281

    ReesH. A.LiuD. R. (2018). Base editing: precision chemistry on the genome and transcriptome of living cells.Nat. Rev. Genet.19770788. 10.1038/s41576-018-0059-1

  • 282

    RemyS.ChenouardV.TessonL.UsalC.MénoretS.BrusselleL.et al (2017). Generation of gene-edited rats by delivery of CRISPR/Cas9 protein and donor DNA into intact zygotes using electroporation.Sci. Rep.7:16554. 10.1038/s41598-017-16328-y

  • 283

    RemyS.TessonL.MenoretS.UsalC.De CianA.ThepenierV.et al (2014). Efficient gene targeting by homology-directed repair in rat zygotes using TALE nucleases.Genome Res.2413711383. 10.1101/gr.171538.113

  • 284

    RenaudJ.-B.BoixC.CharpentierM.De CianA.CochennecJ.Duvernois-BerthetE.et al (2016). Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases.Cell Rep.1422632272. 10.1016/j.celrep.2016.02.018

  • 285

    RenaudS. J.ScottR. L.ChakrabortyD.RumiM. A. K.SoaresM. J. (2017). Natural killer-cell deficiency alters placental development in rats.Biol. Reprod.96145158. 10.1095/biolreprod.116.142752

  • 286

    RichardsonC. D.RayG. J.DeWittM. A.CurieG. L.CornJ. E. (2016). Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA.Nat. Biotechnol.34339344. 10.1038/nbt.3481

  • 287

    RobertsonA. S.MajchrzakM. J.SmithC. M.GagnonR. C.DevidzeN.BanksG. B.et al (2017). Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents.Neuromuscul. Disord.27635645. 10.1016/j.nmd.2017.05.009

  • 288

    RobertsonL.PederickD.PiltzS.WhiteM.NietoA.AhladasM.et al (2018). Expanding the RNA-guided endonuclease toolkit for mouse genome editing.CRISPR J.1431439. 10.1089/crispr.2018.0050

  • 289

    RudemillerN.LundH.JacobH. J.GeurtsA. M.MattsonD. L.PhysGen Knockout Program (2014). CD247 modulates blood pressure by altering T-lymphocyte infiltration in the kidney.Hypertension63559564. 10.1161/HYPERTENSIONAHA.113.02191

  • 290

    RumiM. A. K.DhakalP.KubotaK.ChakrabortyD.LeiT.LarsonM. A.et al (2014). Generation of Esr1-knockout rats using zinc finger nuclease-mediated genome editing.Endocrinology15519911999. 10.1210/en.2013-2150

  • 291

    SamataB.KikuchiT.MiyawakiY.MorizaneA.MashimoT.NakagawaM.et al (2015). X-linked severe combined immunodeficiency (X-SCID) rats for xeno-transplantation and behavioral evaluation.J. Neurosci. Methods2436877. 10.1016/j.jneumeth.2015.01.027

  • 292

    SatoM.TakabayashiS.AkasakaE.NakamuraS. (2020). Recent advances and future perspectives of in vivo targeted delivery of genome-editing reagents to germ cells, embryos, and fetuses in mice.Cells9:799. 10.3390/cells9040799

  • 293

    SaundersT. (2020). Single Copy Transgene Integration in ROSA26 Safe Harbor. International Society for Transgenic Technologies. Available online at: https://www.transtechsociety.org/index.php?src=blog&srctype=detail&blogid=19(accessed September 29, 2020).

  • 294

    SayersE. W.AgarwalaR.BoltonE. E.BristerJ. R.CaneseK.ClarkK.et al (2019). Database resources of the national center for biotechnology information.Nucleic Acids Res.47D23D28. 10.1093/nar/gky1069

  • 295

    SchatoffE. M.ZafraM. P.DowL. E. (2019). Base editing the mammalian genome.Methods164–165100108. 10.1016/j.ymeth.2019.02.022

  • 296

    ScheimannJ. R.MoloneyR. D.MahbodP.MoranoR. L.FitzgeraldM.HoskinsO.et al (2019). Conditional deletion of glucocorticoid receptors in rat brain results in sex-specific deficits in fear and coping behaviors.eLife8:e44672. 10.7554/eLife.44672

  • 297

    SchwartzbergP. L.GoffS. P.RobertsonE. J. (1989). Germ-line transmission of a c-abl mutation produced by targeted gene disruption in ES cells.Science246799803. 10.1126/science.2554496

  • 298

    ScottK. E.SchormansA. L.PacoliK. Y.De OliveiraC.AllmanB. L.SchmidS. (2018). Altered auditory processing, filtering, and reactivity in the Cntnap2 Knock-out rat model for neurodevelopmental disorders.J. Neurosci.3885888604. 10.1523/JNEUROSCI.0759-18.2018

  • 299

    ShapiroJ.IancuO.JacobiA. M.McNeillM. S.TurkR.RettigG. R.et al (2020). Increasing CRISPR efficiency and measuring its specificity in HSPCs using a clinically relevant system.Mol. Ther. Methods Clin. Dev.1710971107. 10.1016/j.omtm.2020.04.027

  • 300

    ShiQ.MattsonJ. G.FahsS. A.GeurtsA. M.WeilerH.MontgomeryR. R. (2020). The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.Blood Adv.45565. 10.1182/bloodadvances.2019000944

  • 301

    ShimoyamaM.SmithJ. R.BrydaE.KuramotoT.SabaL.DwinellM. (2017). Rat Genome and Model Resources.ILAR J.584258. 10.1093/ilar/ilw041

  • 302

    ShultzL. D.SchweitzerP. A.ChristiansonS. W.GottB.SchweitzerI. B.TennentB.et al (1995). Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.J. Immunol.154180191.

  • 303

    ShutoY.ShibasakiT.OtagiriA.KuriyamaH.OhataH.TamuraH.et al (2002). Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity.J. Clin. Invest.10914291436. 10.1172/JCI13300

  • 304

    SinghP.SchimentiJ. C.Bolcun-FilasE. (2015). A mouse geneticist’s practical guide to CRISPR applications.Genetics199115. 10.1534/genetics.114.169771

  • 305

    SinkeviciusK. W.MorrisonT. R.KulkarniP.Caffrey CagliostroM. K.IriahS.MalmbergS.et al (2018). RNaseT2 knockout rats exhibit hippocampal neuropathology and deficits in memory.Dis. Model Mech.11:dmm032631. 10.1242/dmm.032631

  • 306

    SmithJ. R.HaymanG. T.WangS.-J.LaulederkindS. J. F.HoffmanM. J.KaldunskiM. L.et al (2020). The year of the rat: the rat genome database at 20: a multi-species knowledgebase and analysis platform.Nucleic Acids Res.48D731D742. 10.1093/nar/gkz1041

  • 307

    SommerD.PetersA.WirtzT.MaiM.AckermannJ.ThabetY.et al (2014). Efficient genome engineering by targeted homologous recombination in mouse embryos using transcription activator-like effector nucleases.Nat. Commun.5:3045. 10.1038/ncomms4045

  • 308

    SongA. J.PalmiterR. D. (2018). Detecting and avoiding problems when using the Cre-lox system.Trends Genet.34333340. 10.1016/j.tig.2017.12.008

  • 309

    SongJ.YangD.XuJ.ZhuT.ChenY. E.ZhangJ. (2016). RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency.Nat. Commun.7:10548. 10.1038/ncomms10548

  • 310

    SongT.-J.LanX.-Y.WeiM.-P.ZhaiF.-J.BoeckersT. M.WangJ.-N.et al (2019). Altered behaviors and impaired synaptic function in a novel rat model with a complete Shank3 deletion.Front. Cell Neurosci.13:111. 10.3389/fncel.2019.00111

  • 311

    StemmerM.ThumbergerT.KeyerM.delS.WittbrodtJ.MateoJ. L. (2015). CCTop: an intuitive, flexible and reliable CRISPR/Cas9 target prediction tool.PLoS One10:e0124633. 10.1371/journal.pone.0124633

  • 312

    SunJ.KouranovaE.CuiX.MachR. H.XuJ. (2013). Regulation of dopamine presynaptic markers and receptors in the striatum of DJ-1 and Pink1 knockout rats.Neurosci. Lett.557(Pt B), 123128. 10.1016/j.neulet.2013.10.034

  • 313

    SunY.ChenX.XiaoD. (2007). Tetracycline-inducible expression systems: new strategies and practices in the transgenic mouse modeling.Acta Biochim. Biophys. Sin.39235246. 10.1111/j.1745-7270.2007.00258.x

  • 314

    SungY. H.BaekI.-J.KimD. H.JeonJ.LeeJ.LeeK.et al (2013). Knockout mice created by TALEN-mediated gene targeting.Nat. Biotechnol.312324. 10.1038/nbt.2477

  • 315

    SzabóP. J.EbnerJ.KonigX.HamzaO.WatzingerS.TrojanekS.et al (2021). Cardiovascular phenotype of the Dmdmdx rat – a suitable animal model for Duchenne muscular dystrophy.Dis. Model. Mech.14:dmm047704. 10.1242/dmm.047704

  • 316

    SzpirerC. (2020). Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes.bioRxiv [Preprint]10.1101/2020.03.23.003384

  • 317

    Taheri-GhahfarokhiA.TaylorB. J. M.NitschR.LundinA.CavalloA.-L.Madeyski-BengtsonK.et al (2018). Decoding non-random mutational signatures at Cas9 targeted sites.Nucleic Acids Res.4684178434. 10.1093/nar/gky653

  • 318

    TakabayashiS.AoshimaT.KabashimaK.AotoK.OhtsukaM.SatoM. (2018). i-GONAD (improved genome-editing via oviductal nucleic acids delivery), a convenient in vivo tool to produce genome-edited rats.Sci. Rep.8:12059. 10.1038/s41598-018-30137-x

  • 319

    TakahashiG.GurumurthyC. B.WadaK.MiuraH.SatoM.OhtsukaM. (2015). GONAD: genome-editing via oviductal nucleic acids delivery system: a novel microinjection independent genome engineering method in mice.Sci. Rep.5:11406. 10.1038/srep11406

  • 320

    TeixeiraM.PyB. F.BoscC.LaubretonD.MoutinM.-J.MarvelJ.et al (2018). Electroporation of mice zygotes with dual guide RNA/Cas9 complexes for simple and efficient cloning-free genome editing.Sci. Rep.8:474. 10.1038/s41598-017-18826-5

  • 321

    TengF.CuiT.FengG.GuoL.XuK.GaoQ.et al (2018). Repurposing CRISPR-Cas12b for mammalian genome engineering.Cell Discov.4:63. 10.1038/s41421-018-0069-3

  • 322

    TeraoM.TamanoM.HaraS.KatoT.KinoshitaM.TakadaS. (2016). Utilization of the CRISPR/Cas9 system for the efficient production of mutant mice using crRNA/tracrRNA with Cas9 nickase and FokI-dCas9.Exp. Anim.65275283. 10.1538/expanim.15-0116

  • 323

    TessonL.CharreauB.MénoretS.GilbertE.SoulillouJ. P.AnegonI. (1999). Endothelial expression of Fas ligand in transgenic rats under the temporal control of a tetracycline-inducible system.Transplant. Proc.3115331534.

  • 324

    TessonL.UsalC.MénoretS.LeungE.NilesB. J.RemyS.et al (2011). Knockout rats generated by embryo microinjection of TALENs.Nat. Biotechnol.29695696. 10.1038/nbt.1940

  • 325

    The Commission to the European Parliament and the Council (2015-2017). The Commission to the European Parliament and the Council 2019 Report on the Statistics on the use of Animals for Scientific Purposes in the Member States of the European Union in 2015-2017. Eur-lex. Available online at: https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1581689520921&uri=CELEX:52020DC0016 [Accessed July 9, 2020].

  • 326

    ThebaultP.LhermiteN.TillyG.Le TexierL.QuillardT.HeslanM.et al (2009). The C-type lectin-like receptor CLEC-1, expressed by myeloid cells and endothelial cells, is up-regulated by immunoregulatory mediators and moderates T cell activation.J. Immunol.18330993108.

  • 327

    ThomasK. R.CapecchiM. R. (1987). Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells.Cell51503512. 10.1016/0092-8674(87)90646-5

  • 328

    TongC.HuangG.AshtonC.WuH.YanH.YingQ.-L. (2012). Rapid and cost-effective gene targeting in rat embryonic stem cells by TALENs.J. Genet. Genomics39275280. 10.1016/j.jgg.2012.04.004

  • 329

    TongC.LiP.WuN. L.YanY.YingQ.-L. (2010). Production of p53 gene knockout rats by homologous recombination in embryonic stem cells.Nature467211213. 10.1038/nature09368

  • 330

    TranN.-T.BashirS.LiX.RossiusJ.ChuV. T.RajewskyK.et al (2019). Enhancement of precise gene editing by the association of Cas9 with homologous recombination factors.Front. Genet.10:365. 10.3389/fgene.2019.00365

  • 331

    TrimidalS. G.BenjaminR.BaeJ. E.HanM. V.KongE.SingerA.et al (2019). Can designer indels be tailored by gene editing?: can indels be customized?Bioessays41:e1900126. 10.1002/bies.201900126

  • 332

    TsuchidaT.ZhengY.-W.ZhangR.-R.TakebeT.UenoY.SekineK.et al (2014). The development of humanized liver with Rag1 knockout rats.Transplant. Proc.4611911193. 10.1016/j.transproceed.2013.12.026

  • 333

    TuggleK. L.BirketS. E.CuiX.HongJ.WarrenJ.ReidL.et al (2014). Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats.PLoS One9:e91253. 10.1371/journal.pone.0091253

  • 334

    UbelsJ. L.DiegelC. R.FoxaG. E.EthenN. J.LensingJ. N.MadajZ. B.et al (2020). Low-density lipoprotein receptor-related protein 5-deficient rats have reduced bone mass and abnormal development of the retinal vasculature.CRISPR J.3284298. 10.1089/crispr.2020.0009

  • 335

    van BoxtelR.GouldM. N.CuppenE.SmitsB. M. G. (2010). ENU mutagenesis to generate genetically modified rat models.Methods Mol. Biol.597151167. 10.1007/978-1-60327-389-3_11

  • 336

    van BoxtelR.ToonenP. W.van RoekelH. S.VerheulM.SmitsB. M. G.KorvingJ.et al (2008). Lack of DNA mismatch repair protein MSH6 in the rat results in hereditary non-polyposis colorectal cancer-like tumorigenesis.Carcinogenesis2912901297. 10.1093/carcin/bgn094

  • 337

    van den BrandtJ.KwonS.-H.HünigT.McPhersonK. G.ReichardtH. M. (2005). Sustained pre-TCR expression in Notch1IC-transgenic rats impairs T cell maturation and selection.J. Immunol.17478457852. 10.4049/jimmunol.174.12.7845

  • 338

    van VuurenA. J.van RoonJ. A. G.WalravenV.StuijI.HarmsenM. C.McLaughlinP. M. J.et al (2006). CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model.J. Immunol.17658335838. 10.4049/jimmunol.176.10.5833

  • 339

    VerkuijlS. A.RotsM. G. (2019). The influence of eukaryotic chromatin state on CRISPR-Cas9 editing efficiencies.Curr. Opin. Biotechnol.556873. 10.1016/j.copbio.2018.07.005

  • 340

    VichayaE. G.MalikS.SominskyL.FordB. G.SpencerS. J.DantzerR. (2020). Microglia depletion fails to abrogate inflammation-induced sickness in mice and rats.J Neuroinflammation17:172. 10.1186/s12974-020-01832-2

  • 341

    WangH.HuY.-C.MarkoulakiS.WelsteadG. G.ChengA. W.ShivalilaC. S.et al (2013a). TALEN-mediated editing of the mouse Y chromosome.Nat. Biotechnol.31530532. 10.1038/nbt.2595

  • 342

    WangH.YangH.ShivalilaC. S.DawlatyM. M.ChengA. W.ZhangF.et al (2013b). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.Cell153910918. 10.1016/j.cell.2013.04.025

  • 343

    WangJ.DangR.MiyasakaY.HattoriK.TorigoeD.OkamuraT.et al (2019a). Null mutation of the endothelin receptor type B gene causes embryonic death in the GK rat.PLoS One14:e0217132. 10.1371/journal.pone.0217132

  • 344

    WangJ.LiuZ.BellenH. J.YamamotoS. (2019b). Navigating MARRVEL, a web-based tool that integrates human genomics and model organism genetics information.J. Vis. Exp.10.3791/59542

  • 345

    WangL.ShaoY.GuanY.LiL.WuL.ChenF.et al (2015). Large genomic fragment deletion and functional gene cassette knock-in via Cas9 protein mediated genome editing in one-cell rodent embryos.Sci. Rep.5:17517. 10.1038/srep17517

  • 346

    WangL.WangJ.CaiW.ShiY.ZhouX.GuoG.et al (2017). A critical evaluation of liver pathology in humans with danon disease and experimental correlates in a rat model of LAMP-2 deficiency.Clin. Rev. Allergy. Immunol.53105116. 10.1007/s12016-017-8598-3

  • 347

    WangW.KutnyP. M.ByersS. L.LongstaffC. J.DaCostaM. J.PangC.et al (2016). Delivery of Cas9 protein into mouse zygotes through a series of electroporation dramatically increases the efficiency of model creation.J. Genet. Genomics43319327. 10.1016/j.jgg.2016.02.004

  • 348

    WangX.LiuZ.LiG.DangL.HuangS.HeL.et al (2020). Efficient gene silencing by adenine base editor-mediated start codon mutation.Mol. Ther.28431440. 10.1016/j.ymthe.2019.11.022

  • 349

    WangZ.WangY.WangS.GorzalskiA. J.McSwigginH.YuT.et al (2020). Efficient genome editing by CRISPR-Mb3Cas12a in mice.J. Cell. Sci.133:jcs240705. 10.1242/jcs.240705

  • 350

    WangY.ZhouX.-Y.XiangP.-Y.WangL.-L.TangH.XieF.et al (2014). The meganuclease I-SceI containing nuclear localization signal (NLS-I-SceI) efficiently mediated mammalian germline transgenesis via embryo cytoplasmic microinjection.PLoS One9:e108347. 10.1371/journal.pone.0108347

  • 351

    WeberJ.ÖllingerR.FriedrichM.EhmerU.BarenboimM.SteigerK.et al (2015). CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.Proc. Natl. Acad. Sci. U.S.A.1121398213987. 10.1073/pnas.1512392112

  • 352

    WefersB.MeyerM.OrtizO.Hrabé de AngelisM.HansenJ.WurstW.et al (2013). Direct production of mouse disease models by embryo microinjection of TALENs and oligodeoxynucleotides.Proc. Natl. Acad. Sci. U.S.A.11037823787. 10.1073/pnas.1218721110

  • 353

    WetselR. A.FleischerD. T.HavilandD. L. (1990). Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5’-exon.J. Biol. Chem.26524352440.

  • 354

    WildnerG. (2019). Are rats more human than mice?Immunobiology224172176. 10.1016/j.imbio.2018.09.002

  • 355

    XiaC.-H.FergusonI.LiM.KimA.OnishiA.LiL.et al (2018). Essential function of NHE8 in mouse retina demonstrated by AAV-mediated CRISPR/Cas9 knockdown.Exp. Eye Res.1762939. 10.1016/j.exer.2018.06.026

  • 356

    XuC.QiX.DuX.ZouH.GaoF.FengT.et al (2017). piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in mice.Proc. Natl. Acad. Sci. U.S.A.114722727. 10.1073/pnas.1615735114

  • 357

    XuJ.ZhangL.XieM.LiY.HuangP.SaundersT. L.et al (2018). Role of complement in a rat model of paclitaxel-induced peripheral neuropathy.J. Immunol.20040944101. 10.4049/jimmunol.1701716

  • 358

    XuY.WuZ.LiuL.LiuJ.WangY. (2019). Rat model of cockayne syndrome neurological disease.Cell Rep.29800.e5809.e5. 10.1016/j.celrep.2019.09.028

  • 359

    XuY.ZhaoX.-M.LiuJ.WangY.-Y.XiongL.-L.HeX.-Y.et al (2020). Complexin I knockout rats exhibit a complex neurobehavioral phenotype including profound ataxia and marked deficits in lifespan.Pflugers. Arch.472117133. 10.1007/s00424-019-02337-5

  • 360

    YamamotoS.OoshimaY.NakataM.YanoT.NishimuraN.NishigakiR.et al (2015). Efficient gene-targeting in rat embryonic stem cells by CRISPR/Cas and generation of human kynurenine aminotransferase II (KAT II) knock-in rat.Transgenic Res.249911001. 10.1007/s11248-015-9909-1

  • 361

    YangJ.YiN.ZhangJ.HeW.HeD.WuW.et al (2018). Generation and characterization of a hypothyroidism rat model with truncated thyroid stimulating hormone receptor.Sci. Rep.8:4004. 10.1038/s41598-018-22405-7

  • 362

    YangL.ZhangX.WangL.YinS.ZhuB.XieL.et al (2018). Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants.Protein Cell9814819. 10.1007/s13238-018-0568-x

  • 363

    YangX.ZhouJ.HeJ.LiuJ.WangH.LiuY.et al (2018). An immune system-modified rat model for human stem cell transplantation research.Stem Cell Rep.11514521. 10.1016/j.stemcr.2018.06.004

  • 364

    YangL.IkedaH.LaiY.YoshikiT.TakadaK. (2003). Epstein-barr virus infection of rat lymphocytes expressing human CD21 results in restricted latent viral gene expression and not in immunoblastic transformation.J. Med. Virol.70126130. 10.1002/jmv.10369

  • 365

    YangX.LuD.ZhangX.ChenW.GaoS.DongW.et al (2019). Knockout of ISCA1 causes early embryonic death in rats.Anim. Model. Exp. Med.21824. 10.1002/ame2.12059

  • 366

    YaoX.VerkmanA. S. (2017a). Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G.Acta Neuropathol. Commun.5:57. 10.1186/s40478-017-0462-4

  • 367

    YaoX.VerkmanA. S. (2017b). Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G.Acta Neuropathol. Commun.5:15. 10.1186/s40478-017-0417-9

  • 368

    YaoX.WangX.HuX.LiuZ.LiuJ.ZhouH.et al (2017). Homology-mediated end joining-based targeted integration using CRISPR/Cas9.Cell Res.27801814. 10.1038/cr.2017.76

  • 369

    YeL.ParkJ. J.DongM. B.YangQ.ChowR. D.PengL.et al (2019). In vivo CRISPR screening in CD8 T cells with AAV-sleeping beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma.Nat Biotechnol3713021313. 10.1038/s41587-019-0246-4

  • 370

    YehC. D.RichardsonC. D.CornJ. E. (2019). Advances in genome editing through control of DNA repair pathways.Nat. Cell Biol.2114681478. 10.1038/s41556-019-0425-z

  • 371

    YeoJ. H.JungB. K.LeeH.BaekI.-J.SungY. H.ShinH.-S.et al (2019). Development of a Pde6b gene knockout rat model for studies of degenerative retinal diseases.Invest. Ophthalmol. Vis. Sci.6015191526. 10.1167/iovs.18-25556

  • 372

    YoonY.WangD.TaiP. W. L.RileyJ.GaoG.Rivera-PérezJ. A. (2018). Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses.Nat. Commun.9:412. 10.1038/s41467-017-02706-7

  • 373

    YoshimiK.KunihiroY.KanekoT.NagahoraH.VoigtB.MashimoT. (2016). ssODN-mediated knock-in with CRISPR-Cas for large genomic regions in zygotes.Nat. Commun.7:10431. 10.1038/ncomms10431

  • 374

    YouP.HuH.ChenY.ZhaoY.YangY.WangT.et al (2016). Effects of melanocortin 3 and 4 receptor deficiency on energy homeostasis in rats.Sci. Rep.6:34938. 10.1038/srep34938

  • 375

    YuD.ZhongY.LiX.LiY.LiX.CaoJ.et al (2016). Generation of TALEN-mediated FH knockout rat model.Oncotarget76165661669. 10.18632/oncotarget.11429

  • 376

    YuH.KoilkondaR. D.ChouT.-H.PorciattiV.MehtaA.HentallI. D.et al (2015). Consequences of zygote injection and germline transfer of mutant human mitochondrial DNA in mice.Proc. Natl. Acad. Sci. U.S.A.112E5689E5698. 10.1073/pnas.1506129112

  • 377

    YuQ.LiuY.-Z.ZhuY.-B.WangY.-Y.LiQ.YinD.-M. (2019). Genetic labeling reveals temporal and spatial expression pattern of D2 dopamine receptor in rat forebrain.Brain Struct. Funct.22410351049. 10.1007/s00429-018-01824-2

  • 378

    YuY.GuoY.TianQ.LanY.YehH.ZhangM.et al (2020). An efficient gene knock-in strategy using 5’-modified double-stranded DNA donors with short homology arms.Nat. Chem. Biol.16387390. 10.1038/s41589-019-0432-1

  • 379

    Yu-TaegerL.OttT.BonsiP.TomczakC.WassoufZ.MartellaG.et al (2020). Impaired dopamine- and adenosine-mediated signaling and plasticity in a novel rodent model for DYT25 dystonia.Neurobiol. Dis.134:104634. 10.1016/j.nbd.2019.104634

  • 380

    ZallarL. J.TunstallB. J.RichieC. T.ZhangY. J.YouZ. B.GardnerE. L.et al (2019). Development and initial characterization of a novel ghrelin receptor CRISPR/Cas9 knockout wistar rat model.Int. J. Obes.43344354. 10.1038/s41366-018-0013-5

  • 381

    ZanY.HaagJ. D.ChenK.-S.ShepelL. A.WigingtonD.WangY.-R.et al (2003). Production of knockout rats using ENU mutagenesis and a yeast-based screening assay.Nat. Biotechnol.21645651. 10.1038/nbt830

  • 382

    ZhangH.PanH.ZhouC.WeiY.YingW.LiS.et al (2018). Simultaneous zygotic inactivation of multiple genes in mouse through CRISPR/Cas9-mediated base editing.Development145:dev168906. 10.1242/dev.168906

  • 383

    ZhangT.JiangX.XuM.WangH.SangX.QinM.et al (2018). Sleep and circadian abnormalities precede cognitive deficits in R521C FUS knockin rats.Neurobiol. Aging72159170. 10.1016/j.neurobiolaging.2018.08.025

  • 384

    ZhangJ.-P.LiX.-L.LiG.-H.ChenW.ArakakiC.BotimerG. D.et al (2017). Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage.Genome Biol.18:35. 10.1186/s13059-017-1164-8

  • 385

    ZhangL.ShaoY.LiL.TianF.CenJ.ChenX.et al (2016). Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I.Sci. Rep.6:31460. 10.1038/srep31460

  • 386

    ZhangX.LiangP.DingC.ZhangZ.ZhouJ.XieX.et al (2016). Efficient production of gene-modified mice using Staphylococcus aureus Cas9.Sci. Rep.6:32565. 10.1038/srep32565

  • 387

    ZhaoY.YangY.XingR.CuiX.XiaoY.XieL.et al (2018). Hyperlipidemia induces typical atherosclerosis development in Ldlr and apoe deficient rats.Atherosclerosis2712635. 10.1016/j.atherosclerosis.2018.02.015

  • 388

    ZhengR.FangX.HeL.ShaoY.GuoN.WangL.et al (2018). Generation of a primary hyperoxaluria type 1 disease model via CRISPR/Cas9 system in rats.Curr. Mol. Med.18436447. 10.2174/1566524019666181212092440

  • 389

    ZhengR.LiY.WangL.FangX.ZhangJ.HeL.et al (2020). CRISPR/Cas9-mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1.Kidney Int.98947957. 10.1016/j.kint.2020.04.049

  • 390

    ZhouX.XuC.ZouZ.ShenX.XieT.ZhangR.et al (2019). The characteristics of glucose metabolism in the sulfonylurea receptor 1 knockout rat model.Mol. Med.25:2. 10.1186/s10020-018-0067-9

  • 391

    ZijlstraM.LiE.SajjadiF.SubramaniS.JaenischR. (1989). Germ-line transmission of a disrupted beta 2-microglobulin gene produced by homologous recombination in embryonic stem cells.Nature342435438. 10.1038/342435a0

  • 392

    ZschemischN.-H.GlageS.WedekindD.WeinsteinE. J.CuiX.DorschM.et al (2012). Zinc-finger nuclease mediated disruption of Rag1 in the LEW/Ztm rat.BMC Immunol.13:60. 10.1186/1471-2172-13-60

Summary

Keywords

CRISPR-Cas9, rat, knockout, knockin, transgenesis, genetic diseases, immune genes

Citation

Chenouard V, Remy S, Tesson L, Ménoret S, Ouisse L-H, Cherifi Y and Anegon I (2021) Advances in Genome Editing and Application to the Generation of Genetically Modified Rat Models. Front. Genet. 12:615491. doi: 10.3389/fgene.2021.615491

Received

09 October 2020

Accepted

22 February 2021

Published

20 April 2021

Volume

12 - 2021

Edited by

Huaqiang Yang, South China Agricultural University, China

Reviewed by

Rui Chen, Baylor College of Medicine, United States; Yuanwu Ma, Chinese Academy of Medical Sciences and Peking Union Medical College, China; Daniel Davis, University of Missouri, United States

Updates

Copyright

*Correspondence: Ignacio Anegon, ;

This article was submitted to Genomic Assay Technology, a section of the journal Frontiers in Genetics

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics